

CONSOLIDATED FINANCIAL REPORT,
SUPPLEMENTARY INFORMATION, UNIFORM
GUIDANCE REPORTS AND SCHEDULE

Mayo Clinic
Years Ended December 31, 2021 and 2020

Ernst & Young LLP



Mayo Clinic

Consolidated Financial Report, Supplementary Information, Uniform Guidance Reports and Schedule

Years Ended December 31, 2021 and 2020

Contents

Independent auditor's report.....	1
Consolidated financial statements	
Consolidated statements of financial position	4
Consolidated statements of activities	5
Consolidated statements of cash flows	6
Notes to consolidated financial statements.....	7
Supplementary Information	
Financial Responsibility Supplemental Schedule required by the U.S. Department of Education	47
Schedule of Expenditures of Federal Awards	48
Schedule of Expenditures of Florida State Financial Assistance	75
Notes to Schedules of Expenditures of Federal Awards and Florida State Financial Assistance	76
Uniform Guidance Reports and Schedule	
Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With <i>Government Auditing Standards</i>	79
Report of Independent Auditors on Compliance for Each Major Federal Program and State Financial Assistance Project and Report on Internal Control Over Compliance Required by the Uniform Guidance and Chapter 10.650, <i>Rules of the Auditor General of the State of Florida</i>	81
Schedule of Findings and Questioned Costs	88

Report of Independent Auditors

Board of Trustees
Mayo Clinic

Opinion

We have audited the consolidated financial statements of Mayo Clinic (“the Clinic”), which comprise the consolidated statements of financial position as of December 31, 2021 and 2020, and the related consolidated statements of activities and cash flows for the years then ended, and the related notes (collectively referred to as the financial statements).

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Clinic at December 31, 2021 and 2020, and the results of its operations and its cash flows for the years then ended, in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS) and the standards applicable to financial audits contained in *Government Auditing Standards (Government Auditing Standards)* issued by the Comptroller General of the United States. Our responsibilities under those standards are further described in the Auditor’s Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Clinic and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free of material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Clinic’s ability to continue as a going concern for one year after the date that the financial statements are issued.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free of material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and, therefore, is not a guarantee that an audit conducted in accordance with GAAS and *Government Auditing Standards* will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the consolidated financial statements.

In performing an audit in accordance with GAAS and *Government Auditing Standards*, we:

- a. Exercise professional judgment and maintain professional skepticism throughout the audit.
- b. Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- c. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Clinic's internal control. Accordingly, no such opinion is expressed.
- d. Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- e. Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Clinic's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Supplementary Information

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. We have not performed any procedures with respect to the audited consolidated financial statements subsequent to February 18, 2022. The Financial Responsibility Supplemental Schedule required by the U.S. Department of Education and the Schedules of Expenditures of Federal Awards and Florida State Financial Assistance as required by Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards*, and Chapter 10.650, *Rules of the Auditor General of the State of Florida*, are presented for purposes of additional analysis and are not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States. In our opinion, the information is fairly stated, in all material respects, in relation to the financial statements as a whole.

Other Reporting Required by *Government Auditing Standards*

In accordance with *Government Auditing Standards*, we also have issued our report dated February 18, 2022, on our consideration of the Clinic's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Clinic's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Clinic's internal control over financial reporting and compliance.

Ernst & Young LLP

February 18, 2022, except for the schedules
of expenditures of federal awards and
Florida state financial assistance, for which
the date is August 26, 2022



Consolidated Statements of Financial Position
December 31, 2021 and 2020 (In Millions)

	2021	2020
Assets		
Current assets:		
Cash and cash equivalents	\$ 46	\$ 72
Accounts receivable for medical services	1,826	1,756
Other receivables	648	576
Other current assets	317	254
Total current assets	2,837	2,658
Investments	18,021	14,358
Other long-term assets	1,407	1,204
Property, plant, and equipment, net	5,410	4,964
Total assets	\$ 27,675	\$ 23,184
Liabilities and net assets		
Current liabilities:		
Accounts payable	\$ 768	\$ 584
Accrued payroll	818	797
Accrued employee benefits	168	163
Deferred revenue	62	90
Long-term variable-rate debt	620	620
Mandatory tender debt	—	135
Other current liabilities	509	472
Total current liabilities	2,945	2,861
Long-term debt, net of current portion	3,552	3,097
Accrued pension and postretirement benefits, net of current portion	1,378	2,897
Other long-term liabilities	2,133	1,964
Total liabilities	10,008	10,819
Net assets:		
Without donor restrictions	12,431	8,016
With donor restrictions	5,236	4,349
Total net assets	17,667	12,365
Total liabilities and net assets	\$ 27,675	\$ 23,184

See notes to consolidated financial statements.



Consolidated Statements of Activities
Years Ended December 31, 2021 and 2020 (In Millions)

	2021			2020		
	Without Donor Restrictions	With Donor Restrictions	Total	Without Donor Restrictions	With Donor Restrictions	Total
Revenue, gains, and other support:						
Medical service revenue	\$ 13,310	\$ —	\$ 13,310	\$ 11,501	\$ —	\$ 11,501
Grants and contracts	613	—	613	569	—	569
Investment return allocated to current activities	217	24	241	238	32	270
Contributions available for current activities	181	253	434	91	258	349
Other	1,131	—	1,131	1,111	—	1,111
Net assets released from restrictions	430	(430)	—	246	(246)	—
Total revenue, gains, and other support	15,882	(153)	15,729	13,756	44	13,800
Expenses:						
Salaries and benefits	8,661	—	8,661	7,954	—	7,954
Supplies and services	4,767	—	4,767	4,099	—	4,099
Depreciation and amortization	619	—	619	611	—	611
Facilities	326	—	326	276	—	276
Finance and investment	144	—	144	132	—	132
Total expenses	14,517	—	14,517	13,072	—	13,072
Income (loss) from current activities	1,365	(153)	1,212	684	44	728
Noncurrent and other items:						
Contributions not available for current activities, net	(22)	371	349	(21)	250	229
Unallocated investment return, net	1,432	669	2,101	1,254	340	1,594
Income tax expense	(25)	—	(25)	(40)	—	(40)
Benefit credit	61	—	61	62	—	62
Other	(124)	—	(124)	(106)	—	(106)
Total noncurrent and other items	1,322	1,040	2,362	1,149	590	1,739
Increase in net assets before other changes in net assets	2,687	887	3,574	1,833	634	2,467
Pension and other postretirement benefit adjustments	1,728	—	1,728	(496)	—	(496)
Increase in net assets	4,415	887	5,302	1,337	634	1,971
Net assets at beginning of year	8,016	4,349	12,365	6,679	3,715	10,394
Net assets at end of year	\$ 12,431	\$ 5,236	\$ 17,667	\$ 8,016	\$ 4,349	\$ 12,365

See notes to consolidated financial statements.



Consolidated Statements of Cash Flows
Years Ended December 31, 2021 and 2020 (In Millions)

	2021	2020
Cash flows from operating activities:		
Cash from medical services	\$ 12,283	\$ 10,904
Cash from external lab services	957	861
Cash from grants and contracts	616	555
Cash from benefactors	368	271
Cash from other activities	1,030	1,052
Cash for salaries and benefits	(8,350)	(7,827)
Cash for supplies, services, and facilities	(5,136)	(4,369)
Interest and dividends received	222	145
Interest paid	(126)	(115)
Income taxes paid	(63)	(6)
Net cash provided by operating activities	1,801	1,471
Cash flows from investing activities:		
Purchase of property, plant, and equipment	(861)	(642)
Purchases of investments	(6,832)	(5,913)
Sales and maturities from investments	5,291	4,463
Investment in unconsolidated entities	(43)	(50)
Net cash used in investing activities	(2,445)	(2,142)
Cash flows from financing activities:		
Restricted gifts, bequests, and other	265	214
Borrowing on long-term debt	500	630
Payment of long-term debt	(141)	(134)
Payment on leases	(6)	(15)
Medicare advance payments	—	915
Return of Medicare advance payments	—	(915)
Net cash provided by financing activities	618	695
Net (decrease) increase in cash and cash equivalents	(26)	24
Cash and cash equivalents at beginning of year	72	48
Cash and cash equivalents at end of year	\$ 46	\$ 72

See notes to consolidated financial statements.

Note 1. Organization and Summary of Significant Accounting Policies

Organization: Mayo Clinic and its Arizona, Florida, Iowa, Minnesota, and Wisconsin affiliates (the Clinic) provide comprehensive medical care and education in clinical medicine and medical sciences and conduct extensive programs in medical research. The Clinic also provides hospital and outpatient services, and at each major location, the clinical practice is closely integrated with advanced education and research programs. The Clinic and most of its subsidiaries have been determined to qualify as tax-exempt organizations under Section 501(c)(3) of the Internal Revenue Code (the Code) and as a public charity under Section 509(a)(2) of the Code.

Basis of presentation: Included in the Clinic's consolidated financial statements are all of its wholly owned or wholly controlled subsidiaries. All significant intercompany transactions have been eliminated in consolidation. In addition, these statements follow generally accepted accounting principles applicable to the not-for-profit industry as described in the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) *Topic 958, Not-for Profit Entities*.

Certain reclassifications have been made to the 2020 consolidated financial statements to conform with classifications used in 2021. The reclassifications had no significant effect on total assets, total liabilities, total revenue, or total change in net assets previously reported.

Use of estimates: The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements. Estimates also affect the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

New Accounting Standards

Effective January 1, 2021, the Clinic adopted FASB Accounting Standards Update (ASU) No. 2018-14, *Compensation – Retirement Benefits – Defined Benefit Plans (Topic 715)*. This ASU modifies the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans. The adoption of this ASU did not materially impact the consolidated financial statements.

Effective January 1, 2021, the Clinic adopted FASB ASU No. 2018-15, *Intangibles – Goodwill and Other, Internal-Use Software (Subtopic 350-40), Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract*. This ASU aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The adoption of this ASU did not materially impact the consolidated financial statements.

New Accounting Standard Not Yet Adopted

In September 2020, the FASB issued ASU No. 2020-07, *Presentation and Disclosures by Not-for-Profit Entities for Contributed Nonfinancial Assets (Topic 958)*. This ASU requires presentation of contributed nonfinancial assets as a separate line in the consolidated statement of activities, apart from contributions of cash or other financial assets. The ASU is effective January 1, 2022, and will be applied on a retrospective basis. The adoption of this ASU will not materially impact the consolidated financial statements.

Note 1. Organization and Summary of Significant Accounting Policies (Continued)

Cash and cash equivalents: Cash and cash equivalents include currency on hand, demand deposits with banks or other financial institutions, and short-term investments with maturities of three months or less from the date of purchase, which are not managed by the Clinic's investment managers.

Accounts receivable for medical services: Accounts receivable for medical services are based upon the estimated amounts expected to be paid from patients and third-party payors.

Inventories: Inventories, consisting primarily of medical supplies and pharmaceuticals, are stated at the lower of cost or net realizable value.

Investments: Investments in equity and debt securities, including alternative investments, are recorded at fair value (Notes 4 and 6). Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Realized gains and losses are calculated based on the average cost method. Investment income or loss (including realized and unrealized gains and losses on investments, interest, and dividends) is included in the consolidated statements of activities.

Alternative investments (principally limited partnership interests in absolute return, hedge, private equity, real estate, and natural resources funds) represent the Clinic's ownership interest in the respective partnership, which is valued at fair value based on net asset value (NAV) obtained from fund manager statements and historically audited financial statements. The investments in alternative investments may individually expose the Clinic to securities lending, short sales, and trading in futures and forward contract options and other derivative products. The Clinic's risk is limited to the investment's carrying value.

It is the Clinic's intent to maintain a long-term investment portfolio to support research, education, and other activities. Accordingly, the total investment return is reported in the consolidated statements of activities in two categories. The investment return allocated to current activities is determined by a

formula, which involves allocating 5% of a three-year moving average of investments related to endowments, and the matching of financing costs for the assets required for operations. Management believes this return is approximately equal to the real return that the Clinic expects to earn on its investments over the long term. The unallocated investment return, included in noncurrent and other items in the consolidated statements of activities, represents the difference between the total investment return and the amount allocated to current activities, net of investment costs.

Property, plant, and equipment: Property, plant, and equipment are carried at cost if purchased or at fair value on the date received through affiliation or donation, less accumulated depreciation. Plant and equipment are depreciated over their estimated useful lives, ranging from 3 to 50 years using the straight-line method. Depreciation expense includes amortization of assets recorded under capital leases.

Costs associated with the development and installation of internal-use software are accounted for in accordance with *Intangibles—Goodwill and Other, Internal-Use Software (Subtopic 350-40)* of the FASB ASC. Accordingly, internal-use software costs are expensed or capitalized and amortized according to the provisions of the accounting standard.

Note 1. Organization and Summary of Significant Accounting Policies (Continued)

Leases: The Clinic determines if an arrangement is a lease at inception. Operating leases are included in other long-term assets, other current liabilities, and other long-term liabilities in the consolidated statements of financial position. Finance leases are included in property, plant, and equipment, other current liabilities, and other long-term liabilities in the consolidated statements of financial position.

Right-of-use (ROU) assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the commencement date, based on the present value of lease payments over the lease term. As most of the leases do not provide an implicit rate, the Clinic uses an incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The implicit rate is used when readily determinable. The ROU asset also includes any lease payments made and excludes lease incentives. The lease term may include options to extend or terminate the lease when it is reasonably certain the Clinic will exercise the option.

The Clinic defines a short-term lease as any lease arrangement with a lease term of 12 months or less that does not include an option to purchase the underlying asset. Short-term lease payments are recognized as expense on a straight-line basis over the lease term and variable lease payments in the period in which the obligation is incurred.

The Clinic has lease arrangements with lease and non-lease components, which are generally accounted for separately, except the Clinic has elected the practical expedient to not separate non-lease components for real estate leases. Additionally, for certain equipment leases, the Clinic applies a portfolio approach to effectively account for the ROU assets and liabilities.

Deferred revenue: Deferred revenue consists of payments received in advance for grant, subscription, and tuition revenue. Deferred revenues are subsequently recognized as revenue in accordance with the Clinic's revenue recognition policies.

Deferred compensation: The Clinic offers eligible employees a nonqualified, tax-deferred compensation retirement plan. Employees defer compensation into the plan on a pretax basis. For the most part, the plan operates similar to a defined contribution plan and is presented in noncurrent and other items on the consolidated statements of activities.

Asset retirement obligations: The Clinic accounts for the estimated cost of legal obligations associated with long-lived asset retirements in accordance with *Asset Retirement and Environmental Obligations (Topic 410)* of the FASB ASC. The asset retirement liability, recorded in other long-term liabilities, is accreted to the present value of the estimated future costs of these obligations at the end of each period.

Net assets: Net assets, revenues, gains, and losses are classified based on the existence or absence of donor or grantor-imposed restrictions. Accordingly, net assets and changes therein are classified and reported as follows:

Net Assets Without Donor Restrictions – Net assets available for use in general operations and not subject to donor restrictions. The governing board has designated, from net assets without donor restrictions, net assets for an operating reserve and board-designated endowment.

Net Assets With Donor Restrictions – Net assets subject to donor-imposed restrictions. Some donor-imposed restrictions are temporary in nature, such as those that will be met by the passage of time or

Note 1. Organization and Summary of Significant Accounting Policies (Continued)

other events specified by the donor. Other donor-imposed restrictions are perpetual in nature, where the donor stipulates that resources be maintained in perpetuity. Gifts of long-lived assets and gifts of cash restricted for the acquisition on long-lived assets are recognized as revenue when received. Donor-imposed restrictions are released when a restriction expires, that is, when the stipulated time has elapsed, when the stipulated purpose for which the resource was restricted has been fulfilled, or both.

Medical service revenue: Medical service revenue is reported at the amount that reflects the consideration to which the Clinic expects to be entitled in exchange for providing patient care.

Grants and contracts: Reciprocal grants and contracts revenue is recognized when the expenses have been incurred for the purpose specified by the grantor or in accordance with the terms of the agreement.

Contributed grants and contracts revenue is recorded as conditions are met or immediately if deemed an unconditional contribution. Grant and contract amounts due to the Clinic are included in other receivables.

Charity and uncompensated care: The Clinic provides health care services to patients who meet certain criteria under its Charity Care Policy without charge or at amounts less than established rates. Since the Clinic does not pursue collection of these amounts, they are not reported as revenue. The estimated cost of providing these services was \$49 and \$89 in 2021 and 2020, respectively, calculated by multiplying the ratio of cost to gross charges for the Clinic by the gross uncompensated charges associated with providing care to charity patients. In addition to the charges related to the direct patient

care provided under the Clinic's Charity Care Policy, the Clinic has programs offered to benefit the broader community and other governmental reimbursement programs. The Clinic also participates in various state Medicaid programs for indigent patients. The estimated unreimbursed cost of providing services related to Medicaid programs totaled \$601 and \$540 in 2021 and 2020, respectively.

Contributions: The Clinic classifies contributions that are available for current activities as revenue, based on the lack of specific donor restriction or the presence of donor restrictions and the ability of the Clinic to meet those restrictions within the year. Contributions of a perpetual nature or not available for current activities are classified in noncurrent and other items in the consolidated statements of activities.

Development expenses of \$48 (\$26 allocated to current and \$22 allocated to noncurrent) and \$48 (\$27 allocated to current and \$21 allocated to noncurrent) were incurred in 2021 and 2020, respectively. The current portion is recorded in expenses, and the noncurrent portion is netted against contributions not available for current activities in the consolidated statements of activities. Unconditional promises to give and contributions are reported at fair value at the time of the gift. An allowance for uncollectible pledges receivable is estimated, based on a combination of historical experience and specific identification.

Conditional promises to give are recognized at fair value when the barriers to entitlement are overcome or the possibility that a condition will not be met is remote.

The Clinic periodically receives works of art from various benefactors. These items are unique in nature and are held on display for the benefit and enjoyment of the Clinic's patients. It is the Clinic's policy to neither capitalize contributed works of art nor record the related contribution revenue.

Income from current activities: The Clinic's policy is to include in income from current activities all medical service and other revenue, grants and contracts, investment return allocated to current activities, contributions available for current activities, net assets released from restrictions, and substantially all

Notes to Consolidated Financial Statements (In Millions)

Note 1. Organization and Summary of Significant Accounting Policies (Continued)

expenses. Contributions not available for current activities, unallocated investment return, income tax expense, benefit credit, and those items not expected to recur on a regular basis are included in noncurrent and other items in the consolidated statements of activities.

Subsequent events: The Clinic evaluated events and transactions occurring subsequent to December 31, 2021 through February 18, 2022, the date of issuance of the consolidated financial statements. During this period, there were no subsequent events requiring recognition in the consolidated financial statements. Additionally, there were no unrecognized events requiring disclosure.

Note 2. Liquidity and Availability

Financial assets available for general expenditure within one year of the consolidated statement of financial position date are composed of the following at December 31:

	2021	2020
Cash and cash equivalents	\$ 46	\$ 72
Accounts receivable	1,826	1,756
Promises to give	294	234
Grants receivable	134	134
Other receivables	220	208
Investments	11,234	8,878
Total financial assets available within one year	<u>\$ 13,754</u>	<u>\$ 11,282</u>

As part of a liquidity management plan, the Clinic has a policy to structure its financial assets to be available as its general expenditures, liabilities, and other obligations come due. Cash in excess of daily requirements is invested in short-term investments. In the event of an unanticipated liquidity need, the Clinic has \$300 of available lines of credit for working capital at December 31, 2021 and 2020 (see Note 9 – Financing).

The Clinic's endowment funds consist of donor-restricted endowments and funds designated by the board as endowment. Income from endowments is restricted for specific purposes. As described in Note 13 – Endowment, under the Clinic spending policy, \$247 from the endowments was available as of January 1, 2022, and \$224 from the endowments was available at January 1, 2021.

Note 3. Medical Service Revenue

Medical service revenue is reported at the amount that reflects the consideration to which the Clinic expects to be entitled in exchange for providing patient care. These amounts, representing transaction price, are due from patients, third-party payors (including health insurers and government programs), and others and include variable consideration for retroactive revenue adjustments due to settlement of audits, reviews, and investigations. Generally, the Clinic bills the patients and third-party payors several days after the services are performed and/or the patient is discharged from the facility. Revenue is recognized as performance obligations are satisfied.

Note 3. Medical Service Revenue (Continued)

Performance obligations are determined based on the nature of the services provided by the Clinic. Revenue for performance obligations satisfied over time is recognized based on actual charges incurred in relation to total expected (or actual) charges. The Clinic believes that this method provides a faithful depiction of the transfer of services over the term of the performance obligation based on the inputs needed to satisfy the obligation. Generally, performance obligations satisfied over time relate to patients in the Clinic's hospital receiving inpatient acute care services. The Clinic measures the performance obligation from admission into the hospital to the point when it is no longer required to provide services to that patient, which is generally at the time of discharge. Revenue for performance obligations satisfied at a point in time is recognized when goods or services are provided and the Clinic does not believe it is required to provide additional goods or services to the patient.

Because all of its performance obligations relate to contracts with a duration of less than one year, the Clinic has elected to apply the optional exemption provided in *Revenue from Contracts with Customers (Topic 606-10-50-14(a))* and, therefore, is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations referred to above are primarily related to inpatient acute care services at the end of the reporting period. The performance obligations for these contracts are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.

The Clinic determines the transaction price based on standard charges for goods and services provided to patients, reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients in accordance with the Clinic's policy, and/or implicit price concessions based on historical collection experience.

Agreements with third-party payors typically provide for payments at amounts less than established charges. A summary of the payment arrangements with major third-party payors follows:

- **Medicare:** Certain inpatient acute care services are paid at prospectively determined rates per discharge based on clinical, diagnostic, and other factors. Certain services are paid based on cost-reimbursement methodologies subject to certain limits. Physician services are paid based upon established fee schedules. Outpatient services are paid using prospectively determined rates.
- **Medicaid:** Reimbursements for Medicaid services are generally paid at prospectively determined rates per discharge, per occasion of service, or per covered member.
- **Other:** Payment agreements with certain commercial insurance carriers, health maintenance organizations, and preferred provider organizations provide for payment using prospectively determined rates per discharge, discounts from established charges, and prospectively determined daily rates.

Laws and regulations concerning government programs, including Medicare and Medicaid, are complex and subject to varying interpretation. As a result of investigations by governmental agencies, various health care organizations have received requests for information and notices regarding alleged noncompliance with those laws and regulations, which, in some instances, have resulted in organizations entering into significant settlement agreements. Compliance with such laws and regulations may also be

Note 3. Medical Service Revenue (Continued)

subject to future government review and interpretation, as well as significant regulatory action, including fines, penalties, and potential exclusion from the related programs. There can be no assurance that regulatory authorities will not challenge the Clinic's compliance with these laws and regulations, and it is not possible to determine the impact (if any) such claims or penalties would have upon the Clinic. In addition, the contracts that the Clinic has with commercial payors also provide for retroactive audit and review of claims.

Generally, patients who are covered by third-party payors are responsible for related deductibles and coinsurance, which vary in amount. The Clinic also provides services to uninsured patients and offers those uninsured patients a discount, either by policy or law, from standard charges. The Clinic estimates the transaction price for patients with deductibles and coinsurance and from those who are uninsured, based on historical experience and current market conditions. The initial estimate of the transaction price is determined by reducing the standard charge by any contractual adjustments, discounts, and implicit price concessions. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to medical service revenue in the period of the change. For the years ended December 31, 2021 and 2020, revenue recognized due to changes in its estimates of transaction price concessions for performance obligations satisfied in prior years was not significant. Subsequent changes that are determined to be the result of an adverse change in the patient's ability to pay are recorded as bad debt expense. Bad debt expense for the years ended December 31, 2021 and 2020, was not significant.

Settlements with third-party payors for retroactive adjustments due to audits, reviews, or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor, and the Clinic's historical settlement activity, including an assessment to ensure it is probable a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known (that is, new information becomes available) or as years are settled or are no longer subject to such audits, reviews, and investigations. Adjustments arising from a change in the transaction price for the years ended December 31, 2021 and 2020, were not significant.

Patients who meet the Clinic's criteria for charity care are provided care without charge or at amounts less than established rates. Such amounts which are determined to qualify as charity care are not reported as revenue.

Notes to Consolidated Financial Statements (In Millions)

Note 3. Medical Service Revenue (Continued)

The composition of medical service revenue based on the regions of the country in which the Clinic operates, its lines of business, and timing of revenue recognition for the years ended December 31, 2021 and 2020, are as follows:

	Year Ended December 31, 2021			
	Midwest	Southeast	Southwest	Total
Hospital	\$ 5,108	\$ 987	\$ 1,156	\$ 7,251
Clinic	3,353	802	912	5,067
Senior care and nursing home	15	—	—	15
Other	58	1	—	59
Total patient care service revenue	8,534	1,790	2,068	12,392
External lab	918	—	—	918
Total medical service revenue	<u>\$ 9,452</u>	<u>\$ 1,790</u>	<u>\$ 2,068</u>	<u>\$ 13,310</u>
Timing of revenue and recognition:				
At time services are rendered	\$ 4,329	\$ 803	\$ 912	\$ 6,044
Services transferred over time	5,123	987	1,156	7,266
Total	<u>\$ 9,452</u>	<u>\$ 1,790</u>	<u>\$ 2,068</u>	<u>\$ 13,310</u>

	Year Ended December 31, 2020			
	Midwest	Southeast	Southwest	Total
Hospital	\$ 4,353	\$ 840	\$ 1,041	\$ 6,234
Clinic	2,885	649	727	4,261
Senior care and nursing home	16	—	—	16
Other	50	1	—	51
Total patient care service revenue	7,304	1,490	1,768	10,562
External lab	939	—	—	939
Total medical service revenue	<u>\$ 8,243</u>	<u>\$ 1,490</u>	<u>\$ 1,768</u>	<u>\$ 11,501</u>
Timing of revenue and recognition:				
At time services are rendered	\$ 3,874	650	727	\$ 5,251
Services transferred over time	4,369	840	1,041	6,250
Total	<u>\$ 8,243</u>	<u>\$ 1,490</u>	<u>\$ 1,768</u>	<u>\$ 11,501</u>

Hospital revenue includes a variety of services mainly covering inpatient procedures requiring overnight stays or outpatient operations that require anesthesia or use of complex diagnostic and surgical equipment, as well as emergency care for traumas and other critical conditions. Clinic revenue includes services mainly focused on the care of outpatients covering primary and specialty health care needs. The Clinic's practice is to record certain radiology, pathology, and other hospital-related services in the

Note 3. Medical Service Revenue (Continued)

Midwest region as clinic revenue in the amount of \$973 and \$889 for the years ended December 31, 2021 and 2020, respectively. Examples of revenue at the time services are rendered include clinical services, lab and transport, and services transferred over time include hospital and senior care revenue.

The composition of medical service revenue by payor for the years ended December 31 is as follows:

	2021	2020
Medicare	\$ 3,377	\$ 2,833
Medicaid	475	373
Contract	7,705	6,779
Other, including self-pay	1,753	1,516
Total	<u>\$ 13,310</u>	<u>\$ 11,501</u>

The Clinic's practice is to assign a patient to the primary payor and not reflect other uninsured balances (for example, coinsurance and deductibles) as self-pay. Therefore, the payors listed above contain patient responsibility components, such as coinsurance and deductibles.

Financing Component

The Clinic has elected the practical expedient allowed under FASB ASU 2014-09, *Revenue from Contracts with Customers (Topic 606-10-32-18)* and does not adjust the promised amount of consideration from patients and third-party payors for the effects of a significant financing component due to the Clinic's expectation that the period between the time the service is provided to a patient and the time that the patient or a third-party payor pays for that service will be one year or less. However, the Clinic does, in certain instances, enter into payment agreements with patients that allow payments in excess of one year. For those cases, the financing component is not deemed to be significant to the contract.

Note 4. Fair Value Measurements

The Clinic holds certain financial instruments that are required to be measured at fair value on a recurring basis. The valuation techniques used to measure fair value under the *Fair Value Measurement (Topic 820)* of the FASB ASC are based upon observable and unobservable inputs. The standard establishes a three-level valuation hierarchy for disclosure of fair value measurements. The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows:

Level 1: Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 2: Inputs to the valuation methodology include quoted prices for similar assets or liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the same term of the financial instrument.

Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

Note 4. Fair Value Measurements (Continued)

A financial instrument's categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The Clinic's policy is to recognize transfers in and transfers out as of the actual date of the event or change in circumstances that caused the transfer. There were no significant transfers or activity within Levels for the years ended December 31, 2021 and 2020.

Notes to Consolidated Financial Statements (In Millions)

Note 4. Fair Value Measurements (Continued)

The following tables present the financial instruments carried at fair value as of December 31, 2021 and 2020, by caption on the consolidated statements of financial position categorized by the valuation hierarchy and NAV:

	December 31, 2021				Total Fair Value
	Level 1	Level 2	Level 3	NAV	
Assets:					
Securities lending collateral	\$ 6	\$ —	\$ —	\$ —	\$ 6
Investments:					
Cash and cash equivalents	2,593	238	—	—	2,831
Fixed-income securities:					
U.S. government	—	566	—	—	566
U.S. government agencies	—	551	—	—	551
U.S. corporate	—	832	—	—	832
Foreign	—	74	—	—	74
Common and preferred stocks:					
U.S.	1,077	—	—	—	1,077
Foreign	658	—	24	—	682
Funds:					
Fixed income	448	—	—	—	448
Equities	1,021	702	—	—	1,723
Less securities under lending agreement	(95)	—	—	—	(95)
Investments at NAV	—	—	—	9,237	9,237
Total investments	5,702	2,963	24	9,237	17,926
Investments under securities lending agreement	95	—	—	—	95
Other long-term assets:					
Trust receivables	82	32	93	—	207
Technology-based ventures	—	—	138	—	138
Total other long-term assets	82	32	231	—	345
Total assets at fair value	\$ 5,885	\$ 2,995	\$ 255	\$ 9,237	\$ 18,372
Liabilities:					
Securities lending payable	\$ 6	\$ —	\$ —	\$ —	6
Total liabilities at fair value	\$ 6	\$ —	\$ —	\$ —	\$ 6

Notes to Consolidated Financial Statements (In Millions)

Note 4. Fair Value Measurements (Continued)

	December 31, 2020				Total Fair Value
	Level 1	Level 2	Level 3	NAV	
Assets:					
Securities lending collateral	\$ 2	\$ —	\$ —	\$ —	\$ 2
Investments:					
Cash and cash equivalents	1,980	185	—	—	2,165
Fixed-income securities:					
U.S. government	—	450	—	—	450
U.S. government agencies	—	439	—	—	439
U.S. corporate	—	648	15	—	663
Foreign	—	46	—	—	46
Common and preferred stocks:					
U.S.	870	—	—	—	870
Foreign	529	—	25	—	554
Funds:					
Fixed income	451	10	—	—	461
Equities	830	590	—	—	1,420
Less securities under lending agreement	(38)	—	—	—	(38)
Investments at NAV	—	—	—	7,290	7,290
Total investments	4,622	2,368	40	7,290	14,320
Investments under securities lending agreement	38	—	—	—	38
Other long-term assets:					
Trust receivables	74	29	83	—	186
Technology-based ventures	—	—	81	—	81
Total other long-term assets	74	29	164	—	267
Total assets at fair value	\$ 4,736	\$ 2,397	\$ 204	\$ 7,290	\$ 14,627
Liabilities:					
Securities lending payable	\$ 2	\$ —	\$ —	\$ —	2
Total liabilities at fair value	\$ 2	\$ —	\$ —	\$ —	\$ 2

Note 4. Fair Value Measurements (Continued)

The following is a description of the Clinic's valuation methodologies for assets and liabilities measured at fair value. Fair value for Level 1 is based upon quoted market prices. Fair value for Level 2 is based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets and liabilities. Inputs are obtained from various sources, including market participants, dealers, and brokers. Level 3 primarily consists of trusts recorded at fair value based on the underlying value of the assets in the trust or discounted cash flow of the expected payment streams.

The trusts reported as Level 3 are primarily perpetual trusts managed by third parties invested in stocks, mutual funds, and fixed-income securities that are traded in active markets with observable inputs and, since the Clinic will never receive the trust assets, these perpetual trusts are reported as Level 3. In addition, technology-based ventures, composed primarily of shares in start-up companies, are recorded at fair value based on inputs relying on factors such as the financial performance of the company, sales performance, financial projections, sales projections, management representation, industry developments, market analysis, and any other pertinent factors that would affect the fair value or based on the quoted price of an otherwise identical unrestricted security of the same issuer, adjusted for the effect of the restriction.

The methods described above and those recorded at NAV may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Clinic believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.

The following information pertains to those alternative investments recorded at NAV in accordance with *Fair Value Measurement (Topic 820)* of the FASB ASC.

At December 31, 2021, alternative investments recorded at NAV consisted of the following:

	Fair Value	Unfunded Commitment	Redemption Frequency (If Currently Eligible)	Redemption Notice Period
Absolute return/hedge funds (a)	\$ 4,167	\$ 151	Monthly to annually	30–90 days
Private partnerships (b)	5,070	1,635		
Total alternative investments	<u>\$ 9,237</u>	<u>\$ 1,786</u>		

At December 31, 2020, alternative investments recorded at NAV consisted of the following:

	Fair Value	Unfunded Commitment	Redemption Frequency (If Currently Eligible)	Redemption Notice Period
Absolute return/hedge funds (a)	\$ 3,421	\$ 99	Monthly to annually	30–90 days
Private partnerships (b)	3,869	1,447		
Total alternative investments	<u>\$ 7,290</u>	<u>\$ 1,546</u>		

Note 4. Fair Value Measurements (Continued)

- (a) This category includes investments in absolute return/hedge funds, which are actively managed commingled investment vehicles that derive the majority of their returns from factors other than the directional flow of the markets in which they invest. Representative strategies include high-yield credit, distressed debt, merger arbitrage, relative value, and long-short equity strategies. The fair values of the investments in this category have been estimated using the NAV per share of the investments. Investments in this category generally carry “lockup” restrictions that do not allow investors to seek redemption in the first year after acquisition. Following the initial lockup period, liquidity is generally available monthly, quarterly, or annually following a redemption request. Over 90% of the investments in this category have at least annual liquidity.
- (b) This category includes limited partnership interests in closed-end funds that focus on venture capital, private equity, real estate, and resource-related strategies. The fair values of the investments in this category have been estimated using the NAV of the Clinic’s ownership interest in partners’ capital. Distributions from each fund will be received as the underlying investments of the funds are liquidated. It is estimated that the underlying assets of most funds will generally be liquidated over a seven- to ten-year period.

From time to time, the Clinic invests directly in certain derivative contracts that do not qualify for hedge accounting and are recorded at fair value in investments. Changes in fair value are reported as a component of net unrealized gains or losses in the investment returns. These contracts are used in the Clinic’s investment management program to minimize certain investment risks. During the years ended December 31, 2021 and 2020, the realized and unrealized loss from derivative contracts was not significant.

The carrying values of cash and cash equivalents, short-term investments, accounts receivable, other current assets, and accounts payable are reasonable estimates of their fair value due to the short-term nature of these financial instruments. The estimated fair value of long-term debt, based on quoted market prices for the same or similar issues (Level 2), was \$502 and \$572 more than its carrying value at December 31, 2021 and 2020, respectively. Other long-term assets and liabilities have a carrying value that approximates fair value.

The Clinic uses various external investment managers to diversify the investments. The largest allocation to any investment strategy manager as of December 31, 2021 and 2020, was \$831 (6.1%) and \$582 (5.7%), respectively.

The Clinic is required to maintain funds held by trustees under bond indentures and other arrangements. The trustee-held investments, which primarily consist of mutual funds, were \$1,044 and \$884, respectively, at December 31, 2021 and 2020, which includes segregated investments for deferred compensation plans of \$1,041 and \$882 at December 31, 2021 and 2020, respectively.

At December 31, 2021 and 2020, cash and mutual funds included segregated investments owned by Mayo Foundation for Medical Education and Research, a wholly owned subsidiary of the Clinic, for gift annuity reserves of \$131 and \$136, respectively.

The Clinic had internally designated investment balances of \$3,392 and \$2,806 at December 31, 2021 and 2020, respectively, for research, education, and capital replacement and expansion.

Notes to Consolidated Financial Statements (In Millions)

Note 5. Investments in Unconsolidated Entities (Continued)

The Clinic holds certain investments in unconsolidated entities accounted for in accordance with FASB Subtopic 323, *Investments – Equity Method and Joint Ventures*. The investments are presented as other long-term assets in the consolidated statements of financial position. The Clinic's interest in the investment income is reflected in the accompanying consolidated statements of operations.

The following table presents investments in unconsolidated entities as of December 31, 2021 and 2020:

	Ownership Percentage as of December 31, 2021	Carrying Value as of December 31, 2021	Carrying Value as of December 31, 2020
Sheikh Shakhbout Medical City	25%	\$ 89	\$ 87
Medically Home	32%	\$ 57	\$ —
Other investees	various	\$ 14	\$ 11

The Clinic entered into a joint venture agreement with Abu Dhabi Health Services Company PJSC to operate Sheikh Shakhbout Medical City (SSMC), a 741-bed hospital in the United Arab Emirates. In addition to the joint venture agreement, the Clinic has entered into a hospital expertise agreement, brand license agreement, and research contribution agreement with SSMC. The joint venture has an initial commitment period of 20 years and may be extended by 10 years. The Clinic had a \$150 conditional pledge from Sheikh Shakhbout Medical City at December 31, 2021 and 2020.

In July 2021, the Clinic entered into a joint venture agreement with Kaiser Permanente to invest in Medically Home to allow more patients to receive acute care and recovery services in the comfort, convenience, and safety of their homes. The Clinic's 32% equity position is accounted for using the equity method of accounting for investments.

The summarized financial position and results of operations for significant entities accounted for under the equity method as of and for the years ended consisted of the following:

	2021	2020
As of December 31		
Total assets	\$ 794	\$ 540
Total liabilities	\$ 194	\$ 224
Partners' equity/net assets	\$ 600	\$ 317
Year Ended December 31		
Total revenue	\$ 440	\$ 288
Loss from current activities	\$ (65)	\$ (140)

Note 6. Securities Lending

The Clinic has an arrangement with its investment custodian to lend Clinic securities to approved brokers in exchange for a fee. Among other provisions that limit the Clinic's risk, the securities lending agreement specifies that the custodian is responsible for lending securities and obtaining adequate collateral from the borrower. Collateral is limited to cash, government securities, and irrevocable letters of credit. Investments are loaned to various brokers and are returnable on demand. In exchange, the Clinic receives collateral. The cash collateral is shown as both an asset and a liability on the consolidated statements of financial position.

At December 31, 2021 and 2020, the aggregate market value of securities on loan under securities lending agreements totaled \$95 and \$38, respectively, and the total value of the collateral supporting the securities was \$98 and \$39, respectively, which represents 103% and 104%, respectively, of the value of the securities on loan at December 31, 2021 and 2020. The cash portion of the collateral supporting the securities as of December 31, 2021 and 2020, was \$6 and \$2, respectively. The cash portion is presented in other current assets and other current liabilities in the consolidated statements of financial position. Noncash collateral provided to the Clinic is not recorded in the consolidated statements of financial position, as the collateral may not be sold or repledged. The Clinic's claim on such collateral is limited to the market value of loaned securities. In the event of nonperformance by the other parties to the securities lending agreements, the Clinic could be exposed to a loss.

Note 7. Property, Plant, and Equipment, Net

Property, plant, and equipment, net, at December 31 consisted of the following:

	2021	2020
Land	\$ 489	\$ 316
Buildings and improvements	6,935	6,454
Furniture and equipment	4,347	4,249
	11,771	11,019
Accumulated depreciation and amortization	(6,899)	(6,506)
	4,872	4,513
Construction-in-progress	538	451
Total property, plant, and equipment	\$ 5,410	\$ 4,964

The above costs and accumulated depreciation include costs for capitalized software, including costs capitalized in accordance with *Intangibles—Goodwill and Other, Internal-Use Software (Topic 350)* of the FASB ASC. The total cost for capitalized software was \$874 and \$914 at December 31, 2021 and 2020, respectively. The total accumulated amortization was \$581 and \$558 at December 31, 2021 and 2020, respectively. Amortization expense for capitalized software was \$80 and \$81 for 2021 and 2020, respectively.

Note 8. Income Taxes

Most of the income received by the Clinic and its subsidiaries is exempt from taxation under Section 501(a) of the Internal Revenue Code. Some of its subsidiaries are taxable entities, and some of the income received by otherwise exempt entities is subject to taxation as unrelated business income. The Clinic and its subsidiaries file income tax returns in the U.S., including federal and various state returns, as well as certain foreign jurisdictions. The statutes of limitations for tax years 2018 through 2020 remain open in major U.S. taxing jurisdictions in which the Clinic and subsidiaries are subject to taxation.

The Internal Revenue Service (IRS) performed an examination of the tax and information returns of the Clinic and two subsidiaries and ultimately assessed \$12 in taxes for years 2003–2012. The results of this audit were ultimately litigated in the U.S. District Court. On August 6, 2019, the Court issued a summary judgment in favor of the Clinic. The IRS has appealed this decision. This ruling has been taken into consideration during the Clinic's determination of unrecognized tax benefits.

The Clinic has reduced the reserve for uncertain tax positions by \$7, including interest and penalties, during the year ended December 31, 2021. As of December 31, 2021 and 2020, the reserve totaled \$13 and \$20, respectively. It is not anticipated that a significant change in the reserve will occur over the next 12 months.

The Clinic's practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The components of tax expense are as follows:

	Year ended December 31	
	2021	2020
Current – federal	\$ 21	\$ 53
Current – state	5	7
	26	60
Deferred – U.S. domestic	(1)	(20)
Total	\$ 25	\$ 40

Cash payments for income taxes were \$63 and \$6 for the years ended December 31, 2021 and 2020, respectively.

Notes to Consolidated Financial Statements (In Millions)

Note 8. Income Taxes (Continued)

The Clinic records deferred income taxes due to temporary differences between financial reporting and tax reporting for certain assets and liabilities of its taxable activities. The following is a summary of the components of deferred taxes as of December 31:

	2021	2020
Deferred compensation	\$ 13	\$ 12
Pension	9	15
Postretirement benefits	6	7
Net operating loss	18	16
Other	8	11
Total deferred tax asset	54	61
Deferred tax liability	(4)	(7)
Valuation allowance	(14)	(13)
Net deferred tax asset	\$ 36	\$ 41

The Clinic had federal net operating losses of \$51 and \$46 at December 31, 2021 and 2020, respectively.

The Tax Cuts and Jobs Act (TCJA), enacted on December 22, 2017, repealed net operating loss (NOL) carrybacks while permitting indefinite carryforwards. The Coronavirus Aid, Relief, and Economic Security Act enacted on March 27, 2020, temporarily suspended TCJA repeal of NOL carrybacks, allowing for NOLs arising in tax years beginning after December 31, 2017 and before January 1, 2021, to be carried back to the five taxable years preceding the taxable year of such loss. The Clinic expects to fully utilize any NOLs arising in tax years beginning after December 31, 2018 and before January 1, 2022, within one or more of the five tax years preceding the tax year of such loss.

The Clinic's NOLs generated before January 1, 2020, were remeasured based on the rates at which they are expected to reverse in the carryback periods, which is generally 35%. At December 31, 2020, the provisional amount recorded related to the remeasurement of the deferred tax balance was \$5.

Notes to Consolidated Financial Statements (In Millions)

Note 9. Financing

Long-term debt at December 31 consisted of the following:

		2021	2020
City of Rochester, Minnesota Revenue Bonds issued in various series, subject to variable interest rates to a maximum rate of 15.00% (the average rate was 0.08% in 2021 and 0.60% in 2020), principal due in varying amounts from 2028 through 2052	Variable	\$ 545	\$ 545
City of Rochester, Minnesota Revenue Bonds originally issued at variable interest rate, converted in 2017 to fixed interest rate of 2.20% based on a provision to increase the rate if the federal tax rate is decreased, the rate has been adjusted to 2.67% effective January 1, 2018 through 2027, principal due in varying amounts from 2022 through 2032	Fixed	200	200
City of Rochester, Minnesota Revenue Bonds originally issued with fixed interest rate of 4.74%, converted in 2020 to fixed interest rate of 1.54% until 2030, principal due in varying amounts from 2033 through 2038	Fixed	130	130
City of Rochester, Minnesota Revenue Bonds issued in various series with fixed rates of interest ranging from 4.00% to 4.93%, principal due in varying amounts from 2030 through 2048	Fixed	400	535
City of Rochester, Minnesota Health Care Facilities Revenue Refunding Bonds, series 2016B, issued with fixed interest rate of 5.00%, an effective rate of 2.97% in 2021 and 2020 after amortization of premium, principal due in varying amounts from 2029 through 2036 (unamortized premium of \$50 in 2021 and \$55 in 2020)	Fixed	220	220
Industrial Development Authority of the City of Phoenix, Arizona issued in various series, subject to variable interest rates to a maximum rate of 10.00% (the average rate was 0.02% in 2021 and 0.41% in 2020), principal due in varying amounts from 2048 through 2052	Variable	180	180
City of Jacksonville, Florida Health Care Facilities Revenue Refunding Bonds, series 2016, issued in various series, subject to variable interest rates to a maximum rate of 10.00% (the average rate was 0.13% in 2021 and 0.81% in 2020), principal due in varying amounts from 2033 through 2047	Variable	125	125
Mayo Clinic Taxable Bonds issued with fixed interest rates ranging from 3.20% to 4.13%, principal due in varying amounts from 2039 through 2061	Fixed	1,450	950
Fixed-rate notes and bonds, payable to financial companies, interest rates at 1.80% to 4.71%, principal due in varying amounts from 2025 through 2062	Fixed	915	915
Other notes payable		12	13
Unamortized discounts and premiums, net		46	52
Debt issuance cost		(13)	(12)
		4,210	3,853
Long-term variable-rate debt classified as current		(620)	(620)
Long-term debt subject to mandatory tender for purchase		—	(135)
Current maturities included in other current liabilities		(38)	(1)
Long-term debt, net of current portion		\$ 3,552	\$ 3,097

Note 9. Financing (Continued)

The Clinic's outstanding revenue bond issues are limited obligations of various issuing authorities payable solely by the Clinic pursuant to loan agreements between the borrowing entities and the issuing authorities. Under various financing agreements, the Clinic must meet certain operating and financial performance covenants.

At December 31, 2021, the \$850 of variable-rate bonds consisted of variable-rate demand revenue bonds. In conjunction with the issuance of the variable-rate demand revenue bonds, the Clinic has entered into various bank standby purchase and credit agreements in the amount of \$230 of which \$140 will expire in January 2023 and \$90 will expire in January 2025. Under the terms of these agreements, the bank will make liquidity loans to the Clinic in the amount necessary to purchase a portion of the variable-rate demand revenue bonds if not remarketed. The liquidity loans would be payable over a three- to five-year period, with the first payment due after December 31, 2022. The Clinic has provided self-liquidity for the remaining \$620 of variable-rate demand revenue bonds, which have been classified as current in the accompanying consolidated statements of financial position.

The Clinic's \$135 City of Rochester, Minnesota Revenue Series 2011 C fixed-rate bonds were subject to mandatory tender for purchase on November 15, 2021, and, therefore, were classified as current at December 31, 2020. In November 2021, these bonds were paid off.

The \$220 fixed-rate revenue bonds Series 2016B are not callable. The remaining fixed-rate interest revenue bonds are callable from 2022 to 2058 at the option of the Clinic, at a redemption price of 100% of the principal amount or at a price based on U.S. Treasury rates at the time of redemption.

In April 2021, the Clinic issued bonds in the amount of \$500 with a 3.20% fixed rate of interest. The bonds are due in 2061 and will be used for general corporate purposes.

In April 2020, the Clinic entered into a five-year bank loan agreement for \$100 at 1.80%. In May 2020, the Clinic entered into a seven-year bank loan agreement for \$100 at 1.99%. Also in May, the Clinic closed on a private placement transaction with an insurance company in the amount of \$200 with a 3.17% fixed rate with a final maturity in 2062. In September 2020, the Clinic closed on a private placement transaction with an insurance company in the amount of \$100 million with a 3.16% interest rate with a final maturity in 2060. The proceeds of the private placement and bank loans will be used for general corporate purposes. In addition, in May 2020, the Clinic refunded and modified \$130 of bonds by entering into a direct bank purchase for 10 years at 1.54%. The bond modification was accounted for as an extinguishment of debt. The loss on extinguishment was not significant.

The following are scheduled maturities of long-term debt for each of the next five years, assuming the variable-rate demand revenue bonds are remarketed and the standby purchase agreements are renewed. As described above, if such bonds are not remarketed, \$620 may be due in 2022 and \$230 may be due in years from 2023 to 2025.

Years ending December 31:

2022	\$	38
2023		36
2024		18
2025		105
2026		5

Notes to Consolidated Financial Statements (In Millions)

Note 9. Financing (Continued)

Interest payments on long-term debt, net of amounts capitalized for 2021 and 2020, totaled \$118 and \$106, respectively. The amount of interest capitalized, net of related interest income, was \$3 during 2021 and 2020. Interest expense totaled \$121 and \$112 for 2021 and 2020, respectively.

At December 31, 2021 and 2020, the Clinic had unsecured lines of credit available with banks that totaled \$530, with varying renewable terms and interest up to 2.50% over various published rates. There were no amounts drawn during the years ended December 31, 2021 and 2020.

Note 10. Leases

At December 31, 2021 and 2020, the Clinic had operating and finance leases for facilities and certain equipment with lease terms ranging from 1 to 20 years, with some options to extend up to five years or terminate within one year.

Total lease expense for the years ended December 31 consisted of the following:

	2021	2020
Operating lease expense	\$ 34	\$ 37
Finance lease expense:		
Amortization of right-of-use assets	\$ 10	\$ 10
Interest on lease liabilities	1	1
Total finance lease expense	\$ 11	\$ 11
Short-term lease expense	\$ 24	\$ 17

Consolidated supplemental cash flow information related to leases as of December 31 consisted of the following:

	2021	2020
Cash paid for amounts included in the measurement of lease liabilities:		
Operating cash flows for operating leases	\$ 55	\$ 53
Operating cash flows for finance leases	\$ 1	\$ 1
Financing cash flows for finance leases	\$ 6	\$ 15
Right-of-use assets obtained in exchange for lease obligations:		
Operating leases	\$ 21	\$ 11
Finance leases	\$ 4	\$ 12

Notes to Consolidated Financial Statements (In Millions)

Note 10. Leases (Continued)

Consolidated supplemental statement of financial position information related to leases as of the year ended December 31 consisted of the following:

	2021	2020
Operating leases:		
Right-of-use assets	\$ 151	\$ 168
Other current liabilities	\$ 25	\$ 28
Other long-term liabilities	131	143
Total operating lease liabilities	\$ 156	\$ 171

	2021	2020
Finance leases:		
Property, plant, and equipment, gross	\$ 62	\$ 72
Accumulated depreciation	38	32
Property, plant, and equipment, net	\$ 24	\$ 40
Other current liabilities	\$ 6	\$ 9
Other long-term liabilities	16	27
Total finance lease liabilities	\$ 22	\$ 36

Weighted average remaining lease years:

Operating leases	9.85	10.02
Finance leases	4.70	8.06

Weighted average discount rate:

Operating leases	3.37 %	3.54 %
Finance leases	3.04 %	3.49 %

Notes to Consolidated Financial Statements (In Millions)

Note 10. Leases (Continued)

Maturities of lease liabilities for the next five years and thereafter consist of the following:

	Operating	Finance
2022	\$ 29	\$ 6
2023	23	5
2024	21	5
2025	18	3
2026	15	2
Thereafter	82	3
Minimum lease payments	188	24
Less amount representing interest	32	2
Net minimum lease payments	\$ 156	\$ 22

Note 11. Board-Designated Funds

Board-designated funds are subject to expenditure for the following purposes for the years ended December 31:

	2021	2020
Research	\$ 1,545	\$ 1,269
Education	358	296
Buildings and equipment	4	3
Charity care	14	11
Clinical	190	166
Other	1,281	1,061
Total designation for specified purpose	\$ 3,392	\$ 2,806

At December 31, board-designated funds were classified as follows:

	2021	2020
Quasi-endowments	\$ 3,218	\$ 2,694
Professional liability reserve	141	112
Other	\$ 33	\$ —
Total	\$ 3,392	\$ 2,806

Notes to Consolidated Financial Statements (In Millions)

Note 12. Net Assets With Donor Restrictions

The Clinic receives contributions in support of research, education, and clinical activities. Net assets with donor restrictions were available for the following purposes at December 31:

	2021	2020
Subject to expenditure for specified purposes:		
Research	\$ 497	\$ 443
Education	46	42
Buildings and equipment	174	226
Charity care	30	36
Clinical	65	58
Other	53	37
Total expenditure for specified purposes	865	842
Subject to passage of time:		
Pledges and trusts	649	470
Endowments:		
Perpetual in nature:		
Research	1,140	1,078
Education	270	229
Charity care	14	14
Clinical	215	195
Other	33	29
Pledges and trusts	274	293
Total perpetual in nature	1,946	1,838
Subject to endowment spending policy:		
Research	1,028	670
Education	433	320
Charity care	59	36
Clinical	206	135
Other	50	38
Total subject to endowment spending policy	1,776	1,199
Total endowments	3,722	3,037
Total net assets with donor restrictions	\$ 5,236	\$ 4,349

Note 12. Net Assets With Donor Restrictions (Continued)

Net assets were released from donor restrictions as expenditures were made, which satisfied the following restricted purposes for the years ended December 31:

	2021	2020
Research	\$ 188	\$ 162
Education	22	22
Buildings and equipment	197	22
Other	23	40
Total net assets released from donor restrictions	\$ 430	\$ 246

Note 13. Endowment

The Clinic's endowment consists of approximately 2,300 individual funds established for a variety of purposes. The endowment includes both donor-restricted endowment funds and funds designated by the Board of Trustees to function as endowments (quasi-endowments). Net assets associated with endowment funds, including quasi endowments, are classified and reported based on the existence or absence of donor-imposed restrictions. The Board of Trustees retains the right to redesignate quasi endowments for other purposes.

The Board of Trustees of the Clinic has interpreted the Minnesota State Prudent Management of Institutional Funds Act (SPMIFA) as requiring the preservation of the fair value of the original gift as of the gift date of the donor-restricted endowment funds, absent explicit donor stipulations to the contrary. As a result of this interpretation, the Clinic retains in perpetuity: (a) the original value of gifts donated to the permanent endowment, (b) the original value of subsequent gifts to the perpetual endowment, and (c) accumulations to the perpetual endowment made in accordance with the direction of the applicable donor gift instrument at the time the accumulation is added to the fund.

In accordance with SPMIFA, the Clinic considers the following factors in making a determination to appropriate or accumulate donor-restricted funds:

1. The duration and preservation of the fund
2. The purposes of the Clinic and the donor-restricted endowment fund
3. General economic conditions
4. The possible effects of inflation and deflation
5. The expected total return from income and the appreciation of investments
6. Other resources of the Clinic
7. The investment policies of the Clinic

The Clinic has adopted investment and spending policies for endowment assets that attempt to provide a predictable stream of funding to programs supported by its endowment, while seeking to maintain purchasing power of the endowment assets. Endowment assets include those assets of donor-restricted funds that the Clinic must hold in perpetuity or for a donor-specified period(s), as well as quasi-endowments. Under this policy, as approved by the Board of Trustees, the endowment assets are invested in a manner that is intended to produce a real return, net of inflation and investment management costs, of at least 5% over the long term. Actual returns in any given year may vary from this amount.

Note 13. Endowment (Continued)

To satisfy its long-term rate-of-return objectives, the Clinic relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized) and current yield (interest and dividends). The Clinic targets a diversified asset allocation that places a greater emphasis on equity-based and alternative investments to achieve its long-term objective within prudent risk constraints.

The Clinic has a policy of appropriating for distribution each year 5% of its endowment fund's moving average fair value over the prior 36 months as of September 30 of the preceding year in which the distribution is planned. In establishing this policy, the Clinic considered the long-term expected return on its endowment. Accordingly, over the long term, the Clinic expects the current spending policy to allow its endowment to grow at an average of the long-term rate of inflation. This is consistent with the Clinic's objective to maintain the purchasing power of the endowment assets held in perpetuity or for a specific term, as well as to provide additional real growth through new gifts and investment return.

At December 31, 2021, the endowment net asset composition by type of fund consisted of the following:

	Without Donor Restrictions	With Donor Restrictions	Total
Donor-restricted funds	\$ —	\$ 3,722	\$ 3,722
Quasi-endowments	3,218	—	3,218
Total funds	\$ 3,218	\$ 3,722	\$ 6,940

Changes in endowment net assets for the year ended December 31, 2021, consisted of the following:

	Without Donor Restrictions	With Donor Restrictions	Total
Endowment net assets, beginning of year	\$ 2,694	\$ 3,037	\$ 5,731
Investment return:			
Investment income	40	42	82
Net appreciation (realized and unrealized)	581	640	1,221
Total investment return	621	682	1,303
Contributions	—	108	108
Appropriation of endowment assets for expenditure	(119)	(105)	(224)
Other changes:			
Transfers to create quasi-endowments	22		22
Endowment net assets, end of year	\$ 3,218	\$ 3,722	\$ 6,940

Notes to Consolidated Financial Statements (In Millions)

Note 13. Endowment (Continued)

At December 31, 2020, the endowment net asset composition by type of fund consisted of the following:

	Without Donor Restrictions	With Donor Restrictions	Total
Donor-restricted funds	\$ —	\$ 3,037	\$ 3,037
Quasi-endowments	2,694	—	2,694
Total funds	\$ 2,694	\$ 3,037	\$ 5,731

Changes in endowment net assets for the year ended December 31, 2020, consisted of the following:

	Without Donor Restrictions	With Donor Restrictions	Total
Endowment net assets, beginning of year	\$ 2,286	\$ 2,723	\$ 5,009
Investment return:			
Investment income	20	20	40
Net appreciation (realized and unrealized)	345	351	696
Total investment return	365	371	736
Contributions	—	47	47
Appropriation of endowment assets for expenditure	(104)	(104)	(208)
Other changes:			
Transfers to create quasi endowments	147	—	147
Endowment net assets, end of year	\$ 2,694	\$ 3,037	\$ 5,731

Note 14. Promises to Give

At December 31, outstanding pledges from various corporations, foundations, and individuals, included in other receivables and other long-term assets, were as follows:

	2021	2020
Pledges due:		
In less than one year	\$ 294	\$ 234
In one to five years	399	362
In more than five years	35	45
	728	641
Allowance for uncollectible pledges and discounts	(34)	(72)
Total	\$ 694	\$ 569

Notes to Consolidated Financial Statements (In Millions)

Note 14. Promises to Give (Continued)

Estimated cash flows from pledge receivables due after one year are discounted using a risk-adjusted rate, ranging from 1% to 6%, that is commensurate with the pledges' due dates and established in the year the pledge is received.

The Clinic has received interests in various trusts, primarily split interest, which are included in other long-term assets. The trusts are recorded at fair value, based on the underlying value of the assets in the trust or discounted cash flow using a risk-adjusted discount rate of 2.91% and 3.56% at December 31, 2021 and 2020, respectively. During the years ended December 31, 2021 and 2020, there were no contributions recorded related to the split-interest trusts. The balance of the expected payment streams was \$207 and \$186 at December 31, 2021 and 2020, respectively.

Note 15. Functional Expenses

The consolidated financial statements present certain expenses that are attributed to more than one program or supporting function. Therefore, expenses require allocation on a reasonable basis that is consistently applied. Benefits and payroll taxes are allocated based on factors of either salary expense or hours worked. Overhead costs that include professional services, office expenses, information technology, interest, insurance, and other similar expenses are allocated based on a variety of factors, including revenues, hours worked, and salary expense. Costs related to space, including occupancy, depreciation and amortization, and property taxes, are allocated on a square footage basis.

The expenses reported in the consolidated statements of activities for the years ended December 31, 2021 and 2020, supported the following programs and functions:

	2021							
	Patient Care	Lab and Technology Ventures	Research	Graduate and Other Education	General and Administrative	Development Expenses	Other Activities	Total Expenses
Salaries and benefits	\$ 7,330	\$ 187	\$ 653	\$ 331	\$ 103	\$ 16	\$ 41	\$ 8,661
Supplies and services	3,299	1,048	258	61	24	8	69	4,767
Depreciation and amortization	515	8	66	11	15	1	3	619
Facilities	264	4	18	12	26	1	1	326
Finance and investment	150	3	18	1	1	—	(29)	144
Total	\$ 11,558	\$ 1,250	\$ 1,013	\$ 416	\$ 169	\$ 26	\$ 85	\$ 14,517

	2020							
	Patient Care	Lab and Technology Ventures	Research	Graduate and Other Education	General and Administrative	Development Expenses	Other Activities	Total Expenses
Salaries and benefits	\$ 6,750	\$ 174	\$ 609	\$ 307	\$ 52	\$ 19	\$ 43	\$ 7,954
Supplies and services	2,726	1,006	223	52	14	6	72	4,099
Depreciation and amortization	513	8	64	12	11	1	2	611
Facilities	227	5	16	11	15	1	1	276
Finance and investment	138	1	18	1	1	—	(27)	132
Total	\$ 10,354	\$ 1,194	\$ 930	\$ 383	\$ 93	\$ 27	\$ 91	\$ 13,072

Note 16. Employee Benefit Programs

The Clinic serves as plan sponsor for several defined benefit pension funds and other postretirement benefits.

Included in other changes in unrestricted net assets at December 31, 2021 and 2020, are the following amounts, respectively, that have not yet been recognized in net periodic cost: unrecognized actuarial losses of \$3,053 and \$4,837 and unrecognized prior service benefit of \$109 and \$160. Actuarial losses are amortized as a component of net periodic pension cost, only if the losses exceed 10% of the greater of the projected benefit obligation or the fair value of plan assets. Unrecognized prior service benefits are amortized on a straight-line basis over the estimated life of plan participants.

Changes in plan assets and benefit obligations recognized in unrestricted net assets during 2021 and 2020 included the following:

	2021	2020
Current-year actuarial gain (loss)	\$ 1,440	\$ (701)
Amortization of actuarial loss	338	274
Amortization of prior service credit	(50)	(69)
Pension and other postretirement benefit adjustments	<u>\$ 1,728</u>	<u>\$ (496)</u>

Pension Plans

Obligations and funded status: The following is a summary of the changes in the benefit obligation and plan assets, the resulting funded status of the qualified and nonqualified pension plans, and accumulated benefit obligation as of and for the years ended December 31:

	2021	2020
Change in projected benefit obligation:		
Benefit obligation, beginning of year	\$ 12,360	\$ 10,705
Service cost	691	553
Interest cost	350	371
Actuarial (gain) loss	(302)	1,388
Benefits paid	(905)	(657)
Estimated benefit obligation at end of year	<u>\$ 12,194</u>	<u>\$ 12,360</u>
Change in plan assets:		
Fair value of plan assets, beginning of year	\$ 10,642	\$ 9,334
Actual return on plan assets	1,793	1,409
Employer contributions	373	556
Benefits paid	(905)	(657)
Fair value of plan assets at end of year	<u>\$ 11,903</u>	<u>\$ 10,642</u>

Note 16. Employee Benefit Programs (Continued)

	2021	2020
Funded status of the plans	\$ (291)	\$ (1,718)
Accumulated benefit obligation	\$ (11,441)	\$ (11,596)

Amounts recognized in the consolidated statements of financial position consist of the following at December 31:

	2021	2020
Noncurrent liabilities	\$ (291)	\$ (1,718)
Net amount recognized	\$ (291)	\$ (1,718)

Components of net periodic benefit cost are as follows at December 31:

	2021	2020
Service cost	\$ 691	\$ 553
Interest cost	350	371
Expected return on plan assets	(732)	(678)
Amortization of unrecognized:		
Prior service benefit	(50)	(50)
Net actuarial loss	306	244
Net periodic benefit cost	\$ 565	\$ 440

Plan assets: The largest of the pension funds is the Mayo Clinic Master Retirement Trust Plan, which holds \$11,765 of the \$11,903 in combined plan assets at December 31, 2021, and \$10,519 of the \$10,642 in combined plan assets at December 31, 2020. The investment policies described below apply to the Mayo Clinic Master Retirement Trust Plan (the Plan).

The Plan employs a global, multi-asset approach in managing its retirement plan assets. This approach is designed to maximize risk-adjusted returns over a long-term investment horizon, consistent with the nature of the pension liabilities being funded. The plan asset portfolio's target allocation for total return investment strategies, which include public equities, private equities, absolute return, and real assets, is 82.5%. The portfolio's target fixed-income exposure is 17.5%. The fixed-income exposure may include the use of long-term interest rate swap contracts structured to increase the portfolio's interest rate sensitivity and thereby provide a hedge of the plan liabilities resulting from falling long-term interest rates. Investments in private equities, real assets, and absolute return strategies are held to improve diversification and thereby enhance long-term, risk-adjusted returns. However, recognizing that these investments are not as liquid as publicly traded stocks and bonds, portfolio investment policies limit

Notes to Consolidated Financial Statements (In Millions)

Note 16. Employee Benefit Programs (Continued)

overall exposure to these assets. The portfolio's allocation to private equities and real assets is limited to a maximum of 30% (with a target allocation of 22.5%), and exposure to absolute return strategies is limited to a maximum of 35% (with a target of 27.5%). The Clinic reviews performance, asset allocation, and risk management reports for plan asset portfolios on a monthly basis.

The fair values of the Plan's assets at December 31, 2021, by asset category, are as follows:

Assets	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	NAV	Total
Cash and cash equivalents	\$ 518	\$ 61	\$ —	\$ —	\$ 579
Fixed-income securities:					
U.S. government	—	170	—	—	170
U.S. government agencies	—	120	—	—	120
U.S. corporate	—	400	—	—	400
Foreign	—	52	—	—	52
Common and preferred stocks:					
U.S.	1,077	—	—	—	1,077
Foreign	645	—	—	—	645
Funds:					
Fixed income	114	—	—	—	114
Equities	65	718	—	—	783
Foreign	69	—	—	—	69
Investments at NAV	—	—	—	7,756	7,756
Total investments	\$ 2,488	\$ 1,521	\$ —	\$ 7,756	\$ 11,765

Assets	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	NAV	Total
Cash and cash equivalents	\$ 616	\$ 41	\$ —	\$ —	\$ 657
Fixed-income securities:					
U.S. government	—	146	—	—	146
U.S. government agencies	—	126	—	—	126
U.S. corporate	—	406	5	—	411
Foreign	—	33	—	—	33
Common and preferred stocks:					
U.S.	926	—	—	—	926
Foreign	639	—	—	—	639
Funds:					
Fixed income	132	10	—	—	142
Equities	42	654	—	—	696
Foreign	79	—	—	—	79
Investments at NAV	—	—	—	6,664	6,664
Total investments	\$ 2,434	\$ 1,416	\$ 5	\$ 6,664	\$ 10,519

Note 16. Employee Benefit Programs (Continued)

The following is a description of the Plan's valuation methodologies for assets and liabilities measured at fair value. Fair value for Level 1 is based upon quoted market prices. Fair value for Level 2 is based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Inputs are obtained from various sources, including market participants, dealers, and brokers.

A financial instrument's categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The Clinic's policy is to recognize transfers in and transfers out as of the actual date of the event or change in circumstances that caused the transfer. There were no significant transfers in 2021 or 2020.

The methods described above and those recorded at NAV may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.

The following information pertains to those alternative investments recorded at NAV in accordance with *Fair Value Measurement (Topic 820)* of the FASB ASC.

At December 31, 2021, alternative investments recorded at NAV consisted of the following:

	Fair Value	Unfunded Commitment	Redemption Frequency (If Currently Eligible)	Redemption Notice Period
Absolute return/hedge funds (a)	\$ 3,996	\$ 151	Monthly to annually	30–90 days
Private partnerships (b)	3,760	1,245		
	<u>\$ 7,756</u>	<u>\$ 1,396</u>		

At December 31, 2020, alternative investments recorded at NAV consisted of the following:

	Fair Value	Unfunded Commitment	Redemption Frequency (If Currently Eligible)	Redemption Notice Period
Absolute return/hedge funds (a)	\$ 3,613	\$ 99	Monthly to annually	30–90 days
Private partnerships (b)	3,051	1,281		
	<u>\$ 6,664</u>	<u>\$ 1,380</u>		

Note 16. Employee Benefit Programs (Continued)

- (a) This category includes investments in absolute return/hedge funds, which are actively managed commingled investment vehicles that derive the majority of their returns from factors other than the directional flow of the markets in which they invest. Representative strategies include high-yield credit, distressed debt, merger arbitrage, relative value, and long-short equity strategies. The fair values of the investments in this category have been estimated using the NAV per share of the investments. Investments in this category generally carry “lockup” restrictions that do not allow investors to seek redemption in the first year after acquisition. Following the initial lockup period, liquidity is generally available monthly, quarterly, or annually following a redemption request. Over 90% of the investments in this category have at least annual liquidity.
- (b) This category includes limited partnership interests in closed-end funds that focus on venture capital, private equity, real estate, and resource-related strategies. The fair values of the investments in this category have been estimated using the NAV of the Plan’s ownership interest in partners’ capital. These investments cannot be redeemed with the funds. Distributions from each fund will be received as the underlying investments of the funds are liquidated. It is estimated that the underlying assets of most funds will generally be liquidated over a seven- to ten-year period.

No plan assets are expected to be returned to the employer during 2022.

Other Postretirement Benefits

Obligations and funded status: A summary of the changes in the benefit obligation and plan assets and the resulting funded status of the other postretirement plans is as follows as of and for the years ended December 31:

	2021	2020
Change in projected benefit obligation:		
Benefit obligation at beginning of year	\$ 1,228	\$ 1,180
Service cost	9	9
Interest cost	32	39
Plan participants’ contributions	35	31
Amendments	—	—
Medicare subsidy	3	3
Actuarial (gain) loss	(82)	46
Benefits paid	(87)	(80)
Estimated benefit obligation at end of year	<u>\$ 1,138</u>	<u>\$ 1,228</u>
Change in plan assets:		
Fair value of plan assets at beginning of year	\$ —	\$ —
Employer contributions	52	49
Plan participants’ contributions	35	31
Medicare subsidy	—	—
Benefits paid	(87)	(80)
Fair value of plan assets at end of year	<u>\$ —</u>	<u>\$ —</u>
Funded status of the plan	<u>\$ (1,138)</u>	<u>\$ (1,228)</u>

Notes to Consolidated Financial Statements (In Millions)

Note 16. Employee Benefit Programs (Continued)

Amounts recognized in the consolidated statements of financial position for postretirement benefits consist of the following at December 31:

	2021	2020
Current liabilities	\$ (51)	\$ (49)
Noncurrent liabilities	(1,087)	(1,179)
Net amount recognized	<u>\$ (1,138)</u>	<u>\$ (1,228)</u>

Components of net periodic benefit cost for other postretirement benefits are as follows for the years ended December 31:

	2021	2020
Service cost	\$ 9	\$ 9
Interest cost	32	39
Amortization of:		
Unrecognized prior service benefit	—	(19)
Unrecognized net actuarial loss	32	30
Net periodic benefit cost for other postretirement benefits	<u>\$ 73</u>	<u>\$ 59</u>

The Clinic has concluded that the prescription drug benefits under its defined benefit postretirement plan are actuarially equivalent to Medicare Part D under the Medicare Modernization Act (the Act) and that the Clinic will receive the subsidy available under the Act.

The following reflects the expected future Medicare Part D subsidy receipts:

Years ending December 31:

2022	\$ 3
2023	3
2024	3
2025	3
2026	3
2027–2031	3

Plan trend rates are the annual rates of increase expected for the benefits payable from the plan; these rates include health care cost trends plus the leveraging effect of plan design. The assumed plan trend rate is 5.50%.

Note 16. Employee Benefit Programs (Continued)**Pension and postretirement benefits:**

Assumptions: Weighted average assumptions used to determine pension and postretirement benefit obligations at the measurement date are as follows:

	Pension Benefits		Postretirement Benefits	
	2021	2020	2021	2020
Discount rate	3.12%	2.91%	3.04%	2.70%
Rate of compensation increase	3.72%	3.70%	N/A	N/A

Weighted average assumptions used to determine net periodic pension and postretirement benefit cost are as follows:

	Pension Benefits		Postretirement Benefits	
	2021	2020	2021	2020
Discount rate	2.91%	3.56%	2.70%	3.41%
Expected long-term return on plan assets	7.50%	7.50%	N/A	N/A
Rate of compensation increase	3.70%	3.58%	N/A	N/A

The Clinic utilizes a building block approach in determining the expected long-term rate of return for its plan assets. First, historical data on individual asset class returns are studied. Next, the historical correlation among and between asset class returns is studied under both normal conditions and in times of market turbulence. Then, various mixes of asset classes are considered under multiple long-term investment scenarios. Finally, after considering liquidity concerns related to the use of certain alternative asset classes, the plan sponsor selects the portfolio blend that it believes will produce the highest expected long-term return on a risk-adjusted basis.

Cash Flows

Contributions: The Clinic expects to contribute \$388 to its pension plans in 2022.

Estimated future benefit payments: The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid:

	Pension Benefits	Postretirement Benefits
Years ending December 31:		
2022	\$ 673	\$ 51
2023	615	53
2024	613	56
2025	626	57
2026	650	59
2027–2031	3,271	310

Note 16. Employee Benefit Programs (Continued)

In addition to the defined benefit plans, the Clinic sponsors various defined contribution benefit plans. Expense recognized by the Clinic for those plans was \$124 and \$117 for 2021 and 2020, respectively.

Note 17. General and Professional Liability Insurance

The Clinic insures substantially all general and professional liability risks through a combination of a wholly owned captive insurance company and self-insurance. The insurance program combines various levels of self-insured retention with excess commercial insurance coverage. Actuarial consultants have been retained to assist in the estimation of outstanding general and professional liability losses.

The Clinic's general and professional liability as reported in the accompanying consolidated statements of financial position was \$133 and \$118 at December 31, 2021 and 2020, respectively. Provisions for the general and professional liability risks are based on an actuarial estimate of losses using the Clinic's actual loss data, adjusted for industry trends and current conditions, and considering an evaluation of claims by the Clinic's legal counsel. The provision includes estimates of ultimate costs for both reported claims and claims incurred but not reported.

Activity in the liability is summarized as follows for the years ended December 31:

	2021	2020
Balance, beginning of year	\$ 118	\$ 111
Incurred related to captive insurance company liability:		
Current year	29	26
Prior years	—	(4)
Total incurred	29	22
Paid related to captive insurance company liability:		
Current year	(2)	—
Prior years	(10)	(19)
Total paid	(12)	(19)
Net change in self-insurance liability	(2)	4
Balance, end of year	\$ 133	\$ 118

Notes to Consolidated Financial Statements (In Millions)

Note 18. Other Receivables, Other Current and Long-Term Assets, and Other Current and Long-Term Liabilities

At December 31, other receivables consisted of the following:

	2021	2020
Pledges receivable	\$ 294	\$ 234
Grants receivable	134	134
Rebates receivable	38	21
Other tax receivable	33	31
Interest receivable	16	9
Royalty receivable	15	15
Other	118	132
Total other receivables	<u>\$ 648</u>	<u>\$ 576</u>

At December 31, other current assets consisted of the following:

	2021	2020
Inventories	\$ 203	\$ 186
Prepaid expenses	108	66
Other	6	2
Total other current assets	<u>\$ 317</u>	<u>\$ 254</u>

At December 31, other long-term assets consisted of the following:

	2021	2020
Pledges receivable	\$ 400	\$ 335
Trust receivables	207	186
Oil and gas interests	191	165
Investments in unconsolidated entities	160	98
Operating lease right-of-use asset	151	168
Technology-based ventures	138	81
Long-term portion of deferred tax asset	36	41
Notes receivable	16	21
Prepaid maintenance	14	14
Other	94	95
Total other long-term assets	<u>\$ 1,407</u>	<u>\$ 1,204</u>

Notes to Consolidated Financial Statements (In Millions)

Note 18. Other Receivables, Other Current and Long-Term Assets, and Other Current and Long-Term Liabilities (Continued)

At December 31, other current liabilities consisted of the following:

	2021	2020
Other taxes	\$ 83	\$ 81
Oil and gas liability	81	85
Current portion of long-term disability	42	38
Current portion of professional and general liability	38	35
Current maturities of long-term debt	38	1
Short-term disability	36	33
Medicare settlements liability	34	25
Real estate tax accrual	28	28
Operating lease liability	25	28
Refunds/recoupments	21	21
Accrued interest	15	14
Current portion of workers' compensation liability	11	11
Finance lease liability	6	9
Other	51	63
Total other current liabilities	<u>\$ 509</u>	<u>\$ 472</u>

At December 31, other long-term liabilities consisted of the following:

	2021	2020
Deferred compensation	\$ 1,041	\$ 882
Long-term disability	226	211
Operating lease liability	131	143
Electronic medical record	101	105
Professional and general liability	95	83
Retirement community obligations	86	87
Deferred gain	74	56
Gift annuities	67	67
Trust obligations	55	53
Asset retirement obligation	55	52
Financing obligations	53	54
Workers' compensation liability	32	32
Contract deposit	22	22
Finance lease liability	16	27
Other	79	90
Total other long-term liabilities	<u>\$ 2,133</u>	<u>\$ 1,964</u>

Notes to Consolidated Financial Statements (In Millions)

Note 19. Other Revenue

For the years ended December 31, other revenue consisted of the following:

	2021	2020
Retail pharmacy sales	\$ 436	\$ 393
Royalties	166	129
Oil- and gas-producing activities	101	46
Retail stores	67	57
Technology commercialization, health information, and medical products	52	49
Graduate medical and other education revenue	35	22
Cafeteria revenue	29	26
Provider relief funds and other support	1	199
Other	244	190
Total other revenue	\$ 1,131	\$ 1,111

Note 20. Commitments and Contingencies

The Clinic has various construction projects in progress related to patient care, research, and educational facilities. The estimated costs committed to complete the various projects at December 31, 2021, is \$1,316, all of which is expected to be expended over the next three to five years.

While the Clinic is self-insured for a substantial portion of its general and workers' compensation liabilities, the Clinic maintains commercial insurance coverage against catastrophic loss. Additionally, the Clinic maintains a self-insurance program for its long-term disability coverage. The provision for estimated self-insured claims includes estimates of the ultimate costs for both reported claims and claims incurred but not reported.

The Clinic is a defendant in various lawsuits arising in the ordinary course of business and records an estimated liability for probable claims. Although the outcome of these lawsuits cannot be predicted with certainty, management believes the ultimate disposition of such matters will not have a material effect on the Clinic's consolidated financial position or consolidated statement of activities.

Note 21. COVID-19

In March 2020, the World Health Organization declared the novel coronavirus disease (COVID-19) a pandemic. The Center for Disease Control confirmed its spread to the United States and declared a national public health emergency. The Clinic was well-prepared and continues to treat patients with COVID-19 across the organization, especially those with serious or complex medical conditions. However, COVID-19 could still negatively affect the operating margins and financial results of the Clinic, as the duration of the pandemic is unknown.

Notes to Consolidated Financial Statements (In Millions)

Note 22. U.S. Department of Education Financial Responsibility Ratio Information

The following information is required by the U.S. Department of Education for the years ended December 31,

	2021	2020
Net assets with temporary donor restrictions	\$ 3,290	\$ 2,511
Intangible assets	\$ 1	\$ 1
Post-employment and retirement liabilities:		
Accrued pension and postretirement benefits, net of current portion	\$ 1,378	\$ 2,897
Postretirement benefits, current portion	51	49
Total post-employment and retirement liabilities	\$ 1,429	\$ 2,946
Property, plant, and equipment, including construction-in-progress and right-of-use asset, net of accumulated depreciation:		
Property, plant, and equipment, net	\$ 5,410	\$ 4,964
Right-of-use asset	151	168
Total property, plant, and equipment, including construction in progress and right-of-use asset, net of accumulated depreciation	\$ 5,561	\$ 5,132
Long-term debt obtained for long term purposes:		
Long-term debt	\$ 4,210	\$ 3,853
Operating lease liabilities	156	171
Finance lease liabilities	22	36
Total long-term debt obtained for long-term purposes	\$ 4,388	\$ 4,060
Expenses and losses without donor restrictions:		
Operating expenses	\$ 14,517	\$ 13,072
Contributions not available for current activities, net	22	21
Income tax expense	25	40
Other	125	110
Pension and other postretirement benefit adjustments	—	496
Total expenses and losses without donor restrictions	\$ 14,689	\$ 13,739
Revenue without donor restrictions:		
Total revenue, gains, and other support	\$ 15,882	\$ 13,756
Unallocated investment return, net	1,432	1,254
Benefit credit	61	62
Pension and other postretirement benefit adjustments	1,728	—
Other	1	4
Total revenue without donor restrictions	\$ 19,104	\$ 15,076

Supplementary Information

Mayo Clinic

Financial Responsibility Supplemental Schedule Required by the U.S. Department of Education Year Ended December 31, 2021 (In Millions)

Ratio Element	Reference to Financial Statements or Notes	2021
Primary reserve ratio		
Expendable net assets		
Net assets without donor restrictions	Consolidated Statements of Financial Position	\$ 12,431
Net assets with temporary donor restrictions	Note 23 – U.S. Department of Education	3,290
Term endowments with donor restrictions	Note 12 – Net Assets with Donor Restrictions	1,776
Intangible assets	Note 23 – U.S. Department of Education	1
Property, plant, and equipment, including construction-in-progress, and right-of-use asset, net of accumulated depreciation	Note 23 – U.S. Department of Education	5,561
Long-term debt obtained for long-term purposes	Note 23 – U.S. Department of Education	4,388
Post-employment and retirement liabilities	Note 23 – U.S. Department of Education	1,429
Total expenses and losses		
Total expenses and losses without donor restrictions	Note 23 – U.S. Department of Education	14,689
Equity ratio		
Modified net assets		
Net assets with and without donor restrictions	Consolidated Statements of Financial Position	17,667
Intangible assets	Note 23 – U.S. Department of Education	1
Modified assets		
Total assets	Consolidated Statements of Financial Position	27,675
Intangible assets	Note 23 – U.S. Department of Education	1
Net income ratio		
Change in net assets without donor restrictions	Consolidated Statements of Activities	4,415
Total revenue without donor restrictions	Note 23 – U.S. Department of Education	19,104

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2021 - 12/31/2021

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
DEPARTMENT OF COMMERCE									
CLUSTER GRANTS	11.020	ED19HDQ0200083				\$393,208	\$393,208	N/A	\$0
TOTAL DEPARTMENT OF COMMERCE						\$393,208			
DEPARTMENT OF DEFENSE									
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	BMT CTN 1702	NATIONAL MARROW DONOR PROGRAM	BMT CTN 1702		\$45,017	\$8,147,382	RESEARCH AND DEVELOPMENT	\$404,219,504
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	BMT CTN 1703/1801	NATIONAL MARROW DONOR PROGRAM	BMT CTN 1703/1801		\$39,406	\$8,147,382	RESEARCH AND DEVELOPMENT	\$404,219,504
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	BMT CTN 1704	NATIONAL MARROW DONOR PROGRAM	BMT CTN 1704		\$37,866	\$8,147,382	RESEARCH AND DEVELOPMENT	\$404,219,504
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-18-D-7001			\$214,424	\$572,196	\$8,147,382	RESEARCH AND DEVELOPMENT	\$404,219,504
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-19-C-2007			\$494,991	\$3,972,085	\$8,147,382	RESEARCH AND DEVELOPMENT	\$404,219,504
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-19-C-2017			\$93,812	\$2,030,096	\$8,147,382	RESEARCH AND DEVELOPMENT	\$404,219,504
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-19-C-2017				\$843,078	\$8,147,382	RESEARCH AND DEVELOPMENT	\$404,219,504
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-20-1-2726				\$607,638	\$8,147,382	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-0317	CEDARS SINAI MEDICAL CENTER	W81XWH-0317		\$143,645	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-0810			\$288,798	\$303,548	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-14-2-0003	WAKE FOREST	W81XWH-14-2-0003		\$36,922	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-15-1-0115				\$173,232	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-15-1-0269	BRIGHAM AND WOMEN'S HOSPITAL	W81XWH-15-1-0269		\$186,274	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-15-1-0292				\$130,708	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-15-1-0293			\$517,000	\$1,278,742	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-15-1-0705	UNIVERSITY OF ALABAMA AT BIRMINGHAM	W81XWH-15-1-0705		\$3,934	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-15-2-0071			\$47,028	\$47,028	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-1-0265				\$251,468	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-1-0266				\$220,735	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-1-0268				\$208,898	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-1-0269				\$218,815	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-1-0540				\$365,535	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0248				\$124,962	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0249				\$237,796	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0498				\$12,310	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0644	MASSACHUSETTS EYE & EAR INFIRMARY	W81XWH-17-1-0644		\$618	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-2-0037	UNIVERSITY OF ALABAMA AT BIRMINGHAM	W81XWH-17-2-0037		\$10,152	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-2-0073	UNIVERSITY OF PITTSBURGH	W81XWH-17-2-0073		\$48,761	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0074				\$69,383	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0297				\$139,319	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0345				\$154,473	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0563				\$714,898	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0564				\$501,055	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0577	UNIVERSITY OF MINNESOTA	W81XWH-18-1-0577		\$5,695	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0650				\$117,434	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0652				\$206,963	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0676				\$310,924	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0760			\$215,302	\$349,348	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0021				\$109,340	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0029				\$437,636	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0081				\$79,022	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0139	CONTRAFECT CORPORATION	W81XWH-19-1-0139		\$452,397	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0193			\$84,604	\$198,920	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0491	MD ANDERSON CANCER CENTER	W81XWH-19-1-0491		\$6,358	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0534				\$1,852,600	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0583				\$831,852	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0680				\$354,199	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0756				\$241,771	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-2-0042	WASHINGTON UNIVERSITY	W81XWH-19-2-0042		\$35,138	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0214				\$401,858	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0215				\$156,322	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0262			\$57,778	\$318,717	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0322				\$143,435	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0400				\$732,025	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2021 - 12/31/2021

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0432	UNIVERSITY OF MARYLAND BALTIMORE	W81XWH-20-1-0432		\$25,884	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0600	HOUSTON METHODIST RESEARCH	W81XWH-20-1-0600		\$15,067	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0662				\$100,560	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0682	UNIVERSITY OF MINNESOTA	W81XWH-20-1-0682		\$88,500	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0752				\$154,672	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0886				\$255,331	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0903			\$11,484	\$391,925	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0923			\$200,042	\$442,682	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-9-0021	WASHINGTON UNIVERSITY	W81XWH-20-9-0021		\$20,284	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-C-0104	TREADMETRIX	W81XWH-20-C-0104		\$110,711	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0063				\$161,796	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0082				\$358,388	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0182			\$57,531	\$171,322	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0405				\$81,018	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0475				\$120,689	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0480	UNIVERSITY OF PITTSBURGH MEDICAL CENTER	W81XWH-21-1-0480		\$113,911	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0489				\$110,994	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0624				\$34,697	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0704				\$40,766	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0705				\$6,702	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0706				\$18,690	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0798				\$42,382	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0867				\$27,011	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0888				\$8,078	\$15,827,225	RESEARCH AND DEVELOPMENT	\$404,219,504
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910	DARPA	UNIVERSITY OF OXFORD	DARPA		\$133,378	\$133,378	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	12.RD	75D30119C06088			\$174,518	\$226,652	\$7,162,422	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	12.RD	75D30120C07725	CHILDRENS HOSPITAL OF BOSTON	75D30120C07725		\$30,832	\$7,162,422	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	12.RD	75F40119C10080	DUKE UNIVERSITY	75F40119C10080		\$11,467	\$7,162,422	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	12.RD	75F40119D10037	HARVARD PILGRIM HEALTH CARE	75F40119D10037		\$749	\$7,162,422	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	12.RD	75FCMC18D0047	MITRE CORPORATION	75FCMC18D0047		\$3,675	\$7,162,422	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	12.RD	75N91019D00024	UNIVERSITY OF MASSACHUSETTS	75N91019D00024		\$3,148	\$7,162,422	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	12.RD	75N91021C00012	WESTAT	75N91021C00012		\$14,848	\$7,162,422	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	12.RD	75N91021P00840				\$6,933	\$7,162,422	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	12.RD	75N92021P00132				\$19,101	\$7,162,422	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	12.RD	75N93019C00052	UNIVERSITY OF GEORGIA	75N93019C00052		\$191,392	\$7,162,422	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	12.RD	CRB-SSS-5-21-006050	SOCIAL AND SCIENTIFIC SYSTEMS	CRB-SSS-5-21-006050		\$77,756	\$7,162,422	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	12.RD	F-2020-102	UNIVERSITY OF NEBRASKA MEDICAL CENTER	F-2020-102		\$15	\$7,162,422	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	12.RD	FA864921P0717	SPARK NEURO INC.	FA864921P0717		\$7,774	\$7,162,422	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	12.RD	FA8650-19-C-6979				\$340,647	\$7,162,422	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	12.RD	H98230-13-D-0123			\$131,100	\$1,817,063	\$7,162,422	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	12.RD	H98230-18-D-0024			\$100,000	\$3,117,560	\$7,162,422	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	12.RD	HHS-D-2000-2013-M538908	ABT ASSOCIATES INC.	HHS-D-2000-2013-M538908		\$3,000	\$7,162,422	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	12.RD	MTEC 2020-625				\$861,471	\$7,162,422	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	12.RD	N66001-12-D-0088				\$2,031	\$7,162,422	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	12.RD	N68936-19-C-0003				\$4,548	\$7,162,422	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	12.RD	N68936-19-C-0003				\$11,922	\$7,162,422	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	12.RD	SSS #1	SOCIAL AND SCIENTIFIC SYSTEMS	SSS #1		\$9,672	\$7,162,422	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	12.RD	UF-WARS5	UNIVERSITY OF FLORIDA	UF-WARS5		\$20,170	\$7,162,422	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	12.RD	W81XWH-17-C-0029	THE GENEVA FOUNDATION	W81XWH-17-C-0029		\$64,908	\$7,162,422	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	12.RD	W81XWH-20-1-0171	SOUTHWEST AUTISM RESEARCH & RESOURCE CENTER	W81XWH-20-1-0171		\$32,415	\$7,162,422	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	12.RD	W81XWH-20-1-0930	UNIVERSITY OF NEW MEXICO	W81XWH-20-1-0930		\$32,691	\$7,162,422	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	12.RD	W81XWH-20-9-0024	FLOSONICS MEDICAL	W81XWH-20-9-0024		\$105,406	\$7,162,422	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	12.RD	W81XWH-20-C-0013	ENGINEERING & COMPUTER SIMULATIONS, INC.	W81XWH-20-C-0013		\$38,603	\$7,162,422	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	12.RD	W81XWH-21-1-0428				\$5,029	\$7,162,422	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	12.RD	W81XWH-21-1-0490				\$36,329	\$7,162,422	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	12.RD	W81XWH-21-1-0678				\$39,012	\$7,162,422	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	12.RD	W81XWH-21-C-0025	VIVONICS, INC.	W81XWH-21-C-0025		\$25,603	\$7,162,422	RESEARCH AND DEVELOPMENT	\$404,219,504
TOTAL DEPARTMENT OF DEFENSE						\$3,296,534	\$31,270,407		

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2021 - 12/31/2021

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
SUPPORTIVE HOUSING FOR THE ELDERLY	14.157	SUPPORTIVE HOUSING FOR THE ELDERLY				\$604,177	\$604,177	N/A	\$0
SECTION 8 HOUSING CHOICE VOUCHERS	14.871	SECTION 8 HOUSING CHOICE VOUCHERS				\$205,692	\$205,692	HOUSING VOUCHER CLUSTER	\$205,692
TOTAL DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT						<u>\$809,869</u>			
DEPARTMENT OF JUSTICE									
NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT GRANTS	16.560	2020-75-CX-0015				\$175,290	\$175,290	RESEARCH AND DEVELOPMENT	\$404,219,504
CRIME VICTIM ASSISTANCE	16.575	CRIME VICTIM ASSISTANCE				\$125,866	\$125,866	N/A	\$0
TOTAL DEPARTMENT OF JUSTICE						<u>\$301,156</u>			
NATIONAL AERONAUTICS & SPACE ADMINISTRATION									
SCIENCE	43.001	80NSSC20K0116				\$13,215	\$271,593	RESEARCH AND DEVELOPMENT	\$404,219,504
SCIENCE	43.001	80NSSC21C0256	LUNA INNOVATION INCORPORATED	80NSSC21C0256		\$16,169	\$271,593	RESEARCH AND DEVELOPMENT	\$404,219,504
SCIENCE	43.001	80NSSC21K0299				\$242,209	\$271,593	RESEARCH AND DEVELOPMENT	\$404,219,504
EXPLORATION	43.003	80NSSC21K0175				\$47,828	\$47,828	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	43.RD	80JSC019P0041			\$50,312	\$113,986	\$147,551	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	43.RD	80NSSC20C0529	AGNI MEDICAL LLC	80NSSC20C0529		\$33,565	\$147,551	RESEARCH AND DEVELOPMENT	\$404,219,504
TOTAL NATIONAL AERONAUTICS & SPACE ADMINISTRATION					\$50,312	<u>\$466,972</u>			
NATIONAL SCIENCE FOUNDATION									
ENGINEERING	47.041	NSF 2026152	ODONATA MEDICAL	NSF 2026152		\$318	\$318	RESEARCH AND DEVELOPMENT	\$404,219,504
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	NSF #9	GEORGIA INSTITUTE OF TECHNOLOGY	NSF #9		\$101,310	\$111,383	RESEARCH AND DEVELOPMENT	\$404,219,504
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	NSF 2113360				\$10,073	\$111,383	RESEARCH AND DEVELOPMENT	\$404,219,504
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	NSF 1602198				\$13,619	\$540,812	RESEARCH AND DEVELOPMENT	\$404,219,504
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	NSF 1624615				\$90,663	\$540,812	RESEARCH AND DEVELOPMENT	\$404,219,504
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	NSF 1837572				\$97,290	\$540,812	RESEARCH AND DEVELOPMENT	\$404,219,504
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	NSF 1901046	PURDUE UNIVERSITY	NSF 1901046		\$14,686	\$540,812	RESEARCH AND DEVELOPMENT	\$404,219,504
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	NSF 2002540	UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN	NSF 2002540		\$950	\$540,812	RESEARCH AND DEVELOPMENT	\$404,219,504
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	NSF 2041339				\$271,138	\$540,812	RESEARCH AND DEVELOPMENT	\$404,219,504
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	NSF 2123900				\$52,466	\$540,812	RESEARCH AND DEVELOPMENT	\$404,219,504
BIOLOGICAL SCIENCES	47.074	NSF 1744098			\$63,331	\$167,463	\$191,172	RESEARCH AND DEVELOPMENT	\$404,219,504
BIOLOGICAL SCIENCES	47.074	NSF 23494	IOWA STATE UNIVERSITY	NSF 23494		\$23,709	\$191,172	RESEARCH AND DEVELOPMENT	\$404,219,504
EDUCATION AND HUMAN RESOURCES	47.076	NSF GRFP18				\$21,298	\$54,679	RESEARCH AND DEVELOPMENT	\$404,219,504
EDUCATION AND HUMAN RESOURCES	47.076	NSF GRFP19				\$33,381	\$54,679	RESEARCH AND DEVELOPMENT	\$404,219,504
OFFICE OF INTERNATIONAL SCIENCE AND ENGINEERING	47.079	OISE-20-66590	UNIVERSITY OF WISCONSIN-MADISON	OISE-20-66590		\$50,729	\$82,666	RESEARCH AND DEVELOPMENT	\$404,219,504
OFFICE OF INTERNATIONAL SCIENCE AND ENGINEERING	47.079	OISE-9531011	CIVILIAN RESEARCH AND DEVELOPMENT FOUNDATION	OISE-9531011		\$31,937	\$82,666	RESEARCH AND DEVELOPMENT	\$404,219,504
TOTAL NATIONAL SCIENCE FOUNDATION					\$63,331	<u>\$981,030</u>			
DEPARTMENT OF VETERANS AFFAIRS									
CONTRACT	64.RD	IPA AGREEMENT - KAUFMAN				\$49,065	\$143,521	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	64.RD	IPA AGREEMENT-MORROW				\$18,349	\$143,521	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	64.RD	IPA AGREEMENT-PERSAD				\$76,107	\$143,521	RESEARCH AND DEVELOPMENT	\$404,219,504
TOTAL DEPARTMENT OF VETERANS AFFAIRS						<u>\$143,521</u>			
DEPARTMENT OF ENERGY									
OFFICE OF SCIENCE FINANCIAL ASSISTANCE PROGRAM	81.049	DE-SC0021630	UNIVERSITY OF MASSACHUSETTS	DE-SC0021630		\$5,000	\$5,000	RESEARCH AND DEVELOPMENT	\$404,219,504
ADVANCED RESEARCH PROJECTS AGENCY - ENERGY	81.135	AR0001316	SYRACUSE UNIVERSITY	AR0001316		\$32,362	\$32,362	RESEARCH AND DEVELOPMENT	\$404,219,504
TOTAL DEPARTMENT OF ENERGY						<u>\$37,362</u>			

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2021 - 12/31/2021

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
DEPARTMENT OF EDUCATION									
FEDERAL PELL GRANT PROGRAM	84.063	FEDERAL PELL GRANT PROGRAM				\$49,370	\$49,370	STUDENT FINANCIAL ASSISTANCE	\$14,969,045
FEDERAL DIRECT STUDENT LOANS	84.268	FEDERAL DIRECT STUDENT LOANS				\$14,919,675	\$14,919,675	STUDENT FINANCIAL ASSISTANCE	\$14,969,045
COVID-19 EDUCATION STABILIZATION FUND	84.425	COVID-19, 84.425E CARES ACT				\$171,706	\$1,440,714	N/A	\$0
COVID-19 EDUCATION STABILIZATION FUND	84.425	COVID-19, 84.425E CARES ACT GRANT 041020				\$575,507	\$1,440,714	N/A	\$0
COVID-19 EDUCATION STABILIZATION FUND	84.425	COVID-19, 84.425F CARES ACT RELIEF INSTL FUNDS				\$693,501	\$1,440,714	N/A	\$0
TOTAL DEPARTMENT OF EDUCATION						<u>\$16,409,759</u>			
DEPARTMENT OF HEALTH AND HUMAN SERVICES									
BLOOD DISORDER PROGRAM: PREVENTION, SURVEILLANCE, AND RESEARCH	93.080	NU27DD000020	GREAT LAKES HEMOPHILIA FOUNDATION	NU27DD000020		\$23,544	\$23,544	RESEARCH AND DEVELOPMENT	\$404,219,504
FOOD AND DRUG ADMINISTRATION, RESEARCH	93.103	FD005320	CRITICAL PATH INSTITUTE	FD005320	\$49,547	\$250,000	\$2,672,028	RESEARCH AND DEVELOPMENT	\$404,219,504
FOOD AND DRUG ADMINISTRATION, RESEARCH	93.103	FD006102	ARIZONA STATE UNIVERSITY	FD006102		\$103,251	\$2,672,028	RESEARCH AND DEVELOPMENT	\$404,219,504
FOOD AND DRUG ADMINISTRATION, RESEARCH	93.103	FD006102				\$75,802	\$2,672,028	RESEARCH AND DEVELOPMENT	\$404,219,504
FOOD AND DRUG ADMINISTRATION, RESEARCH	93.103	FD05938	YALE UNIVERSITY	FD05938	\$1,907	\$1,285,333	\$2,672,028	RESEARCH AND DEVELOPMENT	\$404,219,504
FOOD AND DRUG ADMINISTRATION, RESEARCH	93.103	FD06102				\$154,657	\$2,672,028	RESEARCH AND DEVELOPMENT	\$404,219,504
FOOD AND DRUG ADMINISTRATION, RESEARCH	93.103	FD06292	MEDICAL DEVICE INNOVATION	FD06292	\$109,458	\$582,357	\$2,672,028	RESEARCH AND DEVELOPMENT	\$404,219,504
FOOD AND DRUG ADMINISTRATION, RESEARCH	93.103	FD07290				\$87,029	\$2,672,028	RESEARCH AND DEVELOPMENT	\$404,219,504
FOOD AND DRUG ADMINISTRATION, RESEARCH	93.103	FD07472				\$70,065	\$2,672,028	RESEARCH AND DEVELOPMENT	\$404,219,504
FOOD AND DRUG ADMINISTRATION, RESEARCH	93.103	FD5938	YALE UNIVERSITY	FD5938		\$23,307	\$2,672,028	RESEARCH AND DEVELOPMENT	\$404,219,504
FOOD AND DRUG ADMINISTRATION, RESEARCH	93.103	FD7288				\$38,687	\$2,672,028	RESEARCH AND DEVELOPMENT	\$404,219,504
FOOD AND DRUG ADMINISTRATION, RESEARCH	93.103	FD7483	UNIVERSITY OF MINNESOTA	FD7483		\$1,540	\$2,672,028	RESEARCH AND DEVELOPMENT	\$404,219,504
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	MC24052	GREAT LAKES HEMOPHILIA FOUNDATION	MC24052		\$7,033	\$7,033	RESEARCH AND DEVELOPMENT	\$404,219,504
ORAL DISEASES AND DISORDERS RESEARCH	93.121	DE28096	UNIVERSITY OF NEW MEXICO	DE28096		\$18,551	\$470,884	RESEARCH AND DEVELOPMENT	\$404,219,504
ORAL DISEASES AND DISORDERS RESEARCH	93.121	DE28105				\$433,388	\$470,884	RESEARCH AND DEVELOPMENT	\$404,219,504
ORAL DISEASES AND DISORDERS RESEARCH	93.121	DE29632	RECOMBINETICS, INC.	DE29632		\$2,402	\$470,884	RESEARCH AND DEVELOPMENT	\$404,219,504
ORAL DISEASES AND DISORDERS RESEARCH	93.121	DE29754	UNIVERSITY OF NORTH CAROLINA	DE29754		\$16,543	\$470,884	RESEARCH AND DEVELOPMENT	\$404,219,504
GRANTS TO INCREASE ORGAN DONATIONS	93.134	EHS32756	ARBOR RESEARCH COLLABORATIVE	EHS32756		\$9,261	\$34,431	RESEARCH AND DEVELOPMENT	\$404,219,504
GRANTS TO INCREASE ORGAN DONATIONS	93.134	HS33878	UNIVERSITY OF KANSAS MEDICAL CENTER	HS33878		\$25,170	\$34,431	RESEARCH AND DEVELOPMENT	\$404,219,504
HUMAN GENOME RESEARCH	93.172	HG06379			\$123,524	\$1,110,336	\$1,649,500	RESEARCH AND DEVELOPMENT	\$404,219,504
HUMAN GENOME RESEARCH	93.172	HG06834	BRIGHAM AND WOMENS HOSPITAL	HG06834		\$140,685	\$1,649,500	RESEARCH AND DEVELOPMENT	\$404,219,504
HUMAN GENOME RESEARCH	93.172	HG08988	UNIVERSITY OF LOUISVILLE	HG08988		\$4,967	\$1,649,500	RESEARCH AND DEVELOPMENT	\$404,219,504
HUMAN GENOME RESEARCH	93.172	HG09542	RESEARCH FOUNDATION			\$194,228	\$1,649,500	RESEARCH AND DEVELOPMENT	\$404,219,504
HUMAN GENOME RESEARCH	93.172	HG09668	CASE WESTERN RESERVE UNIVERSITY	HG09668		\$24,763	\$1,649,500	RESEARCH AND DEVELOPMENT	\$404,219,504
HUMAN GENOME RESEARCH	93.172	HG11662			\$40,172	\$95,415	\$1,649,500	RESEARCH AND DEVELOPMENT	\$404,219,504
HUMAN GENOME RESEARCH	93.172	HG11710				\$56,448	\$1,649,500	RESEARCH AND DEVELOPMENT	\$404,219,504
HUMAN GENOME RESEARCH	93.172	HG11899				\$2,620	\$1,649,500	RESEARCH AND DEVELOPMENT	\$404,219,504
HUMAN GENOME RESEARCH	93.172	HG9668	CASE WESTERN RESERVE	HG9668		\$20,038	\$1,649,500	RESEARCH AND DEVELOPMENT	\$404,219,504
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	DC019564				\$13,931	\$1,105,388	RESEARCH AND DEVELOPMENT	\$404,219,504
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	DC12519				\$562,408	\$1,105,388	RESEARCH AND DEVELOPMENT	\$404,219,504
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	DC13256	UNIVERSITY OF CALIFORNIALOS ANGELES	DC13256		\$17,639	\$1,105,388	RESEARCH AND DEVELOPMENT	\$404,219,504
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	DC14942				\$491,831	\$1,105,388	RESEARCH AND DEVELOPMENT	\$404,219,504
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	DC19475	ARIZONA STATE UNIVERSITY	DC19475		\$19,579	\$1,105,388	RESEARCH AND DEVELOPMENT	\$404,219,504
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	AI134590	IMMUNOGEN X	AI134590		\$89,953	\$569,565	RESEARCH AND DEVELOPMENT	\$404,219,504
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	AT010875				\$372,477	\$569,565	RESEARCH AND DEVELOPMENT	\$404,219,504
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	AT09665	MINNESOTA HEALTHSOLUTIONS CORPORATION	AT09665		\$77,160	\$569,565	RESEARCH AND DEVELOPMENT	\$404,219,504

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2021 - 12/31/2021

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	AT09844	NEW YORK SCHOOL OF MEDICINE	AT09844		\$29,975	\$569,565	RESEARCH AND DEVELOPMENT	\$404,219,504
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	75Q80120D00005			\$32,078	\$353,083	\$1,856,796	RESEARCH AND DEVELOPMENT	\$404,219,504
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS23418	DUKE UNIVERSITY	HS23418		\$12,853	\$1,856,796	RESEARCH AND DEVELOPMENT	\$404,219,504
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS24075	DARTMOUTH COLLEGE	HS24075		\$16,014	\$1,856,796	RESEARCH AND DEVELOPMENT	\$404,219,504
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS25164	UNIVERSITY OF MINNESOTA	HS25164		\$6,715	\$1,856,796	RESEARCH AND DEVELOPMENT	\$404,219,504
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS25402				\$198,854	\$1,856,796	RESEARCH AND DEVELOPMENT	\$404,219,504
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS25412	VIRGINIA COMMONWEALTH UNIVERSITY	HS25412		\$99,825	\$1,856,796	RESEARCH AND DEVELOPMENT	\$404,219,504
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS25713	UNIVERSITY OF WISCONSIN MADISON	HS25713		\$9,633	\$1,856,796	RESEARCH AND DEVELOPMENT	\$404,219,504
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS26379	UNIVERSITY OF MINNESOTA	HS26379		\$205,011	\$1,856,796	RESEARCH AND DEVELOPMENT	\$404,219,504
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS26609			\$52,100	\$796,282	\$1,856,796	RESEARCH AND DEVELOPMENT	\$404,219,504
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS26622	UNIVERSITY OF MICHIGAN	HS26622		\$153,210	\$1,856,796	RESEARCH AND DEVELOPMENT	\$404,219,504
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS28060				\$5,316	\$1,856,796	RESEARCH AND DEVELOPMENT	\$404,219,504
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	HL134808				\$969,776	\$969,788	RESEARCH AND DEVELOPMENT	\$404,219,504
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	HL134885				\$303,790	\$969,788	RESEARCH AND DEVELOPMENT	\$404,219,504
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	HL152948	INNOVATIVE DESIGN LABS INC.	HL152948		\$12,429	\$969,788	RESEARCH AND DEVELOPMENT	\$404,219,504
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	HL65176				\$183,793	\$969,788	RESEARCH AND DEVELOPMENT	\$404,219,504
MENTAL HEALTH RESEARCH GRANTS	93.242	MH106876	YALE UNIVERSITY	MH106876		\$18,676	\$1,706,687	RESEARCH AND DEVELOPMENT	\$404,219,504
MENTAL HEALTH RESEARCH GRANTS	93.242	MH108348	DUKE UNIVERSITY	MH108348		\$26,013	\$1,706,687	RESEARCH AND DEVELOPMENT	\$404,219,504
MENTAL HEALTH RESEARCH GRANTS	93.242	MH109190	MINNESOTA HEALTHSOLUTIONS CORPORATION	MH109190		\$41,401	\$1,706,687	RESEARCH AND DEVELOPMENT	\$404,219,504
MENTAL HEALTH RESEARCH GRANTS	93.242	MH109648	YALE UNIVERSITY	MH109648		\$19,404	\$1,706,687	RESEARCH AND DEVELOPMENT	\$404,219,504
MENTAL HEALTH RESEARCH GRANTS	93.242	MH113700			\$197,205	\$652,366	\$1,706,687	RESEARCH AND DEVELOPMENT	\$404,219,504
MENTAL HEALTH RESEARCH GRANTS	93.242	MH114967	RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC.	MH114967		\$347,161	\$1,706,687	RESEARCH AND DEVELOPMENT	\$404,219,504
MENTAL HEALTH RESEARCH GRANTS	93.242	MH121191	HARVARD SCHOOL OF PUBLIC HEALTH	MH121191		\$52,219	\$1,706,687	RESEARCH AND DEVELOPMENT	\$404,219,504
MENTAL HEALTH RESEARCH GRANTS	93.242	MH121924				\$355,206	\$1,706,687	RESEARCH AND DEVELOPMENT	\$404,219,504
MENTAL HEALTH RESEARCH GRANTS	93.242	MH124655			\$44,022	\$194,241	\$1,706,687	RESEARCH AND DEVELOPMENT	\$404,219,504
ALCOHOL RESEARCH PROGRAMS	93.273	AA20735	UNIVERSITY OF NEBRASKA	AA20735		\$279,473	\$4,655,630	RESEARCH AND DEVELOPMENT	\$404,219,504
ALCOHOL RESEARCH PROGRAMS	93.273	AA21171				\$356,140	\$4,655,630	RESEARCH AND DEVELOPMENT	\$404,219,504
ALCOHOL RESEARCH PROGRAMS	93.273	AA21788				\$400,594	\$4,655,630	RESEARCH AND DEVELOPMENT	\$404,219,504
ALCOHOL RESEARCH PROGRAMS	93.273	AA26875				\$176,479	\$4,655,630	RESEARCH AND DEVELOPMENT	\$404,219,504
ALCOHOL RESEARCH PROGRAMS	93.273	AA26877				\$116,071	\$4,655,630	RESEARCH AND DEVELOPMENT	\$404,219,504
ALCOHOL RESEARCH PROGRAMS	93.273	AA26886				\$104,058	\$4,655,630	RESEARCH AND DEVELOPMENT	\$404,219,504
ALCOHOL RESEARCH PROGRAMS	93.273	AA26887				\$172,551	\$4,655,630	RESEARCH AND DEVELOPMENT	\$404,219,504
ALCOHOL RESEARCH PROGRAMS	93.273	AA26974				\$458,131	\$4,655,630	RESEARCH AND DEVELOPMENT	\$404,219,504
ALCOHOL RESEARCH PROGRAMS	93.273	AA27179			\$148,749	\$444,491	\$4,655,630	RESEARCH AND DEVELOPMENT	\$404,219,504
ALCOHOL RESEARCH PROGRAMS	93.273	AA27486				\$547,429	\$4,655,630	RESEARCH AND DEVELOPMENT	\$404,219,504
ALCOHOL RESEARCH PROGRAMS	93.273	AA27487			\$401,121	\$1,149,298	\$4,655,630	RESEARCH AND DEVELOPMENT	\$404,219,504
ALCOHOL RESEARCH PROGRAMS	93.273	AA27773				\$72,160	\$4,655,630	RESEARCH AND DEVELOPMENT	\$404,219,504
ALCOHOL RESEARCH PROGRAMS	93.273	AA28050				\$121,737	\$4,655,630	RESEARCH AND DEVELOPMENT	\$404,219,504
ALCOHOL RESEARCH PROGRAMS	93.273	AA28968				\$58,350	\$4,655,630	RESEARCH AND DEVELOPMENT	\$404,219,504
ALCOHOL RESEARCH PROGRAMS	93.273	AA29258				\$198,668	\$4,655,630	RESEARCH AND DEVELOPMENT	\$404,219,504
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	DA37299				\$44,479	\$730,454	RESEARCH AND DEVELOPMENT	\$404,219,504
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	DA40316	HENNEPIN HEALTHCARE RESEACH	DA40316		\$9,206	\$730,454	RESEARCH AND DEVELOPMENT	\$404,219,504
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	DA42492				\$430,504	\$730,454	RESEARCH AND DEVELOPMENT	\$404,219,504
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	DA46008			\$45,030	\$118,603	\$730,454	RESEARCH AND DEVELOPMENT	\$404,219,504
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	DA47003	YALE UNIVERSITY	DA47003		\$127,662	\$730,454	RESEARCH AND DEVELOPMENT	\$404,219,504
CENTERS FOR DISEASE CONTROL AND PREVENTION, INVESTIGATIONS AND TECHNICAL ASSISTANCE	93.283	DP06491				\$915,831	\$915,831	RESEARCH AND DEVELOPMENT	\$404,219,504
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB001981				\$407,511	\$5,687,870	RESEARCH AND DEVELOPMENT	\$404,219,504
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB017095				\$12,544	\$5,687,870	RESEARCH AND DEVELOPMENT	\$404,219,504
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB17095				\$719,899	\$5,687,870	RESEARCH AND DEVELOPMENT	\$404,219,504
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB17197				\$375,891	\$5,687,870	RESEARCH AND DEVELOPMENT	\$404,219,504
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB17270	THE RESEARCH FOUNDATION FOR SUNY	EB17270		\$7,300	\$5,687,870	RESEARCH AND DEVELOPMENT	\$404,219,504
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB18965			\$15,188	\$15,188	\$5,687,870	RESEARCH AND DEVELOPMENT	\$404,219,504
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB19403				\$576,927	\$5,687,870	RESEARCH AND DEVELOPMENT	\$404,219,504
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB21027	UNIVERSITY OF MINNESOTA	EB21027		\$34,649	\$5,687,870	RESEARCH AND DEVELOPMENT	\$404,219,504

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2021 - 12/31/2021

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB24403			\$74,614	\$180,811	\$5,687,870	RESEARCH AND DEVELOPMENT	\$404,219,504
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB24450			\$119,480	\$568,661	\$5,687,870	RESEARCH AND DEVELOPMENT	\$404,219,504
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB26284	UNIVERSITY OF SOUTHERN CALIFORNIA	EB26284		\$163,412	\$5,687,870	RESEARCH AND DEVELOPMENT	\$404,219,504
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB26780			\$3,465	\$139,878	\$5,687,870	RESEARCH AND DEVELOPMENT	\$404,219,504
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB26976	GE CAPITAL	EB26976		\$275,510	\$5,687,870	RESEARCH AND DEVELOPMENT	\$404,219,504
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB27064				\$386,825	\$5,687,870	RESEARCH AND DEVELOPMENT	\$404,219,504
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB27100	STANFORD UNIVERSITY	EB27100		\$21,781	\$5,687,870	RESEARCH AND DEVELOPMENT	\$404,219,504
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB27742				\$53,598	\$5,687,870	RESEARCH AND DEVELOPMENT	\$404,219,504
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB28101			\$30,079	\$41,460	\$5,687,870	RESEARCH AND DEVELOPMENT	\$404,219,504
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB28590				\$752,345	\$5,687,870	RESEARCH AND DEVELOPMENT	\$404,219,504
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB28591				\$436,203	\$5,687,870	RESEARCH AND DEVELOPMENT	\$404,219,504
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB28936				\$301,165	\$5,687,870	RESEARCH AND DEVELOPMENT	\$404,219,504
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB30529				\$216,312	\$5,687,870	RESEARCH AND DEVELOPMENT	\$404,219,504
SMALL RURAL HOSPITAL IMPROVEMENT GRANT PROGRAM	93.301	435400-A21				\$166,079	\$223,218	N/A	\$0
SMALL RURAL HOSPITAL IMPROVEMENT GRANT PROGRAM	93.301	886K012				\$14,174	\$223,218	N/A	\$0
SMALL RURAL HOSPITAL IMPROVEMENT GRANT PROGRAM	93.301	H3HRH00007				\$30,424	\$223,218	N/A	\$0
SMALL RURAL HOSPITAL IMPROVEMENT GRANT PROGRAM	93.301	NH23IP922611				\$12,541	\$223,218	N/A	\$0
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	MD007582	FLORIDA A&M UNIVERSITY	MD007582		\$41,021	\$456,426	RESEARCH AND DEVELOPMENT	\$404,219,504
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	MD013490			\$13,552	\$144,863	\$456,426	RESEARCH AND DEVELOPMENT	\$404,219,504
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	MD08934				\$53,006	\$456,426	RESEARCH AND DEVELOPMENT	\$404,219,504
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	MD09682			\$10,787	\$122,256	\$456,426	RESEARCH AND DEVELOPMENT	\$404,219,504
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	MD16230				\$93,042	\$456,426	RESEARCH AND DEVELOPMENT	\$404,219,504
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	MG08934				\$2,238	\$456,426	RESEARCH AND DEVELOPMENT	\$404,219,504
TRANS-NIH RESEARCH SUPPORT	93.310	AI142773				\$408,238	\$22,022,836	RESEARCH AND DEVELOPMENT	\$404,219,504
TRANS-NIH RESEARCH SUPPORT	93.310	CA243545				\$107,161	\$22,022,836	RESEARCH AND DEVELOPMENT	\$404,219,504
TRANS-NIH RESEARCH SUPPORT	93.310	CA268091	UNIVERSITY OF MICHIGAN	CA268091		\$1,162	\$22,022,836	RESEARCH AND DEVELOPMENT	\$404,219,504
TRANS-NIH RESEARCH SUPPORT	93.310	CA268103				\$47,015	\$22,022,836	RESEARCH AND DEVELOPMENT	\$404,219,504
TRANS-NIH RESEARCH SUPPORT	93.310	DK112326				\$1,579,434	\$22,022,836	RESEARCH AND DEVELOPMENT	\$404,219,504
TRANS-NIH RESEARCH SUPPORT	93.310	GM118971	UNIVERSITY OF TEXAS AT EL PASO	GM118971		\$5,643	\$22,022,836	RESEARCH AND DEVELOPMENT	\$404,219,504
TRANS-NIH RESEARCH SUPPORT	93.310	NS105853				\$25,527	\$22,022,836	RESEARCH AND DEVELOPMENT	\$404,219,504
TRANS-NIH RESEARCH SUPPORT	93.310	NS122602	CONWAY MEDICAL, LLC	NS122602		\$9,510	\$22,022,836	RESEARCH AND DEVELOPMENT	\$404,219,504
TRANS-NIH RESEARCH SUPPORT	93.310	OD23121			\$19,140,780	\$22,022,836	\$22,022,836	RESEARCH AND DEVELOPMENT	\$404,219,504
TRANS-NIH RESEARCH SUPPORT	93.310	TR02471				\$698,366	\$22,022,836	RESEARCH AND DEVELOPMENT	\$404,219,504
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	TR002014	PENNSYLVANIA STATE UNIVERSITY	TR002014		\$13,585	\$10,624,416	RESEARCH AND DEVELOPMENT	\$404,219,504
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	TR002306	UNIVERSITY OF COLORADO	TR002306		\$29,071	\$10,624,416	RESEARCH AND DEVELOPMENT	\$404,219,504
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	TR002377			\$17,977	\$5,416,037	\$10,624,416	RESEARCH AND DEVELOPMENT	\$404,219,504
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	TR002379				\$1,481,019	\$10,624,416	RESEARCH AND DEVELOPMENT	\$404,219,504
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	TR01857	UNIVERSITY OF PITTSBURGH	TR01857		\$39,752	\$10,624,416	RESEARCH AND DEVELOPMENT	\$404,219,504
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	TR02062			\$932,927	\$1,250,432	\$10,624,416	RESEARCH AND DEVELOPMENT	\$404,219,504
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	TR02306	JOHNS HOPKINS UNIVERSITY	TR02306		\$39,830	\$10,624,416	RESEARCH AND DEVELOPMENT	\$404,219,504
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	TR02380				\$440,228	\$10,624,416	RESEARCH AND DEVELOPMENT	\$404,219,504
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	TR02494	UNIVERSITY OF MINNESOTA	TR02494		\$51,742	\$10,624,416	RESEARCH AND DEVELOPMENT	\$404,219,504
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	TR02743			\$557,184	\$1,582,299	\$10,624,416	RESEARCH AND DEVELOPMENT	\$404,219,504
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	TR03174				\$280,421	\$10,624,416	RESEARCH AND DEVELOPMENT	\$404,219,504
RESEARCH INFRASTRUCTURE PROGRAMS	93.351	OD20166	IOWA STATE UNIVERSITY	OD20166		\$331,372	\$930,953	RESEARCH AND DEVELOPMENT	\$404,219,504
RESEARCH INFRASTRUCTURE PROGRAMS	93.351	OD28633				\$599,581	\$930,953	RESEARCH AND DEVELOPMENT	\$404,219,504
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	CA15083				\$147,140	\$3,902,461	RESEARCH AND DEVELOPMENT	\$404,219,504
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	CA224018			\$114,075	\$1,096,367	\$3,902,461	RESEARCH AND DEVELOPMENT	\$404,219,504
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	CA233033			\$40,336	\$1,830,010	\$3,902,461	RESEARCH AND DEVELOPMENT	\$404,219,504
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	CA233046	UNIVERSITY OF NORTH CAROLINA	CA233046		\$227,018	\$3,902,461	RESEARCH AND DEVELOPMENT	\$404,219,504

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2021 - 12/31/2021

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY (BARDA), BIODENSE MEDICAL COUNTERMEASURE DEVELOPMENT	93.353	CA246568			\$70,050	\$601,926	\$3,902,461	RESEARCH AND DEVELOPMENT	\$404,219,504
NURSING RESEARCH	93.360	HHS-O-100-2014-000021	DUKE UNIVERSITY	HHS-O-100-2014-000021		\$85,214	\$85,214	RESEARCH AND DEVELOPMENT	\$404,219,504
NURSING RESEARCH	93.361	NR15259				\$331,487	\$1,550,372	RESEARCH AND DEVELOPMENT	\$404,219,504
NURSING RESEARCH	93.361	NR15441			\$60,194	\$225,133	\$1,550,372	RESEARCH AND DEVELOPMENT	\$404,219,504
NURSING RESEARCH	93.361	NR16433			\$35,389	\$588,543	\$1,550,372	RESEARCH AND DEVELOPMENT	\$404,219,504
NURSING RESEARCH	93.361	NR18832				\$405,209	\$1,550,372	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA134514				\$103,834	\$11,929,835	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA154823	JOHNS HOPKINS UNIVERSITY	CA154823		\$910	\$11,929,835	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA167551	STANFORD UNIVERSITY	CA167551		\$269,081	\$11,929,835	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA179243				\$26,645	\$11,929,835	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA192393				\$77,024	\$11,929,835	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA195568			\$530,798	\$1,033,981	\$11,929,835	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA200703			\$118,630	\$377,916	\$11,929,835	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA203923	MEDICAL COLLEGE OF WISCONSIN	CA203923		\$12,056	\$11,929,835	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA203971				\$66,385	\$11,929,835	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA207084			\$381,706	\$671,637	\$11,929,835	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA207360	UNIVERSITY OF CALIFORNIA SAN FRANCISCO	CA207360		\$19,559	\$11,929,835	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA207369	UNIVERSITY OF MASSACHUSETTS	CA207369		\$379,494	\$11,929,835	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA207456	H. LEE MOFFIT CANCER CENTER AND RESEARCH INSTITUTE, INC.	CA207456		\$34,374	\$11,929,835	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA208517				\$319,297	\$11,929,835	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA213645			\$551,750	\$694,862	\$11,929,835	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA214225			\$3,606	\$11,477	\$11,929,835	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA217183				\$383,516	\$11,929,835	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA217889				\$444,119	\$11,929,835	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA222253	UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER	CA222253		\$35,366	\$11,929,835	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA224293	UNIVERSITY OF VIRGINIA	CA224293		\$75,726	\$11,929,835	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA224917				\$463,907	\$11,929,835	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA225662				\$363,228	\$11,929,835	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA226081	STANFORD UNIVERSITY	CA226081		\$16,995	\$11,929,835	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA230712				\$515,087	\$11,929,835	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA233432	KAISER FOUNDATION RESEARCH INSTITUTE	CA233432		\$42,232	\$11,929,835	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA233522			\$36,085	\$454,026	\$11,929,835	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA233610				\$721,797	\$11,929,835	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA233700				\$443,797	\$11,929,835	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA234943				\$98,228	\$11,929,835	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA235026				\$498,776	\$11,929,835	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA237607			\$63,376	\$862,281	\$11,929,835	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA243483	BAYLOR COLLEGE OF MEDICINE	CA243483		\$100,269	\$11,929,835	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA244670	UNIVERSITY OF WASHINGTON	CA244670		\$40,888	\$11,929,835	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA247283	JOHNS HOPKINS UNIVERSITY	CA247283		\$95,330	\$11,929,835	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA247642	ALASKA NATIVE TRIBAL HEALTH CONSORTIUM	CA247642		\$19,870	\$11,929,835	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA248288			\$51,352	\$925,362	\$11,929,835	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA253187				\$930,418	\$11,929,835	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA254395				\$22,164	\$11,929,835	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA254844	CARINA MEDICAL, LLC	CA254844		\$1,885	\$11,929,835	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA254951				\$100,789	\$11,929,835	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA258119	UNIVERSITY OF VERMONT	CA258119		\$1,056	\$11,929,835	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA264600				\$160,041	\$11,929,835	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CAUSE AND PREVENTION RESEARCH	93.393	NS110949	UNIVERSITY OF MINNESOTA	NS110949		\$14,150	\$11,929,835	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	ACRIN 6684	AMERICAN COLLEGE OF RADIOLOGY	ACRIN 6684		\$208	\$10,812,426	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA107476				\$171,944	\$10,812,426	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA116161				\$206,677	\$10,812,426	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA158079	ST. JOSEPH HOSPITAL	CA158079		\$73,109	\$10,812,426	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA161749	UNIVERSITY OF PENNSYLVANIA	CA161749		\$129,995	\$10,812,426	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA168575				\$54,036	\$10,812,426	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA168762				\$231,759	\$10,812,426	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA193541			\$1,666	\$166,920	\$10,812,426	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA195527			\$58,335	\$176,578	\$10,812,426	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA196171	WASHINGTON UNIVERSITY IN ST. LOUIS	CA196171			\$559,742	\$10,812,426	\$404,219,504

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2021 - 12/31/2021

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA197120			\$3,332	\$61,681	\$10,812,426	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA197488	UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN	CA197488		\$4,704	\$10,812,426	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA199058	VARJA INSTRUMENTS	CA199058		\$85,300	\$10,812,426	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA200399	JOHNS HOPKINS UNIVERSITY	CA200399		\$49,515	\$10,812,426	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA204013				\$233,798	\$10,812,426	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA206584				\$293,073	\$10,812,426	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA210138			\$181,320	\$1,209,570	\$10,812,426	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA210509			\$56,326	\$346,736	\$10,812,426	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA212162			\$31,318	\$416,011	\$10,812,426	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA213158	ST. JOSEPH HOSPITAL	CA213158		\$19,810	\$10,812,426	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA214114	FRED HUTCHINSON CANCER RESEARCH CENTER	CA214114		\$24,840	\$10,812,426	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA214125	BAYLOR RESEARCH INSTITUTE	CA214125		\$7,657	\$10,812,426	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA214679				\$337,564	\$10,812,426	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA216855			\$254,357	\$392,059	\$10,812,426	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA217847				\$298,487	\$10,812,426	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA218429	ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY	CA218429		\$35,094	\$10,812,426	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA221938	ST. JOSEPH HOSPITAL	CA221938		\$24,381	\$10,812,426	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA223426	UNIVERSITY OF CHICAGO	CA223426		\$1,109	\$10,812,426	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA229811				\$548,391	\$10,812,426	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA234827				\$129,382	\$10,812,426	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA236612				\$260,689	\$10,812,426	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA237602			\$130,837	\$637,899	\$10,812,426	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA237659	UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER	CA237659		\$65,668	\$10,812,426	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA238926				\$403,936	\$10,812,426	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA239164				\$352,159	\$10,812,426	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA239200			\$251,443	\$594,674	\$10,812,426	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA239548				\$582,162	\$10,812,426	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA240181	PURDUE UNIVERSITY	CA240181		\$152,987	\$10,812,426	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA241020				\$34,659	\$10,812,426	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA241164				\$344,431	\$10,812,426	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA244167				\$101,415	\$10,812,426	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA246704	UNIVERSITY OF CENTRAL FLORIDA	CA246704		\$9,860	\$10,812,426	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA247606	ST. JOSEPH'S HOSPITAL	CA247606		\$51,460	\$10,812,426	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA251065				\$69,978	\$10,812,426	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA251801				\$53,908	\$10,812,426	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA251923				\$169,537	\$10,812,426	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA252156	MD ANDERSON CANCER CENTER	CA252156		\$68,088	\$10,812,426	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA256648				\$172,778	\$10,812,426	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA256969	REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO	CA256969		\$81,084	\$10,812,426	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA257558			\$132,478	\$257,608	\$10,812,426	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	HHS-D-200-2013-M539378	AMERICAN INSTITUTES FOR RESEARCH	HHS-D-200-2013-M539378		\$57,316	\$10,812,426	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA108671	MOUNT SINAI MEDICAL CENTER OF FLORIDA	CA108671		\$565,444	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA150190			\$28,572	\$419,187	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA179157				\$245,845	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA180820	COALITION OF NTL CANCER COOP	CA180820		\$42,035	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA180821	BRIGHAM AND WOMENS HOSPITAL	CA180821		\$312,422	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA180868	NRG ONCOLOGY FOUNDATION	CA180868		\$656	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA180882			\$519,934	\$8,587,599	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA180886	THE CHILDRENS HOSPITAL OF PHILADELPHIA	CA180886		\$15,316	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA181255	UNIVERSITY OF CALIFORNIA SAN FRANCISCO	CA181255		\$354,163	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA184165				\$66,422	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA186686				\$710,253	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA186709	DANA-FARBER CANCER INSTITUTE	CA186709		\$319,835	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA189955	THE CHILDRENS HOSPITAL OF PHILADELPHIA	CA189955		\$7,798	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2021 - 12/31/2021

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
CANCER TREATMENT RESEARCH	93.395	CA190423				\$63,092	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA190473				\$93,024	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA194498				\$229,979	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA195473				\$157,146	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA195503			\$2,068	\$4,819	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA196175	THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL	CA196175		\$4,773	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA200507				\$235,721	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA201226			\$2,409	\$10,997	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA203430	PPD DEVELOPMENT	CA203430		\$156,783	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA203836				\$107,557	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA205406	DANA-FARBER CANCER INSTITUTE	CA205406		\$38,475	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA207183			\$15,555	\$137,903	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA207240				\$433,849	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA207386				\$172,666	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA208851	CEDARS SINAI MEDICAL CENTER	CA208851		\$35,519	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA211887				\$436,878	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA214523	UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN	CA214523		\$24,482	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA216436	UNIVERSITY OF CHICAGO	CA216436		\$88,073	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA216468	MD ANDERSON CANCER CENTER	CA216468		\$95,076	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA217591	SYNTRIX BIOSYSTEMS, INC.	CA217591		\$82,958	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA219960				\$704,609	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA221461	VYRIAD	CA221461		\$6,026	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA222425				\$16,033	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA222866	VETERANS MEDICAL RESEARCH FOUNDATION	CA222866		\$17,179	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA225996				\$475,208	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA227954			\$143,042	\$439,557	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA228823	THE CHILDRENS HOSPITAL OF PHILADELPHIA	CA228823		\$62,654	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA229100			\$1,284,850	\$2,167,543	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA229560				\$319,867	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA229943	UNIVERSITY OF MISSISSIPPI MEDICAL CENTER	CA229943		\$7,416	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA232760				\$1,234,468	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA233024	VYRIAD	CA233024		\$960	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA233878	NORTHWESTERN UNIVERSITY	CA233878		\$66,723	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA235726	UNIVERSITY OF MICHIGAN	CA235726		\$5,687	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA238946	OHIO STATE UNIVERSITY	CA238946		\$24,762	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA242158				\$152,568	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA243078	TRANSLATIONAL GENOMICS RESEARCH INSTITUTE	CA243078		\$91,411	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA248064				\$176,761	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA248147				\$375,531	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA251910	SANFORD-BURNHAM MEDICAL	CA251910		\$132,831	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA25224				\$2,518	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA255176	UNIVERSITY OF LOUISIANA AT MONROE	CA255176		\$17,974	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA256927				\$264,430	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA257241			\$88,841	\$263,365	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA258239				\$224,358	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA259236				\$82,533	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA261854				\$27,923	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA262994				\$26,043	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA264362				\$53,099	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA267098				\$12,050	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA37404				\$6,566	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	CA78383				\$59,799	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	E1411	ECOG-ACRIN CANCER RESEARCH GROUP	E1411		\$2,532	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	E1412	EASTERN COOPERATIVE ONCOLOGY GROUP	E1412		\$1,472	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER TREATMENT RESEARCH	93.395	NMDP #1703	NATIONAL MARROW DONOR PROGRAM	NMDP #1703		\$6,568	\$21,785,769	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER BIOLOGY RESEARCH	93.396	CA130908				\$288,869	\$8,263,688	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER BIOLOGY RESEARCH	93.396	CA136526				\$15,375	\$8,263,688	RESEARCH AND DEVELOPMENT	\$404,219,504

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2021 - 12/31/2021

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CANCER BIOLOGY RESEARCH	93.396	CA172503				\$34,234	\$8,263,688	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER BIOLOGY RESEARCH	93.396	CA186338	UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER	CA186338		\$16,366	\$8,263,688	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER BIOLOGY RESEARCH	93.396	CA193239				\$42,153	\$8,263,688	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER BIOLOGY RESEARCH	93.396	CA194215	UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER	CA194215		\$150,915	\$8,263,688	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER BIOLOGY RESEARCH	93.396	CA196648				\$134,481	\$8,263,688	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER BIOLOGY RESEARCH	93.396	CA196831				\$75,533	\$8,263,688	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER BIOLOGY RESEARCH	93.396	CA200572				\$206,116	\$8,263,688	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER BIOLOGY RESEARCH	93.396	CA203108	UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER	CA203108		\$2,985	\$8,263,688	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER BIOLOGY RESEARCH	93.396	CA203849				\$346,593	\$8,263,688	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER BIOLOGY RESEARCH	93.396	CA206367				\$252,818	\$8,263,688	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER BIOLOGY RESEARCH	93.396	CA214292	BOSTON UNIVERSITY	CA214292		\$74,587	\$8,263,688	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER BIOLOGY RESEARCH	93.396	CA214893				\$212,014	\$8,263,688	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER BIOLOGY RESEARCH	93.396	CA215973	MDI BIOLOGICAL LABORATORY	CA215973		\$203	\$8,263,688	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER BIOLOGY RESEARCH	93.396	CA217833				\$252,446	\$8,263,688	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER BIOLOGY RESEARCH	93.396	CA220378			\$63,415	\$723,170	\$8,263,688	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER BIOLOGY RESEARCH	93.396	CA224921				\$350,629	\$8,263,688	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER BIOLOGY RESEARCH	93.396	CA225680				\$147,573	\$8,263,688	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER BIOLOGY RESEARCH	93.396	CA233790				\$415,037	\$8,263,688	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER BIOLOGY RESEARCH	93.396	CA234181				\$437,131	\$8,263,688	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER BIOLOGY RESEARCH	93.396	CA238720	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	CA238720		\$6,709	\$8,263,688	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER BIOLOGY RESEARCH	93.396	CA239726				\$126,634	\$8,263,688	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER BIOLOGY RESEARCH	93.396	CA240323				\$349,569	\$8,263,688	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER BIOLOGY RESEARCH	93.396	CA241123	UNIVERSITY AT BUFFALO	CA241123		\$79,892	\$8,263,688	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER BIOLOGY RESEARCH	93.396	CA242023				\$466,189	\$8,263,688	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER BIOLOGY RESEARCH	93.396	CA243545			\$3,466	\$489,393	\$8,263,688	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER BIOLOGY RESEARCH	93.396	CA247929				\$49,930	\$8,263,688	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER BIOLOGY RESEARCH	93.396	CA248019	UNIVERSITY OF MINNESOTA	CA248019		\$5,548	\$8,263,688	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER BIOLOGY RESEARCH	93.396	CA249116				\$472,161	\$8,263,688	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER BIOLOGY RESEARCH	93.396	CA250481			\$49,261	\$444,760	\$8,263,688	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER BIOLOGY RESEARCH	93.396	CA254961				\$172,436	\$8,263,688	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER BIOLOGY RESEARCH	93.396	CA255068				\$38,801	\$8,263,688	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER BIOLOGY RESEARCH	93.396	CA256481	UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN	CA256481		\$54,049	\$8,263,688	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER BIOLOGY RESEARCH	93.396	CA258274			\$28,542	\$224,465	\$8,263,688	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER BIOLOGY RESEARCH	93.396	CA261932				\$109,650	\$8,263,688	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER BIOLOGY RESEARCH	93.396	CA264048				\$84,614	\$8,263,688	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER BIOLOGY RESEARCH	93.396	CA81436				\$400,320	\$8,263,688	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER BIOLOGY RESEARCH	93.396	CA96985				\$509,340	\$8,263,688	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CENTERS SUPPORT GRANTS	93.397	CA116201			\$229,582	\$1,771,319	\$13,319,122	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CENTERS SUPPORT GRANTS	93.397	CA136393				\$465,953	\$13,319,122	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CENTERS SUPPORT GRANTS	93.397	CA15083			\$8,071	\$6,137,997	\$13,319,122	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CENTERS SUPPORT GRANTS	93.397	CA163004	COLUMBIA UNIVERSITY CASE WESTERN RESERVE UNIVERSITY	CA163004		\$239,483	\$13,319,122	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CENTERS SUPPORT GRANTS	93.397	CA163060				\$61,248	\$13,319,122	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CENTERS SUPPORT GRANTS	93.397	CA168504	DANA-FARBER CANCER INSTITUTE	CA168504		\$25,153	\$13,319,122	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CENTERS SUPPORT GRANTS	93.397	CA186781				\$119,853	\$13,319,122	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CENTERS SUPPORT GRANTS	93.397	CA186784	BAYLOR COLLEGE OF MEDICINE	CA186784		\$3,052	\$13,319,122	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CENTERS SUPPORT GRANTS	93.397	CA210180	MASSACHUSETTS INSTITUTE	CA210180		\$483,446	\$13,319,122	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CENTERS SUPPORT GRANTS	93.397	CA210181	METHODIST HOSPITAL RESEARCH	CA210181		\$29,813	\$13,319,122	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CENTERS SUPPORT GRANTS	93.397	CA210190	UNIVERSITY OF MINNESOTA	CA210190		\$80,392	\$13,319,122	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CENTERS SUPPORT GRANTS	93.397	CA210964			\$342,107	\$2,268,468	\$13,319,122	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CENTERS SUPPORT GRANTS	93.397	CA221205	NORTHWESTERN UNIVERSITY	CA221205		\$24,117	\$13,319,122	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CENTERS SUPPORT GRANTS	93.397	CA233444	UNIVERSITY OF FLORIDA	CA233444		\$7,915	\$13,319,122	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CENTERS SUPPORT GRANTS	93.397	CA97274	UNIVERSITY OF IOWA	CA97274	\$3,400	\$1,600,913	\$13,319,122	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER RESEARCH MANPOWER	93.398	CA210334				\$19,088	\$2,296,945	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER RESEARCH MANPOWER	93.398	CA213737				\$54,658	\$2,296,945	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER RESEARCH MANPOWER	93.398	CA215105				\$202,142	\$2,296,945	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER RESEARCH MANPOWER	93.398	CA217836				\$257,666	\$2,296,945	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER RESEARCH MANPOWER	93.398	CA220660				\$21,015	\$2,296,945	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER RESEARCH MANPOWER	93.398	CA225786				\$187,325	\$2,296,945	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER RESEARCH MANPOWER	93.398	CA234324				\$113,099	\$2,296,945	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER RESEARCH MANPOWER	93.398	CA235848				\$54,344	\$2,296,945	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER RESEARCH MANPOWER	93.398	CA236874				\$328,884	\$2,296,945	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER RESEARCH MANPOWER	93.398	CA237875				\$190,941	\$2,296,945	RESEARCH AND DEVELOPMENT	\$404,219,504

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2021 - 12/31/2021

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
CANCER RESEARCH MANPOWER	93.398	CA248972	UNIVERSITY OF FLORIDA	CA248972		\$16,778	\$2,296,945	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER RESEARCH MANPOWER	93.398	CA250122				\$34,575	\$2,296,945	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER RESEARCH MANPOWER	93.398	CA250326				\$45,373	\$2,296,945	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER RESEARCH MANPOWER	93.398	CA257228				\$38,181	\$2,296,945	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER RESEARCH MANPOWER	93.398	CA90628				\$732,876	\$2,296,945	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CONTROL	93.399	CA189823	OHIO STATE UNIVERSITY	CA189823		\$1,763,731	\$2,462,809	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CONTROL	93.399	CA220242				\$668,399	\$2,462,809	RESEARCH AND DEVELOPMENT	\$404,219,504
CANCER CONTROL	93.399	CA242635	UNIVERSITY OF WISCONSIN MADISON	CA242635		\$30,679	\$2,462,809	RESEARCH AND DEVELOPMENT	\$404,219,504
ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING, AND REHABILITATION RESEARCH	93.433	90DPHF0006	INDIANA UNIVERSITY	90DPHF0006		\$4,050	\$540,248	RESEARCH AND DEVELOPMENT	\$404,219,504
ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING, AND REHABILITATION RESEARCH	93.433	90DPTB0012				\$522,999	\$540,248	RESEARCH AND DEVELOPMENT	\$404,219,504
ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING, AND REHABILITATION RESEARCH	93.433	90DPTB0017	CRAIG HOSPITAL	90DPTB0017		\$13,199	\$540,248	RESEARCH AND DEVELOPMENT	\$404,219,504
COVID-19 HRSA COVID-19 CLAIMS REIMBURSEMENT FOR THE UNINSURED PROGRAM AND THE COVID-19 COVERAGE ASSISTANCE FUND	93.461	COVID-19 UNINSURED				\$9,969,127	\$9,969,127	N/A	\$0
COVID-19 PROVIDER RELIEF FUND AND AMERICAN RESCUE PLAN (ARP)									
RURAL DISTRIBUTION	93.498	COVID-19 PRF				\$181,999,200	\$181,999,200	N/A	\$0
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL07111				\$307,909	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL107304			\$23,087	\$616,277	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL111437	UNIVERSITY OF CALIFORNIA LOS ANGELES	HL111437		\$10,650	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL112460	ADVANCED MEDICAL ELECTRONIC CORPORATION	HL112460		\$23,967	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL115153	UNIVERSITY OF CALIFORNIA BERKELEY	HL115153		\$97,706	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL117823			\$50,869	\$555,084	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL117913				\$149,314	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL119795			\$9,906	\$191,684	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL120877	OKLAHOMA MEDICAL RESEARCH FOUNDATION	HL120877		\$175,903	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL121079				\$14,825	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL126638				\$57,797	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL128526				\$447,282	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL128606			\$23,745	\$382,183	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL128859			\$81	\$110,726	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL129941	VANDERBILT UNIVERSITY MEDICAL CENTER	HL129941		\$116,959	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL131535			\$106,433	\$214,973	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL132746	THERMEDICAL, INC.	HL132746		\$84,372	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL132854				\$213,619	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL133501				\$137,197	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL134664				\$169,856	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL134668				\$272,398	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL134864				\$290,248	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL134905	UNIVERSITY OF PENNSYLVANIA	HL134905		\$52,921	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL135165	UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER	HL135165		\$34,754	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL135288				\$230,735	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL135879				\$567,531	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL136340				\$364,452	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL136348				\$643,665	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL136440				\$336,655	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL136659				\$476,823	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL136679	UNIVERSITY OF MINNESOTA	HL136679		\$8,159	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL137010				\$135,889	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL140411			\$423	\$368,270	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL140669	VOLUMETRIX LLC	HL140669		\$17,395	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL140951			\$276,919	\$543,270	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL141448				\$139,916	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL141819				\$398,802	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL142068				\$159,420	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL142627				\$314,660	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL143070	MASSACHUSETTS GENERAL HOSPITAL	HL143070		\$5,315	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL144529			\$42,646	\$519,098	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL145121				\$49,974	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2021 - 12/31/2021

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL145268			\$376,892	\$849,158	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL146127	UNIVERSITY OF CHICAGO	HL146127		\$19,296	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL147155				\$1,221,067	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL148120	VERSITI	HL148120		\$21,016	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL148144				\$93,521	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL148339				\$206,775	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL148664	UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN	HL148664		\$290,578	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL149131				\$16,096	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL150086				\$193,862	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL151079	NORTHWESTERN UNIVERSITY	HL151079		\$33,493	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL152873	MARBLEHEAD MEDICAL, LLC	HL152873		\$38,837	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL153098				\$191,199	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL155040				\$51,938	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL155834	UNIVERSITY OF MICHIGAN	HL155834		\$35,993	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL158517				\$52,239	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL158932				\$82,556	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL36634				\$81,648	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL66216				\$264,715	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL81753				\$208,778	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL84155				\$230,940	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL92621				\$105,696	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL96812	JOHNS HOPKINS UNIVERSITY	HL96812		\$293,188	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL98967				\$559,099	\$15,150,321	RESEARCH AND DEVELOPMENT	\$404,219,504
LUNG DISEASES RESEARCH	93.838	HL105355				\$562,210	\$9,959,044	RESEARCH AND DEVELOPMENT	\$404,219,504
LUNG DISEASES RESEARCH	93.838	HL108800	VANDERBILT UNIVERSITY	HL108800		\$33,194	\$9,959,044	RESEARCH AND DEVELOPMENT	\$404,219,504
LUNG DISEASES RESEARCH	93.838	HL123494	NORTH DAKOTA STATE UNIVERSITY	HL123494		\$5,030	\$9,959,044	RESEARCH AND DEVELOPMENT	\$404,219,504
LUNG DISEASES RESEARCH	93.838	HL125119	ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY	HL125119		\$46,095	\$9,959,044	RESEARCH AND DEVELOPMENT	\$404,219,504
LUNG DISEASES RESEARCH	93.838	HL125234				\$114,091	\$9,959,044	RESEARCH AND DEVELOPMENT	\$404,219,504
LUNG DISEASES RESEARCH	93.838	HL126667			\$49,404	\$493,973	\$9,959,044	RESEARCH AND DEVELOPMENT	\$404,219,504
LUNG DISEASES RESEARCH	93.838	HL128954	UNIVERSITY OF PITTSBURGH	HL128954		\$508	\$9,959,044	RESEARCH AND DEVELOPMENT	\$404,219,504
LUNG DISEASES RESEARCH	93.838	HL130881			\$95,075	\$442,533	\$9,959,044	RESEARCH AND DEVELOPMENT	\$404,219,504
LUNG DISEASES RESEARCH	93.838	HL133320				\$5,253	\$9,959,044	RESEARCH AND DEVELOPMENT	\$404,219,504
LUNG DISEASES RESEARCH	93.838	HL137366	PARTNERS HEALTH CARE RES MGMT	HL137366		\$40,462	\$9,959,044	RESEARCH AND DEVELOPMENT	\$404,219,504
LUNG DISEASES RESEARCH	93.838	HL138150			\$6,005	\$160,005	\$9,959,044	RESEARCH AND DEVELOPMENT	\$404,219,504
LUNG DISEASES RESEARCH	93.838	HL138402	CASE WESTERN RESERVE UNIVERSITY	HL138402		\$15,846	\$9,959,044	RESEARCH AND DEVELOPMENT	\$404,219,504
LUNG DISEASES RESEARCH	93.838	HL138998	UNIVERSITY OF NORTH CAROLINA	HL138998		\$87,195	\$9,959,044	RESEARCH AND DEVELOPMENT	\$404,219,504
LUNG DISEASES RESEARCH	93.838	HL139054	UNIVERSITY OF ARIZONA	HL139054		\$877	\$9,959,044	RESEARCH AND DEVELOPMENT	\$404,219,504
LUNG DISEASES RESEARCH	93.838	HL139126	INDIANA UNIVERSITY	HL139126		\$12,804	\$9,959,044	RESEARCH AND DEVELOPMENT	\$404,219,504
LUNG DISEASES RESEARCH	93.838	HL140177	MASSACHUSETTS GENERAL HOSPITAL	HL140177		\$63,411	\$9,959,044	RESEARCH AND DEVELOPMENT	\$404,219,504
LUNG DISEASES RESEARCH	93.838	HL140287				\$28,918	\$9,959,044	RESEARCH AND DEVELOPMENT	\$404,219,504
LUNG DISEASES RESEARCH	93.838	HL140486			\$119,971	\$523,518	\$9,959,044	RESEARCH AND DEVELOPMENT	\$404,219,504
LUNG DISEASES RESEARCH	93.838	HL141722	STANFORD UNIVERSITY	HL141722		\$243,212	\$9,959,044	RESEARCH AND DEVELOPMENT	\$404,219,504
LUNG DISEASES RESEARCH	93.838	HL142061				\$460,103	\$9,959,044	RESEARCH AND DEVELOPMENT	\$404,219,504
LUNG DISEASES RESEARCH	93.838	HL142093	BRIGHAM AND WOMENS HOSPITAL	HL142093		\$155,654	\$9,959,044	RESEARCH AND DEVELOPMENT	\$404,219,504
LUNG DISEASES RESEARCH	93.838	HL142269	UNIVERSITY OF PENNSYLVANIA	HL142269		\$82,661	\$9,959,044	RESEARCH AND DEVELOPMENT	\$404,219,504
LUNG DISEASES RESEARCH	93.838	HL142596	BOSTON UNIVERSITY	HL142596		\$31,199	\$9,959,044	RESEARCH AND DEVELOPMENT	\$404,219,504
LUNG DISEASES RESEARCH	93.838	HL142933			\$58,703	\$512,877	\$9,959,044	RESEARCH AND DEVELOPMENT	\$404,219,504
LUNG DISEASES RESEARCH	93.838	HL144427				\$67,808	\$9,959,044	RESEARCH AND DEVELOPMENT	\$404,219,504
LUNG DISEASES RESEARCH	93.838	HL145265	UNIVERSITY OF MICHIGAN	HL145265		\$2,618	\$9,959,044	RESEARCH AND DEVELOPMENT	\$404,219,504
LUNG DISEASES RESEARCH	93.838	HL146114				\$592,814	\$9,959,044	RESEARCH AND DEVELOPMENT	\$404,219,504
LUNG DISEASES RESEARCH	93.838	HL146705	NORTH DAKOTA STATE UNIVERSITY	HL146705		\$106,786	\$9,959,044	RESEARCH AND DEVELOPMENT	\$404,219,504
LUNG DISEASES RESEARCH	93.838	HL146741				\$158,508	\$9,959,044	RESEARCH AND DEVELOPMENT	\$404,219,504
LUNG DISEASES RESEARCH	93.838	HL147261	UNIVERSITY OF MICHIGAN	HL147261		\$12,628	\$9,959,044	RESEARCH AND DEVELOPMENT	\$404,219,504
LUNG DISEASES RESEARCH	93.838	HL148437	NATIONAL JEWISH HEALTH	HL148437		\$28,296	\$9,959,044	RESEARCH AND DEVELOPMENT	\$404,219,504
LUNG DISEASES RESEARCH	93.838	HL150086				\$96,172	\$9,959,044	RESEARCH AND DEVELOPMENT	\$404,219,504
LUNG DISEASES RESEARCH	93.838	HL151461	MINNESOTA HEALTHSOLUTIONS CORPORATION	HL151461		\$66,072	\$9,959,044	RESEARCH AND DEVELOPMENT	\$404,219,504
LUNG DISEASES RESEARCH	93.838	HL151671				\$12,965	\$9,959,044	RESEARCH AND DEVELOPMENT	\$404,219,504
LUNG DISEASES RESEARCH	93.838	HL152967			\$11,186	\$175,892	\$9,959,044	RESEARCH AND DEVELOPMENT	\$404,219,504

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2021 - 12/31/2021

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
LUNG DISEASES RESEARCH	93.838	HL153026				\$468,855	\$9,959,044	RESEARCH AND DEVELOPMENT	\$404,219,504
LUNG DISEASES RESEARCH	93.838	HL156812	UNIVERSITY OF ARIZONA	HL156812		\$10,846	\$9,959,044	RESEARCH AND DEVELOPMENT	\$404,219,504
LUNG DISEASES RESEARCH	93.838	HL156812	UNIVERSITY OF ARIZONA	HL156812		\$409,082	\$9,959,044	RESEARCH AND DEVELOPMENT	\$404,219,504
LUNG DISEASES RESEARCH	93.838	HL157984				\$495,333	\$9,959,044	RESEARCH AND DEVELOPMENT	\$404,219,504
LUNG DISEASES RESEARCH	93.838	HL161847	NYU GROSSMAN SCHOOL OF MEDICINE	HL161847		\$1,742,541	\$9,959,044	RESEARCH AND DEVELOPMENT	\$404,219,504
LUNG DISEASES RESEARCH	93.838	HL56470				\$84,698	\$9,959,044	RESEARCH AND DEVELOPMENT	\$404,219,504
LUNG DISEASES RESEARCH	93.838	HL62150				\$275,923	\$9,959,044	RESEARCH AND DEVELOPMENT	\$404,219,504
LUNG DISEASES RESEARCH	93.838	HL88029				\$549,365	\$9,959,044	RESEARCH AND DEVELOPMENT	\$404,219,504
LUNG DISEASES RESEARCH	93.838	HL92961			\$120,846	\$480,213	\$9,959,044	RESEARCH AND DEVELOPMENT	\$404,219,504
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	BMT CTN 1101	NATIONAL MARROW DONOR PROGRAM	BMT CTN 1101		\$1,797	\$2,914,727	RESEARCH AND DEVELOPMENT	\$404,219,504
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	BMT CTN 1506	NATIONAL MARROW DONOR PROGRAM	BMT CTN 1506		\$21,029	\$2,914,727	RESEARCH AND DEVELOPMENT	\$404,219,504
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL121232			-\$565	\$97	\$2,914,727	RESEARCH AND DEVELOPMENT	\$404,219,504
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL126589	FRED HUTCHINSON CANCER RESEARCH CENTER	HL126589		\$3,235	\$2,914,727	RESEARCH AND DEVELOPMENT	\$404,219,504
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL133479				\$202,064	\$2,914,727	RESEARCH AND DEVELOPMENT	\$404,219,504
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL133817	DUKE CLINICAL RESEARCH INSTITUTE	HL133817		\$677	\$2,914,727	RESEARCH AND DEVELOPMENT	\$404,219,504
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL137193			\$277,019	\$531,482	\$2,914,727	RESEARCH AND DEVELOPMENT	\$404,219,504
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL138645	UNIVERSITY OF ALABAMA	HL138645		\$23,257	\$2,914,727	RESEARCH AND DEVELOPMENT	\$404,219,504
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL139854				\$813,792	\$2,914,727	RESEARCH AND DEVELOPMENT	\$404,219,504
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL140097	CLEVELAND CLINIC FOUNDATION	HL140097		\$29,926	\$2,914,727	RESEARCH AND DEVELOPMENT	\$404,219,504
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL141112				\$269,943	\$2,914,727	RESEARCH AND DEVELOPMENT	\$404,219,504
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL146508				\$468,905	\$2,914,727	RESEARCH AND DEVELOPMENT	\$404,219,504
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL147852				\$194,896	\$2,914,727	RESEARCH AND DEVELOPMENT	\$404,219,504
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL153310				\$89,819	\$2,914,727	RESEARCH AND DEVELOPMENT	\$404,219,504
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL154320				\$82,194	\$2,914,727	RESEARCH AND DEVELOPMENT	\$404,219,504
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL154385	UNIVERSITY OF WASHINGTON	HL154385		\$93,732	\$2,914,727	RESEARCH AND DEVELOPMENT	\$404,219,504
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL158397	OBSIDIO, INC.	HL158397		\$87,882	\$2,914,727	RESEARCH AND DEVELOPMENT	\$404,219,504
TRANSLATION AND IMPLEMENTATION SCIENCE RESEARCH FOR HEART, LUNG, BLOOD DISEASES, AND SLEEP DISORDERS	93.840	HL151662			\$279,166	\$715,865	\$830,383	RESEARCH AND DEVELOPMENT	\$404,219,504
TRANSLATION AND IMPLEMENTATION SCIENCE RESEARCH FOR HEART, LUNG, BLOOD DISEASES, AND SLEEP DISORDERS	93.840	HL156812	UNIVERSITY OF ARIZONA	HL156812		\$114,518	\$830,383	RESEARCH AND DEVELOPMENT	\$404,219,504
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR056950				\$225,040	\$7,419,285	RESEARCH AND DEVELOPMENT	\$404,219,504
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR27065			\$25,119	\$298,398	\$7,419,285	RESEARCH AND DEVELOPMENT	\$404,219,504
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR46849				\$687,640	\$7,419,285	RESEARCH AND DEVELOPMENT	\$404,219,504
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR49069				\$211,292	\$7,419,285	RESEARCH AND DEVELOPMENT	\$404,219,504
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR55557	BRIGHAM AND WOMENS HOSPITAL	AR55557		\$13,047	\$7,419,285	RESEARCH AND DEVELOPMENT	\$404,219,504
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR55563			\$92,075	\$252,852	\$7,419,285	RESEARCH AND DEVELOPMENT	\$404,219,504
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR56212				\$10,788	\$7,419,285	RESEARCH AND DEVELOPMENT	\$404,219,504
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR56647				\$206,038	\$7,419,285	RESEARCH AND DEVELOPMENT	\$404,219,504
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR56950				\$170,072	\$7,419,285	RESEARCH AND DEVELOPMENT	\$404,219,504
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR57319	UNIVERSITY OF PENNSYLVANIA	AR57319		\$31,413	\$7,419,285	RESEARCH AND DEVELOPMENT	\$404,219,504
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR57745				\$59,186	\$7,419,285	RESEARCH AND DEVELOPMENT	\$404,219,504
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR65402				\$138,864	\$7,419,285	RESEARCH AND DEVELOPMENT	\$404,219,504
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR67129				\$202,248	\$7,419,285	RESEARCH AND DEVELOPMENT	\$404,219,504
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR67707				\$110,520	\$7,419,285	RESEARCH AND DEVELOPMENT	\$404,219,504
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR68103			\$7,061	\$162,352	\$7,419,285	RESEARCH AND DEVELOPMENT	\$404,219,504
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR68275				\$80,710	\$7,419,285	RESEARCH AND DEVELOPMENT	\$404,219,504
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR69400	EMMYON, INC.	AR69400		\$103,503	\$7,419,285	RESEARCH AND DEVELOPMENT	\$404,219,504
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR70241				\$63,645	\$7,419,285	RESEARCH AND DEVELOPMENT	\$404,219,504
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR71338			\$29,030	\$536,858	\$7,419,285	RESEARCH AND DEVELOPMENT	\$404,219,504
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR71762			\$53,326	\$336,839	\$7,419,285	RESEARCH AND DEVELOPMENT	\$404,219,504
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR72597				\$439,751	\$7,419,285	RESEARCH AND DEVELOPMENT	\$404,219,504
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR72634	UNIVERSITY OF MINNESOTA	AR72634		\$31,801	\$7,419,285	RESEARCH AND DEVELOPMENT	\$404,219,504
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR73147			\$151,825	\$721,110	\$7,419,285	RESEARCH AND DEVELOPMENT	\$404,219,504
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR73811				\$227,282	\$7,419,285	RESEARCH AND DEVELOPMENT	\$404,219,504
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR74228				\$128,463	\$7,419,285	RESEARCH AND DEVELOPMENT	\$404,219,504
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR74395			\$86,980	\$453,310	\$7,419,285	RESEARCH AND DEVELOPMENT	\$404,219,504
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR74859	NEUROMUSCULAR DYNAMICS, LLC	AR74859		\$1,999	\$7,419,285	RESEARCH AND DEVELOPMENT	\$404,219,504
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR75037				\$569,452	\$7,419,285	RESEARCH AND DEVELOPMENT	\$404,219,504
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR75370				\$122,718	\$7,419,285	RESEARCH AND DEVELOPMENT	\$404,219,504

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2021 - 12/31/2021

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR75803	UNIVERSITY OF NORTH CAROLINA	AR75803		\$8,807	\$7,419,285	RESEARCH AND DEVELOPMENT	\$404,219,504
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR76312			\$116,929	\$534,896	\$7,419,285	RESEARCH AND DEVELOPMENT	\$404,219,504
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR76339				\$128,630	\$7,419,285	RESEARCH AND DEVELOPMENT	\$404,219,504
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR76347	INDIANA UNIVERSITY	AR76347		\$3,958	\$7,419,285	RESEARCH AND DEVELOPMENT	\$404,219,504
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR76568	UNIVERSITY OF PITTSBURGH	AR76568		\$55,072	\$7,419,285	RESEARCH AND DEVELOPMENT	\$404,219,504
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR77518				\$20,825	\$7,419,285	RESEARCH AND DEVELOPMENT	\$404,219,504
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR78254				\$44,515	\$7,419,285	RESEARCH AND DEVELOPMENT	\$404,219,504
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR78389	UNIVERSITY OF CALIFORNIA IRVINE	AR78389		\$4,405	\$7,419,285	RESEARCH AND DEVELOPMENT	\$404,219,504
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR79098			\$5,235	\$20,986	\$7,419,285	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	APOL1	UNIVERSITY OF MIAMI	APOL1		\$1,191	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK067071				\$106,653	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK07013				\$164,638	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK07198				\$362,374	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK07352				\$405,553	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK078646			\$74,652	\$668,077	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK100846	UNIVERSITY OF PENNSYLVANIA	DK100846		\$12,113	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK100866	THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL	DK100866		\$443	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK101402	UNIVERSITY OF MINNESOTA	DK101402		\$27,872	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK101405				\$140,471	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK104500	RECOMBINETICS, INC.	DK104500		\$12,181	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK104764	UNIVERSITY OF WASHINGTON	DK104764		\$1,012	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK104833	MEDICAL UNIVERSITY OF SOUTH CAROLINA	DK104833		\$59,346	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK104876	NORTHWESTERN UNIVERSITY	DK104876		\$23,361	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK106130	UNIVERSITY OF MINNESOTA	DK106130		\$5,620	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK106667				\$55,704	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK106957				\$59,147	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK107255				\$165,252	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK107733	UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER	DK107733		\$150,345	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK107870				\$88,734	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK108288	UNIVERSITY OF TEXAS	DK108288		\$169,253	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK108288				\$584,979	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK108328	UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER	DK108328		\$180	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK108483	UNIVERSITY OF VIRGINIA	DK108483		\$33,001	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK108743	SANFORD-BURNHAM MEDICAL	DK108743		\$12,827	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK109006				\$96,625	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK109096				\$130,702	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2021 - 12/31/2021

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK109134				\$200,173	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK110024			\$207,995	\$435,898	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK110136				\$105,149	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK110172	NORTHWESTERN UNIVERSITY	DK110172		\$147,134	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK110988	DUKE UNIVERSITY	DK110988		\$273,509	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK111024	EMORY UNIVERSITY	DK111024		\$8,027	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK111378				\$287,396	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK112915				\$2,432	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK113111	UNIVERSITY OF KANSAS MEDICAL CENTER	DK113111		\$180,130	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK113999			\$209,100	\$351,520	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK114007				\$320,889	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK114460				\$222,533	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK114497				\$161,933	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK115255	GEORGIA REGENTS UNIVERSITY	DK115255		\$54,432	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK115402			\$145,615	\$329,241	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK115575	UNIVERSITY OF NORTH CAROLINA	DK115575		\$360,463	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK115594				\$211,568	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK115950				\$420,481	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK116092	UNIVERSITY OF WISCONSIN MADISON	DK116092		\$7,183	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK116102	JOSLIN DIABETES CENTER	DK116102		\$11,853	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK116231			\$61,013	\$417,755	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK116743	MEDICAL UNIVERSITY OF SOUTH CAROLINA	DK116743		\$90	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK116963	INDIANA UNIVERSITY	DK116963		\$8,959	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK117133	SANFORD-BURNHAM MEDICAL	DK117133		\$363,135	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK117212			\$57,119	\$120,820	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK117236	MASSACHUSETTS GENERAL HOSPITAL	DK117236		\$29,349	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK117861				\$391,708	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK117910				\$230,043	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK118120				\$168,778	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK118358				\$38,729	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK118391				\$147,991	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK118619			\$488,026	\$824,980	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK119167				\$471,274	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK119646				\$555,793	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2021 - 12/31/2021

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK119683				\$3,602	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK120292				\$448,561	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK120358	HARVARD UNIVERSITY	DK120358		\$157,756	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK120559				\$345,188	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK120745				\$88,808	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK120808				\$127,594	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK121240	JAEB CENTER FOR HEALTH RESEARCH	DK121240		\$63,791	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK121330	UNIVERSITY OF TEXAS-HOUSTON	DK121330		\$86,761	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK121766				\$387,541	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK121888				\$146,486	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK121943				\$173,023	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK122137				\$129,679	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK122187				\$135,282	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK122280				\$529,215	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK122603	JAEB CENTER FOR HEALTH RESEARCH	DK122603		\$185,666	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK122734				\$625,212	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK122948				\$398,027	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK123313				\$153,808	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK123441	ARIZONA STATE UNIVERSITY	DK123441		\$84,175	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK123492				\$217,086	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK123549				\$535,851	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK123834				\$32,335	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK123858				\$28,520	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK124182				\$352,572	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK124190				\$85,093	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK124358				\$175,517	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK125252			\$171,992	\$574,677	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK125431	UNIVERSITY OF MINNESOTA	DK125431		\$462,511	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK125495	CEDARS SINAI MEDICAL CENTER	DK125495		\$2,868	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK125632				\$103,335	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK126206			\$42,472	\$581,674	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK126607	SONOVOL, INC.	DK126607		\$55,001	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK126662				\$491,296	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK126691				\$243,923	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2021 - 12/31/2021

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK126700				\$85,684	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK127010				\$74,603	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK127064				\$15,831	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK127403	CEDARS SINAI MEDICAL CENTER	DK127403		\$14,605	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK127564				\$19,343	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK127992				\$208,448	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK127998				\$8,956	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK128017				\$152,409	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK128127				\$108,048	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK128552				\$257,545	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK128844				\$260,249	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK128913				\$33,916	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK128987				\$25,878	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK129208				\$42,283	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK129240				\$1,945	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK129241				\$64,622	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK129315				\$61,718	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK129886				\$35,199	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK130331				\$6,635	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK130884				\$46,016	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK131455				\$25,221	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK24031				\$563,714	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK29953	UNIVERSITY OF VIRGINIA	DK29953		\$31,344	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK40484				\$435,995	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK41876				\$56,159	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK44650				\$68,056	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK45343				\$695,632	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK52766				\$385,992	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK57061				\$360,496	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK57993				\$376,092	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK58185			\$14,374	\$29,008	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK58816				\$532,007	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK59597				\$417,827	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK59615				\$275,890	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2021 - 12/31/2021

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK68055			\$1,819	\$326,641	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK74008	JOHNS HOPKINS UNIVERSITY	DK74008		\$386,146	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK78924				\$403,074	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK83912	UNIVERSITY OF MICHIGAN	DK83912		\$66,728	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK84097				\$6,260	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK84567				\$1,236,904	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK85516	UNIVERSITY OF VIRGINIA	DK85516		\$225,352	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK88925	UNIVERSITY OF WISCONSIN-MADISON	DK88925		\$23,940	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK90358				\$453,251	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK92255			\$63,569	\$523,908	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK92460				\$467,449	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK94157	CASE WESTERN RESERVE UNIVERSITY	DK94157		\$117,685	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK98468				\$444,683	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK99160				\$259,944	\$30,330,767	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS062835	UNIVERSITY OF TEXAS AT AUSTIN	NS062835		\$675,432	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS085070				\$525,804	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS095869	UNIVERSITY OF CINCINNATI	NS095869		\$24,927	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS100620				\$1,461,260	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS100693			\$316,750	\$649,198	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS100699	UNIVERSITY OF CINCINNATI	NS100699		\$26,147	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS101721				\$209,574	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS102233	TUFTS MEDICAL CENTER, INC.	NS102233		\$54,284	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS102289	UNIVERSITY OF CINCINNATI	NS102289		\$7,182	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS102360				\$336,753	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS103212				\$424,084	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS103670	MARBLEHEAD MEDICAL, LLC	NS103670		\$15,426	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS103870			\$479,365	\$921,256	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS104095	UNIVERSITY OF SOUTHERN CALIFORNIA	NS104095		\$62,526	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS104157	UNIVERSITY OF CHICAGO	NS104157		\$74,368	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS105853				\$395,862	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS105894	JOHNS HOPKINS UNIVERSITY	NS105894		\$2,627	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS106513	UNIVERSITY OF CINCINNATI	NS106513		\$8,582	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS107048	NEUROGAMI MEDICAL, INC.	NS107048		\$69,728	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS107111	ANCURE LLC	NS107111		\$97,660	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2021 - 12/31/2021

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS107265				\$323,535	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS107336			\$6,835	\$36,552	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS107946				\$89,651	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS108916	HEALTH RESEARCH, INC.	NS108916		\$34,359	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS109491				\$494,668	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS110085				\$582,370	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS110114	ENDOMIMETICS, LLC	NS110114		\$33,580	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS110335	EYENUK, INC.	NS110335		\$35,165	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS11043				\$21,864	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS110435			\$1,554,255	\$2,809,627	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS110438	COLUMBIA UNIVERSITY	NS110438		\$424,854	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS110728	UNIVERSITY OF CINCINNATI	NS110728		\$6,797	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS110772	UNIVERSITY OF CINCINNATI	NS110772		\$2,563	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS110825	UNIVERSITY OF MARYLAND	NS110825		\$205,222	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS110930				\$290,904	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS110949				\$563,575	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS110960			\$283,751	\$463,446	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS110994				\$84,588	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS111039	DUKE UNIVERSITY	NS111039		\$73,200	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS111085	SANFORD-BURNHAM MEDICAL	NS111085		\$201,556	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS111756				\$78,492	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS111978	UNIVERSITY OF CALIFORNIA SAN FRANCISCO	NS111978		\$64,100	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS111981	CLEVELAND CLINIC FOUNDATION	NS111981		\$95,852	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS112144			\$13,958	\$662,791	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS112144A				\$118,217	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS112153				\$246,046	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS112176			\$88,400	\$310,444	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS112339				\$184,049	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS112611				\$98,095	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS112826	YALE UNIVERSITY	NS112826		\$232,279	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS113315			\$273,251	\$799,730	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS113637	UNIVERSITY OF CALIFORNIA SAN FRANCISCO	NS113637		\$105,345	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS113724	EVOGEN, INC.	NS113724		\$78,348	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS113760				\$337,207	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2021 - 12/31/2021

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS113776				\$723,436	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS113803				\$676,487	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS113828				\$370,550	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS113851	NORTHWESTERN UNIVERSITY	NS113851		\$269	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS114040				\$45,426	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS114117				\$261,007	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS114147			\$29,646	\$59,625	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS114365				\$74,868	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS114552	UNIVERSITY OF CHICAGO	NS114552		\$46,091	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS115126				\$838,637	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS115198			\$792,039	\$1,859,120	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS115202				\$41,782	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS115358				\$28,843	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS115388	MASSACHUSETTS GENERAL HOSPITAL	NS115388	\$85,908	\$1,364,264	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS115708	UNIVERSITY OF PITTSBURGH	NS115708		\$1,178	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS115877				\$529,787	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS116924				\$45,759	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS117214	CND LIFE SCIENCES	NS117214		\$9,399	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS117432			\$63,037	\$503,650	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS117461				\$155,846	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS117799				\$19,471	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS118513			\$196,644	\$499,114	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS118790				\$196,455	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS119169				\$11,872	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS119714	SCRIPPS RESEARCH INSTITUTE	NS119714		\$61,128	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS120348			\$155,034	\$443,970	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS120496	UNIVERSITY OF TEXAS SOUTHWEST MEDICAL CENTER	NS120496		\$12,872	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS120605				\$10,728	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS120877				\$66,277	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS120992				\$166,303	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS121125				\$373,249	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS121928	CASE WESTERN RESERVE	NS121928		\$95,286	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS122174				\$404,390	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS124065	UNIVERSITY OF MINNESOTA	NS124065		\$13,129	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2021 - 12/31/2021

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS125417				\$11,085	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS31744			\$141,010	\$352,077	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS65705	UNIVERSITY OF CALIFORNIA SAN FRANCISCO	NS65705		\$3,476	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS73610			\$219,775	\$356,122	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS74969	WASHINGTON UNIVERSITY IN ST. LOUIS	NS74969		\$367,200	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS76491			\$96,287	\$278,464	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS80168			\$3,830,796	\$5,417,097	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS84974			\$1,363,265	\$1,951,739	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS88260				\$74,498	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS88627				\$301,359	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS89757				\$787,225	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS92091	UNIVERSITY OF MIAMI	NS92091		\$59,754	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS92625				\$203,435	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS92882			\$32,685	\$407,272	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS92891				\$192,638	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS93334	BOSTON UNIVERSITY	NS93334	\$12,383	\$75,598	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS94124				\$165,780	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS95495			\$17,938	\$638,377	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS95869	UNIVERSITY OF CINCINNATI	NS95869		\$3,615	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS97273				\$1,310,859	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS97495				\$276,108	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS97719	CLEVELAND CLINIC FOUNDATION	NS97719		\$141,440	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS97876	COLUMBIA UNIVERSITY	NS97876	\$94,812	\$155,506	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS99043	UNIVERSITY OF CINCINNATI	NS99043		\$47,812	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS99114	SCRIPPS RESEARCH INSTITUTE	NS99114		\$329,609	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS99268	UNIVERSITY OF CALIFORNIA SAN FRANCISCO	NS99268		\$7,096	\$40,157,260	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI104681	DUKE UNIVERSITY	AI104681		\$646,147	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI105066				\$70,230	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI108682	UNIVERSITY OF CHICAGO	AI108682		\$134,008	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI108891				\$154,678	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI108906				\$278,867	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI109565	BENAROYA RESEARCH INSTITUTE	AI109565		\$101,656	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI110173				\$593,114	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI112844				\$252,856	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI113362	UNIVERSITY OF CALIFORNIA SAN FRANCISCO	AI113362		\$790	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI116501	WASHINGTON UNIVERSITY	AI116501		\$11,305	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI117804	CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER	AI117804		\$19,413	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI120698				\$473,896	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI120959				\$225,172	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI121054			\$426,566	\$656,484	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI122369	UNIVERSITY OF PITTSBURGH	AI122369		\$63,492	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2021 - 12/31/2021

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI122742	UNIVERSITY OF MINNESOTA	AI122742		\$19,592	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI122838				\$99,616	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI125053	UNIVERSITY OF WISCONSIN MADISON	AI125053		\$26,311	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI127365				\$302,452	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI128729			\$288,149	\$456,442	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI129191				\$163,737	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI131566	EMORY UNIVERSITY	AI131566		\$216,725	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI132165				\$138,410	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI132348				\$379,168	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI132402	UNIVERSITY OF IOWA	AI132402		\$38,304	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI132405	ICAHN SCHOOL OF MEDICINE	AI132405		\$165,548	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI134406	UNIVERSITY OF MINNESOTA	AI134406		\$62,388	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI134770	UNIVERSITY OF MASSACHUSETTS	AI134770		\$201,082	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI134937				\$541,581	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI135858				\$39,651	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI136718			\$316,388	\$451,206	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI138965				\$641,017	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI138993	ARIZONA STATE UNIVERSITY	AI138993		\$11,997	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI139381				\$266,819	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI141591	UNIVERSITY OF MICHIGAN	AI141591		\$210,781	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI141765				\$215,042	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI142702				\$63,019	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI142978	SONORAN BIOSCIENCES, INC.	AI142978		\$19,418	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI143791			\$136,246	\$375,499	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI143882				\$202,987	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI144301	JOAN & SANFORD I. WEILL MEDICAL COLLEGE	AI144301		\$36,593	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI144721				\$279,135	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI145108	UNIVERSITY OF VIRGINIA	AI145108		\$245,144	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI145356			\$7,559	\$29,680	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI145407				\$69,194	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI146431			\$46,050	\$201,584	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI146644	SCRIPPS RESEARCH INSTITUTE	AI146644		\$16,252	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI147368				\$158,451	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI147394				\$906,781	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI147438				\$41,759	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI148963	ICAHN SCHOOL OF MEDICINE	AI148963		\$19,667	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI150100				\$466,223	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI150599				\$362,136	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI150649				\$168,054	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI151208				\$86,200	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI152042			\$119,795	\$155,927	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI152318				\$172,751	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI154470	BOSTON CHILDREN'S HOSPITAL	AI154470		\$3,406	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI154598			\$5,608	\$437,810	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI154927				\$87,486	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI155378				\$38,610	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI155826				\$156,097	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI155907	ARIZONA STATE UNIVERSITY	AI155907		\$55,751	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI157328				\$176,473	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI159230				\$121,927	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI163302				\$37,424	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI164562	EMORY UNIVERSITY	AI164562		\$4,436	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI21747	UNIVERSITY OF CONNECTICUT	AI21747		\$77,785	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI33144				\$198,471	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI48793				\$206,211	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI52417				\$166,811	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI57266	EMORY UNIVERSITY	AI57266		\$151,230	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI68641	INSTITUTE FOR CLINICAL RESEARCH	AI68641		\$176	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI71106			\$84,000	\$862,559	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI89714				\$513,347	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI91594			\$89,050	\$308,032	\$16,010,473	RESEARCH AND DEVELOPMENT	\$404,219,504
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM063904			\$13,820	\$61,219	\$7,508,164	RESEARCH AND DEVELOPMENT	\$404,219,504
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM075148				\$309,371	\$7,508,164	RESEARCH AND DEVELOPMENT	\$404,219,504
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM08685				\$511,822	\$7,508,164	RESEARCH AND DEVELOPMENT	\$404,219,504
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM105688	CORNELL COLLEGE-VET MEDICINE	GM105688		\$74,006	\$7,508,164	RESEARCH AND DEVELOPMENT	\$404,219,504
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM118079	UNIVERSITY OF MINNESOTA	GM118079		\$14,405	\$7,508,164	RESEARCH AND DEVELOPMENT	\$404,219,504

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2021 - 12/31/2021

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM120079	UNIVERSITY OF MINNESOTA	GM120079		\$52,556	\$7,508,164	RESEARCH AND DEVELOPMENT	\$404,219,504
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM123757			\$125,325	\$377,277	\$7,508,164	RESEARCH AND DEVELOPMENT	\$404,219,504
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM125633			\$25,212	\$306,916	\$7,508,164	RESEARCH AND DEVELOPMENT	\$404,219,504
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM126086			\$161,337	\$760,292	\$7,508,164	RESEARCH AND DEVELOPMENT	\$404,219,504
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM128253			\$39,425	\$233,531	\$7,508,164	RESEARCH AND DEVELOPMENT	\$404,219,504
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM128579				\$305,009	\$7,508,164	RESEARCH AND DEVELOPMENT	\$404,219,504
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM128594				\$247,302	\$7,508,164	RESEARCH AND DEVELOPMENT	\$404,219,504
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM130556			\$465,230	\$566,788	\$7,508,164	RESEARCH AND DEVELOPMENT	\$404,219,504
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM132095			\$89,851	\$349,096	\$7,508,164	RESEARCH AND DEVELOPMENT	\$404,219,504
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM132100				\$321,034	\$7,508,164	RESEARCH AND DEVELOPMENT	\$404,219,504
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM134732				\$596,632	\$7,508,164	RESEARCH AND DEVELOPMENT	\$404,219,504
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM135488				\$83,848	\$7,508,164	RESEARCH AND DEVELOPMENT	\$404,219,504
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM136262				\$478,580	\$7,508,164	RESEARCH AND DEVELOPMENT	\$404,219,504
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM136869				\$114,115	\$7,508,164	RESEARCH AND DEVELOPMENT	\$404,219,504
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM137368	UNIVERSITY OF PUERTO RICO MEDICAL CENTER	GM137368		\$12,896	\$7,508,164	RESEARCH AND DEVELOPMENT	\$404,219,504
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM140487				\$210,346	\$7,508,164	RESEARCH AND DEVELOPMENT	\$404,219,504
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM28157				\$60,228	\$7,508,164	RESEARCH AND DEVELOPMENT	\$404,219,504
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM55252				\$487,615	\$7,508,164	RESEARCH AND DEVELOPMENT	\$404,219,504
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM65450				\$169,326	\$7,508,164	RESEARCH AND DEVELOPMENT	\$404,219,504
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM65841				\$586,870	\$7,508,164	RESEARCH AND DEVELOPMENT	\$404,219,504
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM72474				\$94,125	\$7,508,164	RESEARCH AND DEVELOPMENT	\$404,219,504
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	OD21879			\$36,199	\$122,959	\$7,508,164	RESEARCH AND DEVELOPMENT	\$404,219,504
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD100251	SERSENSE, INC.	HD100251		\$7,380	\$2,150,675	RESEARCH AND DEVELOPMENT	\$404,219,504
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD100540	JOHNS HOPKINS UNIVERSITY MASSACHUSETTS GENERAL HOSPITAL	HD100540		\$714	\$2,150,675	RESEARCH AND DEVELOPMENT	\$404,219,504
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD103099		HD103099		\$10,435	\$2,150,675	RESEARCH AND DEVELOPMENT	\$404,219,504
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD103498			\$5,881	\$36,609	\$2,150,675	RESEARCH AND DEVELOPMENT	\$404,219,504
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD44763	UNIVERSITY OF MINNESOTA	HD44763		\$138,243	\$2,150,675	RESEARCH AND DEVELOPMENT	\$404,219,504
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD65987				\$585,355	\$2,150,675	RESEARCH AND DEVELOPMENT	\$404,219,504
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD79439				\$242,956	\$2,150,675	RESEARCH AND DEVELOPMENT	\$404,219,504
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD84423			\$7,859	\$131,354	\$2,150,675	RESEARCH AND DEVELOPMENT	\$404,219,504
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD86843	UNIVERSITY OF PITTSBURGH	HD86843		\$67,159	\$2,150,675	RESEARCH AND DEVELOPMENT	\$404,219,504
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD87413	UNIVERSITY OF VIRGINIA	HD87413		\$12,593	\$2,150,675	RESEARCH AND DEVELOPMENT	\$404,219,504
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD91337				\$2,883	\$2,150,675	RESEARCH AND DEVELOPMENT	\$404,219,504
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD97843	MOORHOUSE SCHOOL OF MEDICINE	HD97843		\$46,856	\$2,150,675	RESEARCH AND DEVELOPMENT	\$404,219,504
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD99147			\$425,318	\$813,059	\$2,150,675	RESEARCH AND DEVELOPMENT	\$404,219,504
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	LM13438				\$55,079	\$2,150,675	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG03949	ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY	AG03949		\$80,475	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG046205				\$433,245	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG04875				\$92,271	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG054014	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	AG054014		\$30,151	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG055104	THE JACKSON LABORATORY	AG055104		\$94,961	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG057181				\$16,791	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG057195	INDIANA UNIVERSITY	AG057195		\$6,475	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG057437	UNIVERSITY OF SOUTHERN CALIFORNIA	AG057437		\$70,655	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG058812				\$14,200	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG061359	DUKE UNIVERSITY	AG061359		\$23,999	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG061796				\$1,165,338	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG062110				\$271,497	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG062348	BOSTON UNIVERSITY	AG062348		\$102,319	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG067593				\$977,449	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG06786			\$29,425	\$5,299,938	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG10483	UNIVERSITY OF CALIFORNIA SAN DIEGO	AG10483		\$8,839	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG11378				\$985,199	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG13925			\$79,663	\$1,012,478	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG16574				\$319,261	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG167418	UCB PHARMA, INC.	AG167418		\$179,210	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2021 - 12/31/2021

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
AGING RESEARCH	93.866	AG16976	UNIVERSITY OF WASHINGTON	AG16976		\$31,366	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG19610	SUN HEALTH RESEARCH INSTITUTE	AG19610		\$147,509	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG24904	UNIVERSITY OF CALIFORNIA SAN DIEGO	AG24904		\$421,387	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG27924	WASHINGTON UNIVERSITY IN ST. LOUIS	AG27924		\$1,197,097	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG32438	WASHINGTON UNIVERSITY IN ST. LOUIS	AG32438		\$251,296	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG37491	UNIVERSITY OF SOUTHERN CALIFORNIA	AG37491		\$477,301	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG38791	UNIVERSITY OF SOUTHERN CALIFORNIA	AG38791		\$257	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG39449	BRIGHAM AND WOMENS HOSPITAL	AG39449		\$1,250	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG40282	JOHNS HOPKINS UNIVERSITY	AG40282		\$4,153	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG41851	JOHNS HOPKINS UNIVERSITY	AG41851		\$357,856	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG44170	JOHNS HOPKINS UNIVERSITY	AG44170		\$1,924,074	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG44615	JOHNS HOPKINS UNIVERSITY	AG44615		\$651,754	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG45779	JOHNS HOPKINS UNIVERSITY	AG45779		\$127,937	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG46139	UNIVERSITY OF FLORIDA	AG46139		\$122,014	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG46139	UNIVERSITY OF FLORIDA	AG46139	\$1,821,641	\$3,453,576	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG47156	UNIVERSITY OF FLORIDA	AG47156		\$35,682	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG49672	UNIVERSITY OF FLORIDA	AG49672		\$238,339	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG49810	UNIVERSITY OF CALIFORNIA SAN DIEGO	AG49810		\$82,584	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG50603	UNIVERSITY OF CALIFORNIA SAN DIEGO	AG50603		\$667,379	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG51406	UNIVERSITY OF PITTSBURGH	AG51406		\$113,767	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG51574	NORTH DAKOTA STATE UNIVERSITY	AG51574		\$173,023	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG51679	NORTH DAKOTA STATE UNIVERSITY	AG51679		\$102,286	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG52350	UNIVERSITY OF SOUTHERN CALIFORNIA	AG52350		\$3,168	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG52425	UNIVERSITY OF SOUTHERN CALIFORNIA	AG52425	\$55,737	\$747,195	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG52564	UNIVERSITY OF MINNESOTA	AG52564		\$34,380	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG52822	UNIVERSITY OF MINNESOTA	AG52822		\$40,776	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG52943	UNIVERSITY OF PENNSYLVANIA	AG52943		\$48,490	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG53229	UNIVERSITY OF PENNSYLVANIA	AG53229		\$176,999	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG53267	WASHINGTON UNIVERSITY	AG53267		\$27,545	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG53798	UNIVERSITY OF SOUTHERN CALIFORNIA	AG53798		\$92,396	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG53832	UNIVERSITY OF SOUTHERN CALIFORNIA	AG53832	\$30,606	\$194,567	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG54029	MASSACHUSETTS GENERAL HOSPITAL	AG54029		\$357,958	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG54048	ARIZONA STATE UNIVERSITY	AG54048		\$23,573	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG54199	ARIZONA STATE UNIVERSITY	AG54199		\$6,231	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG54449	ARIZONA STATE UNIVERSITY	AG54449		\$775,234	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG54454	ARIZONA STATE UNIVERSITY	AG54454		\$721,773	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG54491	JOHNS HOPKINS UNIVERSITY	AG54491		\$26,249	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG54672	BRIGHAM AND WOMENS HOSPITAL	AG54672		\$84,771	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG54787	UNIVERSITY OF MISSISSIPPI MEDICAL CENTER	AG54787		\$208,579	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG55151	UNIVERSITY OF MISSISSIPPI MEDICAL CENTER	AG55151		\$808,933	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG55152	INNOVATIVE DESIGN LABS INC.	AG55152		\$162,662	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG55444	BANNER ALZHEIMER'S INSTITUTE	AG55444		\$31,036	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG55529	BANNER ALZHEIMER'S INSTITUTE	AG55529	\$53,864	\$676,954	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG55549	BANNER ALZHEIMER'S INSTITUTE	AG55549		\$625,607	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG56130	SANFORD-BURNHAM MEDICAL	AG56130		\$361,920	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG56255	SANFORD-BURNHAM MEDICAL	AG56255	\$391,089	\$556,597	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG56270	COLUMBIA UNIVERSITY	AG56270		\$119,910	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG56315	COLUMBIA UNIVERSITY	AG56315		\$375,041	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG56318	BOSTON UNIVERSITY	AG56318	\$81,062	\$389,423	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG56366	BOSTON UNIVERSITY	AG56366	\$50,645	\$571,893	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG56933	JOHNS HOPKINS UNIVERSITY	AG56933		\$121,542	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG57015	JOHNS HOPKINS UNIVERSITY	AG57015		\$240,695	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG57052	JOHNS HOPKINS UNIVERSITY	AG57052		\$349,718	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG57181	JOHNS HOPKINS UNIVERSITY	AG57181	\$93,915	\$413,015	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG57195	INDIANA UNIVERSITY	AG57195		\$742,568	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG57437	UNIVERSITY OF SOUTHERN CALIFORNIA	AG57437		\$516,202	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2021 - 12/31/2021

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
AGING RESEARCH	93.866	AG57441	NORTHWESTERN UNIVERSITY	AG57441		\$22,115	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG57493				\$523,183	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG57531	UNIVERSITY OF NEW SOUTH WALES	AG57531		\$19,715	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG57547			\$1,465,442	\$2,438,442	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG57708	BARROW NEUROLOGICAL INSTITUTE	AG57708		\$98,145	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG58266			\$60,412	\$968,240	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG58560				\$134,161	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG58676	UNIVERSITY OF MELBOURNE	AG58676		\$24,030	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG58729	HENNEPIN HEALTHCARE RESEARCH	AG58729		\$72,607	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG58738				\$916,220	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG58798				\$253,544	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG58812				\$260,534	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG59009	UNIVERSITY OF CALIFORNIASAN FRANCISCO	AG59009		\$54,466	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG59093	DUKE UNIVERSITY	AG59093		\$44,146	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG59654	UNIVERSITY OF MINNESOTA	AG59654		\$18,911	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG59798	WASHINGTON UNIVERSITY	AG59798		\$48,271	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG60139				\$47,410	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG60502	JOHNS HOPKINS UNIVERSITY	AG60502		\$13,699	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG60626	DANA-FARBER CANCER INSTITUTE	AG60626		\$175,141	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG60637			\$72,517	\$465,452	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG60907	CALIFORNIA PACIFIC MEDICAL CENTER	AG60907		\$247,686	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG60920				\$975,950	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG61100	PARTNERS HEALTH CARE RES MGMT	AG61100		\$118,792	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG61414	UNIVERSITY OF CENTRAL FLORIDA	AG61414		\$6,048	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG61427	YALE UNIVERSITY	AG61427		\$50,074	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG61456			\$242,457	\$696,759	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG61848	UNIVERSITY OF SOUTHERN CALIFORNIA	AG61848		\$12,955	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG62077				\$286,390	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG62104				\$143,487	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG62110				\$406,652	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG62135	UNIVERSITY OF MINNESOTA	AG62135		\$222,444	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG62171	JOHNS HOPKINS UNIVERSITY	AG62171		\$31,070	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG62413			\$561,153	\$3,184,894	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG62436			\$55,146	\$471,249	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG62556				\$217,081	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG62580			\$11,929	\$91,143	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG62620	THE UNIVERSITY OF ARIZONA	AG62620		\$52,231	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG62677				\$2,746,827	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG62689	UNIVERSITY OF CALIFORNIA BERKELEY	AG62689		\$257,995	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG62823	ARIZONA STATE UNIVERSITY	AG62823		\$97,217	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG62859				\$85,858	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG63689	UNIVERSITY OF SOUTHERN CALIFORNIA	AG63689		\$194,964	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG63707				\$405,770	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG63780				\$290,495	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG63911			\$4,743,311	\$8,454,165	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG64029				\$221,507	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG64165	BRIGHAM AND WOMENS HOSPITAL	AG64165		\$75,635	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG64804				\$140,522	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG65014	BIOSENSICS LLC	AG65014		\$97,398	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG65088	MINNESOTA HEALTHSOLUTIONS CORPORATION	AG65088		\$61,286	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG65143				\$195,193	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG65154			\$820,262	\$1,336,556	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG65188	DUKE UNIVERSITY	AG65188		\$91,319	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG65219				\$324,247	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG65311	BETH ISRAEL DEACONESS MEDICAL	AG65311		\$23,053	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2021 - 12/31/2021

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
AGING RESEARCH	93.866	AG65639				\$151,363	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG65653				\$291,395	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG65660				\$217,223	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG65868				\$188,988	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG65942	ARIZONA STATE UNIVERSITY	AG65942		\$17,947	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG66134	COLUMBIA UNIVERSITY	AG66134		\$19,891	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG66395				\$780,790	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG66429				\$694,962	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG67151	MASSACHUSETTS INSTITUTE	AG67151		\$290,950	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG67418	UCB PHARMA, INC.	AG67418		\$269,615	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG67593				\$187,103	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG67631	INDIANA UNIVERSITY	AG67631		\$20,021	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG67763				\$99,824	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG68007				\$405,618	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG68034	NORTH DAKOTA STATE UNIVERSITY	AG68034		\$84,390	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG68048				\$605,654	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG68054	UNIVERSITY OF PITTSBURGH	AG68054		\$56,361	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG68076				\$417,127	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG68128	UNIVERSITY OF FLORIDA	AG68128		\$54,989	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG68182				\$377,561	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG68192				\$594,743	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG68206				\$407,021	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG68368				\$77,768	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG68509				\$34,435	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG68581	ST. JUDE CHILDREN'S HOSPITAL	AG68581		\$704,443	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG68620				\$109,513	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG69052				\$328,298	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG69264				\$602,884	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG69453	BANNER ALZHEIMER'S ISTITUTE	AG69453		\$159,673	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG69701			\$122,018	\$1,041,059	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG69745	UTAH STATE UNIVERSITY	AG69745		\$108,311	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG69767			\$62,448	\$268,947	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG70113				\$137,660	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG70486				\$56,945	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG71190				\$134,788	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG71226				\$302,920	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG71686				\$433,420	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG71754	WASHINGTON UNIVERSITY	AG71754		\$248,630	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG72122	WASHINGTON UNIVERSITY	AG72122		\$418	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG72301			\$73,753	\$710,275	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG72719				\$90,426	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG72799	UNIVERSITY OF TEXAS HOUSTON	AG72799		\$40,936	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG72898				\$490,305	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG73119	UNIVERSITY OF CONNECTICUT	AG73119		\$11,318	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG73282				\$14,103	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG73967				\$42,346	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG73987				\$27,343	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AG74127	MINNESOTA HEALTH SOLUTIONS CORP	AG74127		\$15,728	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	AJ07425				\$155,822	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	CA242158				\$128,250	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
AGING RESEARCH	93.866	DK126827				\$475,141	\$75,025,195	RESEARCH AND DEVELOPMENT	\$404,219,504
VISION RESEARCH	93.867	EY11751	JAEB CENTER FOR HEALTH RESEARCH	EY11751		\$404,775	\$1,435,154	RESEARCH AND DEVELOPMENT	\$404,219,504
VISION RESEARCH	93.867	EY21727			\$28,365	\$465,650	\$1,435,154	RESEARCH AND DEVELOPMENT	\$404,219,504
VISION RESEARCH	93.867	EY22124	OHIO STATE UNIVERSITY	EY22124		\$96,779	\$1,435,154	RESEARCH AND DEVELOPMENT	\$404,219,504
VISION RESEARCH	93.867	EY24333			\$26,341	\$174,923	\$1,435,154	RESEARCH AND DEVELOPMENT	\$404,219,504
VISION RESEARCH	93.867	EY26869	NEW YORK SCHOOL OF MEDICINE	EY26869		\$23,726	\$1,435,154	RESEARCH AND DEVELOPMENT	\$404,219,504
VISION RESEARCH	93.867	EY28803	IMACULAR REGENERATION	EY28803		\$19,993	\$1,435,154	RESEARCH AND DEVELOPMENT	\$404,219,504
VISION RESEARCH	93.867	EY30819	ABBE VISION INC.	EY30819		\$117,522	\$1,435,154	RESEARCH AND DEVELOPMENT	\$404,219,504
VISION RESEARCH	93.867	EY31301				\$96,386	\$1,435,154	RESEARCH AND DEVELOPMENT	\$404,219,504
VISION RESEARCH	93.867	EY31758				\$35,400	\$1,435,154	RESEARCH AND DEVELOPMENT	\$404,219,504
MEDICAL LIBRARY ASSISTANCE	93.879	LM11563	UNIVERSITY OF WASHINGTON	LM11563		\$8,136	\$43,270	RESEARCH AND DEVELOPMENT	\$404,219,504
MEDICAL LIBRARY ASSISTANCE	93.879	LM11934				\$17,564	\$43,270	RESEARCH AND DEVELOPMENT	\$404,219,504
MEDICAL LIBRARY ASSISTANCE	93.879	LM13438	ARIZONA STATE UNIVERSITY	LM13438		\$12,392	\$43,270	RESEARCH AND DEVELOPMENT	\$404,219,504
MEDICAL LIBRARY ASSISTANCE	93.879	LM13501	NESTED KNOWLEDGE, INC.	LM13501		\$5,178	\$43,270	RESEARCH AND DEVELOPMENT	\$404,219,504
PRIMARY CARE TRAINING AND ENHANCEMENT	93.884	HL156812	UNIVERSITY OF ARIZONA	HL156812		\$7,147	\$540,501	RESEARCH AND DEVELOPMENT	\$404,219,504
PRIMARY CARE TRAINING AND ENHANCEMENT	93.884	HP33881			\$253,329	\$547,648	\$540,501	RESEARCH AND DEVELOPMENT	\$404,219,504

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2021 - 12/31/2021

<i>Federal Awarding Agency/Program Title</i>	<i>Federal Assistance Listing Number</i>	<i>Additional Award Identification</i>	<i>Name of Funder Pass-Through Entity</i>	<i>Identifying Number Assigned By Funder Pass-Through Entity</i>	<i>Total Amount Provided to Sub-Recipients</i>	<i>Federal Expenditures</i>	<i>Federal Program Total</i>	<i>Cluster Name</i>	<i>Cluster Total</i>
NATIONAL BIOTERRORISM HOSPITAL PREPAREDNESS PROGRAM	93.889	47383				\$183,385	\$763,414	N/A	\$0
NATIONAL BIOTERRORISM HOSPITAL PREPAREDNESS PROGRAM	93.889	MDH10327	MINNESOTA DEPARTMENT OF HEALTH	MDH10327		\$580,029	\$763,414	N/A	\$0
CONTRACT	93.RD	16X237	LEIDOS BIOMEDICAL RESEARCH	16X237		\$598,163	\$27,630,754	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	93.RD	75A50120C00096				\$8,840,986	\$27,630,754	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	93.RD	75A50121P00001				\$15,616,142	\$27,630,754	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	93.RD	75N91019C00016	PACT & HEALTH LLC	75N91019C00016		\$578	\$27,630,754	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	93.RD	75N91019C00035	NVIGEN, INC.	75N91019C00035		\$36,585	\$27,630,754	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	93.RD	75N91019C00043	PACT & HEALTH LLC	75N91019C00043		\$5,427	\$27,630,754	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	93.RD	75N91020P00907				\$13,934	\$27,630,754	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	93.RD	75N91020P00909				\$2,995	\$27,630,754	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	93.RD	75N91020P00921				\$63,194	\$27,630,754	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	93.RD	75N92019D00031	BOSTON UNIVERSITY	75N92019D00031		\$30,654	\$27,630,754	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	93.RD	75N97019P00280	THE BROAD INSTITUTE, INC.	75N97019P00280		\$49,689	\$27,630,754	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	93.RD	HHNS-2-68-2018-00010I	UNIVERSITY OF MISSISSIPPI MEDICAL CENTER	HHNS-2-68-2018-00010I		\$15,628	\$27,630,754	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	93.RD	HHS-N-261-2012-00035I	NORTHWESTERN UNIVERSITY	HHS-N-261-2012-00035I		\$16,550	\$27,630,754	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	93.RD	HHS-N-261-2012-00042I			\$282,036	\$985,311	\$27,630,754	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	93.RD	HHS-N-261-2016-00024I				\$47,079	\$27,630,754	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	93.RD	HHS-N-268-2018-00005I	MOUNT SINAI SCHOOL OF MEDICINE AT NYU	HHS-N-268-2018-00005I		\$3,809	\$27,630,754	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	93.RD	HHS-N-268-2018-00010I	UNIVERSITY OF MISSISSIPPI MEDICAL CENTER	HHS-N-268-2018-00010I		\$149	\$27,630,754	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	93.RD	HHS-N-272-2017-00078C	PPD DEVELOPMENT, LP	HHS-N-272-2017-00078C		\$35,657	\$27,630,754	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	93.RD	HHS-N-273-2018-00005I	SOCIAL & SCIENTIFIC SYSTEMS, INC.	HHS-N-273-2018-00005I		\$29,796	\$27,630,754	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	93.RD	HHS-N-275-2018-00003I	DUKE UNIVERSITY	HHS-N-275-2018-00003I		\$13,916	\$27,630,754	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	93.RD	HHS-N-275-2018-00005I			\$333,132	\$638,622	\$27,630,754	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	93.RD	HHS-O-100-2016-00009C				\$98,253	\$27,630,754	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	93.RD	HHS-P-233-2016-00031I	JRS INTERNATIONAL	HHS-P-233-2016-00031I		\$91,541	\$27,630,754	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	93.RD	N02-CM-62212	THE CHILDRENS HOSPITAL OF PHILADELPHIA	N02-CM-62212		\$37	\$27,630,754	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	93.RD	PC35143	UNIVERSITY OF IOWA	PC35143		\$154,089	\$27,630,754	RESEARCH AND DEVELOPMENT	\$404,219,504
CONTRACT	93.RD	W911QY-20-9-0012	JOHNS HOPKINS UNIVERSITY	W911QY-20-9-0012		\$241,970	\$27,630,754	RESEARCH AND DEVELOPMENT	\$404,219,504
MILITARY HEALTH PROFESSIONS SCHOLARSHIPS	93.U01	OFFICE OF THE SURGEON GENERAL				\$252,270	\$252,270	N/A	\$0
TOTAL DEPARTMENT OF HEALTH AND HUMAN SERVICES					\$37,989,567	\$564,352,151			
TOTAL EXPENDITURES OF FEDERAL AWARDS					\$41,399,744	\$615,165,435			

Please Note:

Italicized award lines indicate pass-through funding

See accompanying notes to schedules of expenditures of federal awards and Florida state financial assistance.



**Schedule of Expenditures of Florida State Financial Assistance
Year Ended December 31, 2021**

Sponsor/CSFA Description/Project Description	CSFA Number	Contract / Grant / Subaward Number	Expenditures	Pass-Through to Subrecipients
STATE OF FLORIDA				
Department of Elder Affairs				
Direct Awards				
Alzheimer Model Day Care, Memory Disorder Clinics, and Alzheimer Special Projects	65.002	XZ707	\$ 55,717	\$ -
Alzheimer Model Day Care, Memory Disorder Clinics, and Alzheimer Special Projects	65.002	XZ908	351,644	-
Subtotal Direct Awards			407,361	-
Total Department of Elder Affairs			407,361	-
Department of Health				
Direct Awards				
James and Esther King Biomedical Research Program	64.041	20K02	188,915	-
Bankhead-Coley Cancer Research Program	64.078	20B02	13,043	-
Bankhead-Coley Cancer Research Program	64.078	8BC01	434,742	-
Bankhead-Coley Cancer Research Program	64.078	MOG13	63,871	-
Endowed Chair for Cancer Research	64.130	MOG07	1,354,313	-
Ed and Ethel Moore Alzheimer's Disease Research Program	64.135	7AZ22	8,783	-
Ed and Ethel Moore Alzheimer's Disease Research Program	64.135	8AZ06	36,140	-
Ed and Ethel Moore Alzheimer's Disease Research Program	64.135	8AZ07	13,189	-
Ed and Ethel Moore Alzheimer's Disease Research Program	64.135	8AZ08	108,506	-
Ed and Ethel Moore Alzheimer's Disease Research Program	64.135	9AZ08	(7,906)	-
Ed and Ethel Moore Alzheimer's Disease Research Program	64.135	9AZ09	13,619	-
Ed and Ethel Moore Alzheimer's Disease Research Program	64.135	20A07	16,073	-
Ed and Ethel Moore Alzheimer's Disease Research Program	64.135	20A10	141,628	-
Ed and Ethel Moore Alzheimer's Disease Research Program	64.135	20A20	47,060	-
Ed and Ethel Moore Alzheimer's Disease Research Program	64.135	20A22	18,727	-
Subtotal Direct Awards			2,450,703	-
Total Department of Health			2,450,703	-
Total Expenditures of State Financial Assistance			\$ 2,858,064	\$ -

See accompanying notes to schedules of expenditures of federal awards and Florida state financial assistance.

Mayo Clinic

Notes to Schedules of Expenditures of Federal Awards and Florida State Financial Assistance

December 31, 2021

1. Significant Accounting Policies

The accompanying schedules of expenditures of federal awards and Florida state financial assistance (the Schedules) include the federal and Florida state grant activity of Mayo Clinic under programs of the federal and Florida state government for the year ended December 31, 2021. The information in the Schedules is presented in accordance with the requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (the Uniform Guidance), and Chapter 10.650, *Rules of the Auditor General of the State of Florida*. Because the Schedules only present a selected portion of the operations of Mayo Clinic, they are not intended to, and do not, present the financial position, results of operations, or cash flows of Mayo Clinic.

Expenditures reported in the Schedules are reported on the cash basis of accounting, except for Assistance Listing No. 93.461, COVID-19 HRSA COVID-19 Claims Reimbursement for the Uninsured Program and the COVID-19 Coverage Assistance Fund, Assistance Listing No. 93.498, COVID-19 Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution, and the Student Financial Assistance Cluster, which are reported on the accrual basis of accounting. Under the cash basis, expenditures are recognized when paid rather than when the obligation is incurred. Such expenditures are reported following the cost principles contained in the Uniform Guidance, wherein certain types of expenditures are not allowable or are limited as to reimbursement. Negative amounts reported on the Schedules represent adjustments or credits made in the normal course of business to amounts reported as expenditures in prior years.

2. 10% De Minimis Cost Rate

Indirect cost rates for Mayo Clinic were based on applicable U.S. Department of Health and Human Services (HHS) negotiated rates, the 10% de minimis indirect cost rate allowed by the Uniform Guidance, or sponsor-specific (capped) rates.

3. Section 202 Direct Loans and Federal Direct Loans

The Supportive Housing for the Elderly, Section 202 Direct Loan (Assistance Listing No. 14.157) is considered a federal award until the outstanding balance is paid in full. At December 31, 2021, Luther Lakeside Apartments, Inc.'s outstanding balance is \$227,351 and Bloomer Lakeview, Inc.'s outstanding balance is \$233,075.

Mayo Clinic

Notes to Schedules of Expenditures of Federal Awards and Florida State Financial Assistance (continued)

3. Section 202 Direct Loans and Federal Direct Loans (continued)

During the year, Mayo Clinic expended \$14,919,675 in Federal Direct Student Loans (Assistance Listing No. 84.268), which includes Direct Stafford Loan and Parent Loan for Undergraduate Students from the federal government. The federal government is responsible for billings and collections of the loans. Mayo Clinic assists the federal government by processing the applications and applying funds to student accounts from the federal government. Since this program is administered by the federal government, new loans made in the fiscal year ended December 31, 2021, related to Federal Direct Student Loans are considered current year federal expenditures, whereas the outstanding loan balances are not.

4. COVID-19 Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution (Assistance Listing No. 93.498)

The Schedule includes \$181,884,275 received from HHS between April 10, 2020 through December 31, 2020, under the Provider Relief Fund (PRF) program of Assistance Listing No. 93.498. In accordance with guidance from HHS, \$114,925 in interest income earned on funds received from HHS has been included as a reportable PRF payment. These amounts are reported as Period 1 and Period 2 in the HHS PRF Reporting Portal. These amounts were recognized as other revenue and investment income in Mayo Clinic's consolidated financial statements in the accompanying consolidated statements of operations and changes in net assets for the years ended December 31, 2021 and 2020.

Mayo Clinic

Notes to Schedules of Expenditures of Federal Awards and Florida State Financial Assistance (continued)

4. COVID-19 Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution (Assistance Listing No. 93.498) (continued)

The amount presented on the Schedule for PRF is for the year ended December 31, 2021. The amount presented reconciles to the PRF information reported to HHS as follows:

Name of Reporting Entity for HHS Reporting Periods 1 and 2 Provider Relief Fund Report	Reporting Entity Tax Identification Number (TIN)	Type of Distribution	Total Other Provider Relief Fund Expenses Reported	Total Lost Revenues Reported	Total
Mayo Clinic Rochester	416011702	General	\$ 34,784,734	\$ 45,948,215	\$ 80,732,949
Mayo Clinic Jacksonville	593337028	General	12,658,504	–	12,658,504
Mayo Clinic Health System Fairmont	410760836	General	868,614	766,809	1,635,423
Mayo Clinic Health System Fairmont	410760836	Targeted	–	4,749,663	4,749,663
Mayo Clinic Health System – Southwest Minnesota Region	411236756	General	4,785,088	5,007,111	9,792,199
Mayo Clinic Health System – Southwest Minnesota Region	411236756	Targeted	–	7,635,467	7,635,467
Mayo Clinic Health System – Southeast Minnesota Region	411404075	General	3,315,508	6,993,192	10,308,700
Mayo Clinic Health System – Southeast Minnesota Region	411404075	Targeted	–	16,317,466	16,317,466
Mayo Clinic Health System – Northwest Wisconsin Region	390813418	General	7,254,397	9,037,312	16,291,709
Mayo Clinic Health System – Franciscan Medical Center	390806374	General	5,260,513	4,405,476	9,665,989
Mayo Clinic Health System – Franciscan Medical Center	390806374	Targeted	–	12,211,131	12,211,131
			<u>\$ 68,927,358</u>	<u>\$ 113,071,842</u>	<u>\$ 181,999,200</u>

Uniform Guidance Reports and Schedule

Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With *Government Auditing Standards*

Board of Trustees, Chief Executive Officer and
President, and Chief Financial Officer
Mayo Clinic

We have audited, in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States (*Government Auditing Standards*), the financial statements of Mayo Clinic (“the Clinic”), which comprise the consolidated statements of financial position as of December 31, 2021, and the related consolidated statements of activities and cash flows for the years then ended, and the related notes to the financial statements, and have issued our report thereon dated February 18, 2022.

Report on Internal Control Over Financial Reporting

In planning and performing our audit of the financial statements, we considered the Clinic’s internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Clinic’s internal control. Accordingly, we do not express an opinion on the effectiveness of the Clinic’s internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct misstatements, on a timely basis. A *material weakness* is a deficiency, or combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity’s financial statements will not be prevented, or detected and corrected on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified.

Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether the Clinic's financial statements are free of material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of This Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the entity's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

Ernst + Young LLP

February 18, 2022

**Report of Independent Auditors on Compliance for Each Major Federal Program and State Financial Assistance Project and Report on Internal Control Over Compliance Required by the Uniform Guidance and Chapter 10.650,
*Rules of the Auditor General of the State of Florida***

Board of Trustees, Chief Executive Officer and
President, and Chief Financial Officer
Mayo Clinic

Report of Independent Auditors on Compliance for Each Major Federal Program and State Financial Assistance Project

Qualified and Unmodified Opinions

We have audited Mayo Clinic's ("the Clinic") compliance with the types of compliance requirements identified as subject to audit in the U.S. Office of Management and Budget (OMB) *Compliance Supplement* and the requirements described in the Florida Department of Financial Services' *State Projects Compliance Supplement* that could have a direct and material effect on each of the Clinic's major federal programs and state financial assistance projects for the year ended December 31, 2021. The Clinic's major federal programs and state financial assistance projects are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

Qualified Opinion on Assistance Listing No. 93.461, COVID-19 HRSA COVID-19 Claims Reimbursement for the Uninsured Program and the COVID-19 Coverage Assistance Fund

In our opinion, except for the noncompliance described in the Basis for Qualified and Unmodified Opinions section of our report, Mayo Clinic complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on Assistance Listing No. 93.461, COVID-19 HRSA COVID-19 Claims Reimbursement for the Uninsured Program and the COVID-19 Coverage Assistance Fund for the year ended December 31, 2021.

Unmodified Opinion on Each of the Other Major Federal Programs and State Financial Assistance Projects

In our opinion, the Clinic complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on each of its other major federal programs and major state financial assistance projects identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs for the year ended December 31, 2021.

Basis for Qualified and Unmodified Opinions

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America (GAAS); the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States (*Government Auditing Standards*); the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance); and Chapter 10.650, *Rules of the Auditor General of the State of Florida*. Our responsibilities under those standards, the Uniform Guidance and Chapter 10.650, *Rules of the Auditor General of the State of Florida* are further described in the Auditor's Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of the Clinic and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on compliance for each major federal program and major state financial assistance project. Our audit does not provide a legal determination of the Clinic's compliance with the compliance requirements referred to above.

Matter Giving Rise to Qualified Opinion on Assistance Listing No. 93.461, COVID-19 HRSA COVID-19 Claims Reimbursement for the Uninsured Program and the COVID-19 Coverage Assistance Fund

As described in the accompanying schedule of findings and questioned costs, the Clinic did not comply with requirements regarding Assistance Listing No. 93.461, COVID-19 HRSA COVID-19 Claims Reimbursement for the Uninsured Program and the COVID-19 Coverage Assistance Fund, as described in finding number 2021-002 for A. Activities Allowed or Unallowed and E. Eligibility.

Compliance with such requirements is necessary, in our opinion, for the Clinic to comply with requirements applicable to that program.

Responsibilities of Management for Compliance

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules, and provisions of contracts or grant agreements applicable to the Clinic's federal programs and state projects.

Auditor's Responsibilities for the Audit of Compliance

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on the Clinic's compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS, *Government Auditing Standards*, the Uniform Guidance, and Chapter 10.650, *Rules of the Auditor General of the State of Florida* will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material, if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about the Clinic's compliance with the requirements of each major federal program and state financial assistance project as a whole.

In performing an audit in accordance with GAAS, *Government Auditing Standards*, the Uniform Guidance, and Chapter 10.650, *Rules of the Auditor General of the State of Florida*, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material noncompliance, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the Clinic's compliance with the compliance requirements referred to above and performing such other procedures as we considered necessary in the circumstances.
- Obtain an understanding of the Clinic's internal control over compliance relevant to the audit in order to design audit procedures that are appropriate in the circumstances and to test and report on internal control over compliance in accordance with the Uniform Guidance and Chapter 10.650, *Rules of the Auditor General of the State of Florida*, but not for the purpose of expressing an opinion on the effectiveness of the Clinic's internal control over compliance. Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.

Other Matters

The results of our auditing procedures disclosed other instances of noncompliance, which are required to be reported in accordance with the Uniform Guidance, and which are described in the accompanying schedule of findings and questioned costs as follows:

Finding No.	Assistance Listing No.	Program (or Cluster) Name	Compliance Requirement
2021-005	84.268	Student Financial Assistance Cluster	N. Special Tests and Provisions: N2. Disbursement to or on Behalf of Students
2021-006	84.063 and 84.268	Student Financial Assistance Cluster	N. Special Tests and Provisions: N12. Gramm-Leach-Bliley Act – Student Information Security

Our opinion on each major federal program is not modified with respect to these matters.

We performed audit procedures with respect to the Student Financial Assistance Cluster major federal program related to compliance requirements in Special Test and Provision N12, *Gramm-Leach Bliley Act – Student Information Security* as outlined in the OMB *Compliance Supplement* for the year ended December 31, 2021. We determined whether the Clinic has designated an individual to coordinate the information security program. We determined whether the Clinic performed a risk assessment that addresses the three required areas noted in 16 CFR 314.4 (b) and whether the Clinic documented a safeguard for each risk identified from the three required to be risk-assessed by 16 CFR 314.4 (b). Our audit procedures did not evaluate whether the designated individual that coordinated the information security program is competent to oversee the program nor whether the individual possessed the adequate authority to carry out those duties. Our audit procedures also did not determine whether the risk assessment sufficiently addressed the required areas, whether the risks identified are the appropriate risks or that the identified risks appear to be a complete list. Further, our audit procedures did not determine whether the documented safeguards have been put in place or that they will effectively mitigate, reduce, or even address the identified risks. Our opinion on the Student Financial Assistance Cluster major federal program is not modified with respect to this matter.

Our audit of the major federal program identified as Assistance Listing Number 93.461 included certain audit procedures for the compliance requirement associated with activities allowed or unallowed that were limited to tests of compliance that reimbursements received, or expected to be received, related to health services allowed under this federal program. Our audit of compliance was not designed to test or provide assurance on the determination of whether a service was medically necessary, obtained through a legally appropriate referral, properly performed, rendered

in a quality manner from a clinical perspective, adequately supervised, accurately documented and classified (i.e., that the correct medical bill code assigned represents the health service performed), or rendered and billed by non-sanctioned individuals. Performing procedures related to these matters is not within our professional expertise. Additional information on the nature of our procedures is available in the AICPA Audit and Accounting Guide, *Health Care Entities*. Our audit procedures for the compliance requirement associated with eligibility were limited to tests of compliance that services reimbursed, or expected to be reimbursed, were for individuals who received a temporary member identification number from the third-party service provider used by HRSA to identify a lack of active health care coverage.

Government Auditing Standards requires the auditor to perform limited procedures on the Clinic's response to the noncompliance findings identified in our audit described in the accompanying schedule of findings and questioned costs. The Clinic's response was not subjected to the other auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.

Report on Internal Control Over Compliance

Our consideration of internal control over compliance was for the limited purpose described in the Auditor's Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies, and therefore, material weaknesses or significant deficiencies may exist that were not identified. However, as discussed below, we did identify certain deficiencies in internal control over compliance that we consider to be material weaknesses and significant deficiencies.

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program or state financial assistance project on a timely basis. *A material weakness in internal control over compliance* is a deficiency, or combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program or state financial assistance project will not be prevented, or detected and corrected, on a timely basis. We consider the deficiencies in internal control over compliance described in the accompanying schedule of findings and questioned costs to be material weaknesses as follows:

Finding No.	Assistance Listing No.	Program (or Cluster) Name	Compliance Requirement
2021-002	93.461	COVID-19 HRSA COVID-19 Claims Reimbursement for the Uninsured Program and the COVID-19 Coverage Assistance Fund	A. Activities Allowed or Unallowed and E. Eligibility

Finding No.	Assistance Listing No.	Program (or Cluster) Name	Compliance Requirement
2021-004	Various	Research and Development Cluster	C. Cash Management
2021-006	84.063 and 84.268	Student Financial Assistance Cluster	N. Special Tests and Provisions: N12. Gramm-Leach-Bliley Act – Student Information Security
2021-009	93.498	COVID-19 Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution	A. Activities Allowed or Unallowed and B. Allowable Costs/Cost Principles

A significant deficiency in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program or state financial assistance project that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance. We consider the deficiencies in internal control over compliance described in the accompanying schedule of findings and questioned costs to be significant deficiencies as follows:

Finding No.	Assistance Listing No.	Program (or Cluster) Name	Compliance Requirement
2021-001	Various	Research and Development Cluster	A. Activities Allowed or Unallowed and B. Allowable Costs/Cost Principles
2021-003	Various	Research and Development Cluster	M. Subrecipient Monitoring
2021-005	84.268	Student Financial Assistance Cluster	N. Special Tests and Provisions: N2. Disbursement to or on Behalf of Students
2021-007	84.063 and 84.268	Student Financial Assistance Cluster	N. Special Tests and Provisions: N4. Enrollment Reporting
2021-008	84.063 and 84.268	Student Financial Assistance Cluster	A. Activities Allowed or Unallowed and E. Eligibility

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

Government Auditing Standards requires the auditor to perform limited procedures on the Clinic's response to the internal control over compliance findings identified in our audit described in the accompanying schedule of findings and questioned costs. The Clinic's response was not subjected to the other auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance and Chapter 10.650, *Rules of the Auditor General of the State of Florida*. Accordingly, this report is not suitable for any other purpose.

Ernst & Young LLP

August 26, 2022

Mayo Clinic

Schedule of Findings and Questioned Costs

For the Year Ended December 31, 2021

Section I – Summary of Auditor’s Results

Financial Statements

Type of report the auditor issued on whether the financial statements audited were prepared in accordance with GAAP: Unmodified

Internal control over financial reporting:

Material weakness(es) identified?	<u> </u> Yes	<u> X </u> No
Significant deficiency(ies) identified?	<u> </u> Yes	<u> X </u> None Reported

Noncompliance material to financial statements noted?

<u> </u> Yes	<u> X </u> No
--------------------------	------------------------

Federal Awards

Internal control over major federal programs:

Material weakness(es) identified?	<u> X </u> Yes	<u> </u> No
Significant deficiency(ies) identified?	<u> X </u> Yes	<u> </u> None Reported

Type of auditor’s report issued on compliance for major federal programs: Unmodified – Research and Development Cluster; Student Financial Assistance Cluster; and COVID-19 Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution
Qualified – COVID-19 HRSA COVID-19 Claims Reimbursement for the Uninsured Program and the COVID-19 Coverage Assistance Fund

Any audit findings disclosed that are required to be reported in accordance with 2 CFR 200.516(a)? X **Yes** **No**

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section I – Summary of Auditor’s Results (continued)

Identification of major federal programs:

Assistance Listing Numbers	Name of Federal Program or Cluster
Multiple 84.063 and 84.268 93.461	Research and Development Cluster Student Financial Assistance Cluster COVID-19 HRSA COVID-19 Claims Reimbursement for the Uninsured Program and the COVID-19 Coverage Assistance Fund
93.498	COVID-19 Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution

Dollar threshold used to distinguish between
Type A and Type B programs:

\$ 3,000,000

Auditee qualified as low-risk auditee?

 Yes X **No**

Florida State Financial Assistance Projects

Internal control over major state financial
assistance projects:

Material weakness(es) identified?

 Yes X **No**

Significant deficiency(ies) identified?

 Yes X **None Reported**

Type of auditor’s report issued on compliance
for major state financial assistance projects:

Unmodified

Any audit findings disclosed that are required
to be reported in accordance with Chapter
10.650, *Rules of the Auditor General of the
State of Florida*?

 Yes X **No**

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section I – Summary of Auditor’s Results (continued)

Identification of major state projects:

State CSFA Numbers	Name of State Project
64.041	James and Esther King Biomedical Research Program
64.130	Endowed Chair for Cancer Research
Dollar threshold used to distinguish between Type A and Type B programs:	<u>\$750,000</u>

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section II – Financial Statement Findings

None identified.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs

Finding 2021-001

Identification of the federal program:

Federal Agencies: U.S. Department of Defense, National Aeronautics and Space Administration, National Science Foundation, and U.S. Department of Health and Human Services

Pass-Through Entities: Various

Federal Cluster: Research and Development (R&D)

Assistance Listing Nos.: 12.300, 12.RD, 47.070, 93.286, 93.310, 93.353, 93.393, 93.394, 93.395, 93.397, 93.399, 93.837, 93.838, 93.846, 93.847, 93.853, 93.865, 93.866, 93.RD

Award Numbers: Various

Award Periods: Various

Criteria or specific requirement (including statutory, regulatory or other citation):

Section 200.303 of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance) states the following regarding internal control:

“The non-Federal entity must:

- (a) Establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should be in compliance with guidance in “Standards for Internal Control in the Federal Government” issued by the Comptroller General of the United States or the “Internal Control Integrated Framework”, issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).”

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs (continued)

Condition:

Approval of Information System (IS) Programmers internal service charges by the Principal Investigator (PI) or appropriate individual with authority on the grant was not consistently maintained during the fiscal year. In addition, approval for the annual IS Programmer billing rate was not retained.

Cause:

Revised internal controls established in October 2020 which required that (1) the Principal Investigator, or authorized lab personnel, initiate new requests for service; (2) the intake process capture the requestor and project to be charged; and (3) confirmation to be received before work begins were not fully implemented during the fiscal year for both new and ongoing research activities. In addition, the annual IS Programmer billing rate letter was prepared, but evidence of approval was not retained.

Effect or potential effect:

IS Programmer costs could be charged to the incorrect federal grant activity within the general ledger.

Questioned costs:

None.

Context:

For 22 of 25 IS Programmer internal service charges sampled, there was insufficient evidence of review and approval of the costs to be charged to the research activity by the PI or authorized lab personnel.

IS Programmer expenditures reported in the schedule of expenditures of federal awards for the Research and Development Cluster are \$2,947,706 for the year ended December 31, 2021. Total federal expenditures for the Research and Development Cluster are \$404,219,504 for the year ended December 31, 2021.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs (continued)

Identification as a repeat finding, if applicable:

The finding is a repeat of Finding 2020-001 in the prior year.

Recommendation:

The Clinic should ensure that all R&D awards, subawards, and contracts that use IS Programmer services comply with the updated policies, procedures, and internal controls established in October 2020.

Views of responsible officials:

Management agrees with this finding and has implemented, and continues to reinforce, the corrective action plans developed following completion of the 2019 and 2020 single audits. Management will ensure appropriate documentation supporting implementation of the IS Programmer rate is retained.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs (continued)

Finding 2021-002

Identification of the federal program:

Federal Agency: U.S. Department of Health and Human Services, Health Resources and Services Administration (HRSA)

Assistance Listing No.: 93.461, COVID-19 HRSA COVID-19 Claims Reimbursement for the Uninsured Program and the COVID-19 Coverage Assistance Fund (COVID-19 Uninsured Program)

Award Numbers: Various

Award Period: January 1, 2021 through December 31, 2021

Criteria or specific requirement (including statutory, regulatory or other citation):

Section 200.303 of the Uniform Guidance states the following regarding internal control:

“The non-Federal entity must:

- (a) Establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should be in compliance with guidance in “Standards for Internal Control in the Federal Government” issued by the Comptroller General of the United States or the “Internal Control Integrated Framework”, issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).”

Health and Human Services (HHS) – Health Resources and Services and Administrative (HRSA) issued *Terms and Conditions for Participation in the HRSA COVID-19 Claims Reimbursement to Health Care Providers and Facilities for Testing, Treatment, and Vaccine Administration for the Uninsured Program* (T&Cs) outlining requirements that recipients of funding from the HRSA COVID-19 Uninsured Program must comply with, including the following sections: Testing Services, Treatment Services and Vaccine Administration, and General Provisions in FY2020 Consolidated Appropriations.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs (continued)

Per the HRSA T&Cs and further clarified in the HRSA *FAQs for COVID-19 Claims Reimbursement to Health Care Providers and Facilities for Testing, Treatment and Vaccine Administration*, the FAQ states the following:

“If a provider tests for COVID-19 as part of pre-operative or other medical treatment unrelated to COVID-19, is the test eligible for reimbursement?

For the HRSA COVID-19 Uninsured Program, COVID-19 testing is eligible for reimbursement if one of the following diagnoses codes is included in any position on the claim:

- Z03.818 – Encounter for observation for suspected exposure to other biological agents ruled out (possible exposure to COVID-19)
- Z11.59 – Encounter for screening for other viral diseases (asymptomatic)
- Z20.828 – Contact with and (suspected) exposure to other viral communicable (confirmed exposure to COVID-19)
- Z11.52 – Encounter for screening for COVID-19 (asymptomatic)
- Z20.822 – Contact with and (suspected) exposure to COVID-19
- Z86.16 – Personal history of COVID-19

Related treatment visits and services are not eligible for reimbursement given the primary reason for treatment is not COVID-19.”

Per the HRSA T&Cs (for COVID-19 testing and testing-related items):

“FFCRA Uninsured Individuals means individuals who, as of the date of service for which Recipient seeks Payment, are not enrolled in—

- A Federal health care program (as defined under section 1128B(f) of the Social Security Act (42 U.S.C. 1320a-7b(f)), including an individual who is eligible for medical assistance only because of subsection (a)(10)(A)(ii)(XXIII) of Section 1902 of the Social Security Act; or
- A group health plan or health insurance coverage offered by a health insurance issuer in the group or individual market (as such terms are defined in section 2791 of the Public Health Service Act (42 U.S.C. 300gg-91)), or a health plan offered under chapter 89 of title 5, United States Code.”

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs (continued)

Per the HRSA T&Cs (for COVID-19 treatment):

Uninsured individuals are “individuals who do not have any health care coverage at the time the services were provided.”

Condition:

The Clinic did not document its compliance with the HRSA COVID-19 Uninsured Program T&Cs.

For certain emergency department and physician office visits that included COVID-19 testing, but COVID-19 was not the primary reason for the related treatment visit and services, the Clinic erroneously billed the HRSA COVID-19 Uninsured Program for the entire encounter, which was not in compliance with the HRSA COVID-19 Uninsured Program regulations.

Internal controls over the determination of a patient’s uninsured/self-pay status were not operating effectively. In addition, inadequate support was retained in the patient billing and record-keeping system related to the determination of the patient’s uninsured/self-pay status and in some instances, no support was retained.

Refunds required to be made to the HRSA COVID-19 Uninsured Program were not identified.

Furthermore, a risk exists that the data relevant to the HRSA COVID-19 Uninsured Program stored within the patient accounting system may be inappropriately created or modified. Evidence of the operation of controls identified to address this risk during the fiscal period under audit was not retained.

Cause:

The Clinic did not have internal controls in place to formally document its compliance with the HRSA COVID-19 Uninsured Program T&Cs.

The Clinic did not have internal controls in place to monitor the Program T&Cs and underlying HRSA COVID-19 Uninsured Program regulations during the COVID-19 pandemic.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs (continued)

The Clinic did not have internal controls in place to formally document its compliance with the HRSA COVID-19 Uninsured Program's allowability requirements. Outpatient encounters that included a COVID-19 testing diagnosis code, where the primary treatment diagnosis code was not COVID-19 related, were not reviewed prior to submission to HRSA to verify treatment costs were allowable under the HRSA COVID-19 Uninsured Program.

Internal controls were not consistently performed and documented related to the determination of a patient's uninsured/self-pay status.

The Clinic did not have suitably designed controls in place to ensure that the HRSA COVID-19 Uninsured Program is reimbursed for services provided to patients who have retroactively been approved for alternate insurance coverage.

Management did not retain sufficient supporting documentation to provide evidence that controls over data integrity for this major program were designed effectively and placed in operation during the period under audit.

Effect or potential effect:

The Clinic could be in noncompliance with the HRSA COVID-19 Uninsured Program T&Cs.

Certain claims submitted to the HRSA COVID-19 Uninsured Program were for unallowable activities and were, therefore, not eligible for reimbursement under the HRSA COVID-19 Uninsured Program.

A patient may not be uninsured, and, therefore, the related encounter may be ineligible for reimbursement under the HRSA COVID-19 Uninsured Program.

Credit balances may not be resolved timely, and refunds to the HRSA COVID-19 Uninsured Program may not be identified or completed in a timely manner.

Evidence of controls addressing the risk that data within the patient accounting system may be inappropriately created or modified was not retained. Potential effects of ineffective controls related to this risk include ineligible patients could be inappropriately identified as eligible, services could be reimbursed by HRSA for unallowable charges, or patients could be inappropriately billed for services that HRSA reimbursed under this program.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs (continued)

Questioned costs:

Assistance Listing No. 93.461

Questioned Costs	Total
1. Inappropriate billings related to 2021 dates of services – amounts returned by Mayo Clinic 2022 (includes hospital and professional billings)	\$ 663,077
2. Inadequate support for patient self-pay/uninsured status	5,404
	<u>\$ 668,481</u>

Context:

We sampled 60 claims (totaling \$409,414 in federal expenditures) for services occurring during the award period that were billed to the HRSA COVID-19 Uninsured Program and noted six emergency and physician office claims that were inappropriately billed to HRSA (totaling \$12,651 in federal expenditures). Management performed a full analysis over claims submitted to HRSA related to services with discharge dates during the award period, indicating that 490 patient accounts totaling \$663,077 related to certain outpatient claims that were inappropriately billed to HRSA. The \$663,077 was refunded to HRSA during 2022. The six claims noted above in our sample are included in the \$663,077 total amount returned to HRSA.

We sampled 60 claims (totaling \$409,414 in federal expenditures) for services occurring during the award period that were billed to the HRSA COVID-19 Uninsured Program for internal controls over and compliance with the determination of a patient's uninsured/self-pay status. We identified control deviations and compliance exceptions for six patient encounters (totaling \$5,404 in federal expenditures). For these six patient encounters, there was no self-pay flag and/or notes within the patient billing and record-keeping system supporting the patient's uninsured/self-pay status at the time of service/patient intake.

Total federal expenditures for Assistance Listing No. 93.461 totaled \$9,969,127 for the year ended December 31, 2021.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs (continued)

Identification as a repeat finding, if applicable:

This is a repeat finding and is related to finding 2020-002 from the prior year.

Recommendation:

The Clinic should implement internal controls to document its review and compliance with the HRSA COVID-19 Uninsured Program T&Cs.

The Clinic should implement sufficiently precise internal controls to review changes to the HRSA COVID-19 Uninsured Program to ensure it is administering the program in compliance with the HRSA COVID-19 Uninsured Program regulations. In addition, internal controls should be implemented to ensure claims submitted to the HRSA COVID-19 Uninsured Program meet the allowability criteria established by the HRSA COVID-19 Uninsured Program regulations before claims are submitted to HRSA for reimbursement.

Standard policies, procedures, and internal controls over the review for patient insurance coverage and review of credit balances should be updated to address the unique aspects of the HRSA COVID-19 Uninsured Program.

Management should retain documentation of the operation of controls responsive to risks related to the data stored in its IT systems as evidence of control activities.

Views of responsible officials:

Management agrees with this finding and performed a review of claims submitted to the HRSA COVID-19 Uninsured Program for potential payments for ineligible services and has resubmitted any claims that require reprocessing due to overpayment. In March 2022, HRSA announced the discontinuance of the HRSA COVID-19 Uninsured Program and therefore remediation of internal controls is no longer applicable.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs (continued)

Finding 2021-003

Identification of the federal program:

Federal Agencies: U.S. Department of Defense, National Aeronautics and Space Administration, National Science Foundation, and U.S. Department of Health and Human Services

Pass-Through Entities: Various

Federal Cluster: Research and Development (R&D)

Assistance Listing Nos.: 12.300, 12.420, 12.RD, 43.RD, 47.074, 93.103, 93.172, 93.226, 93.242, 93.273, 93.279, 93.286, 93.307, 93.350, 93.353, 93.361, 93.393, 93.394, 93.395, 93.396, 93.397, 93.837, 93.838, 93.839, 93.840, 93.846, 93.847, 93.853, 93.855, 93.859, 93.865, 93.866, 93.867, 93.884, and 93.RD

Award Numbers: Various

Award Periods: Various

Criteria or specific requirement (including statutory, regulatory or other citation):

Section 200.303 of the Uniform Guidance states the following regarding internal control:

“The non-Federal entity must:

- (a) Establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should be in compliance with guidance in “Standards for Internal Control in the Federal Government” issued by the Comptroller General of the United States or the “Internal Control Integrated Framework”, issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).”

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs (continued)

Condition:

The Clinic maintains a monthly balanced scorecard to monitor that subrecipient risk assessments are being completed timely. For 8 of 12 months during the fiscal year, there was no evidence of review and approval of the calculated metric.

Cause:

Evidence of review and approval was not retained for all monthly balanced scorecards.

Effect or potential effect:

Subrecipients may not be monitored timely.

Questioned costs:

None.

Context:

Total amount of federal monies passed through to subrecipients reported in the schedule of expenditures of federal awards for the Research and Development Cluster are \$41,399,744 for the year ended December 31, 2021. Total federal expenditures for the Research and Development Cluster are \$404,219,504 for the year ended December 31, 2021.

Identification as a repeat finding, if applicable:

This is a repeat finding and is related to finding 2020-003 from the prior year.

Recommendation:

The Clinic should ensure that evidence is retained to support the operating effectiveness of established internal controls.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs (continued)

Views of responsible officials:

Management agrees with this finding and has corrected the finding as of January 1, 2022. From that date, proper documentation has been and will continue to be retained to support the operating effectiveness of established internal controls.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs (continued)

Finding 2021-004

Identification of the federal program:

Federal Agencies: U.S. Department of Defense, National Aeronautics and Space Administration, National Science Foundation, and U.S. Department of Health and Human Services

Pass-Through Entities: Various

Federal Cluster: Research and Development (R&D)

Assistance Listing Nos.: 12.300, 12.420, 12.RD, 43.RD, 47.074, 93.103, 93.172, 93.226, 93.242, 93.273, 93.279, 93.286, 93.307, 93.350, 93.353, 93.361, 93.393, 93.394, 93.395, 93.396, 93.397, 93.837, 93.838, 93.839, 93.840, 93.846, 93.847, 93.853, 93.855, 93.859, 93.865, 93.866, 93.867, 93.884, and 93.RD

Award Numbers: Various

Award Periods: Various

Criteria or specific requirement (including statutory, regulatory or other citation):

Section 200.303 of Title 2 U.S. *Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance) states the following regarding internal control:

“The non-Federal entity must:

- (a) Establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should be in compliance with guidance in “Standards for Internal Control in the Federal Government” issued by the Comptroller General of the United States or the “Internal Control Integrated Framework”, issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).”

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs (continued)

Condition:

The Clinic does not have an internal control in place over the review and approval of subrecipient invoices to ensure that the payment to the subrecipient is consistent with the terms and conditions of the subaward agreement.

Cause:

Each subrecipient signs a subaward agreement acknowledging that it will be paid on a reimbursement basis. Annually, a purchase order is set up for each subrecipient for the total amount of the annual subaward. Invoices submitted for payment are matched to the purchase order by the purchasing system and approved for payment. However, there is no review and approval of the individual subrecipient invoice to determine compliance with subrecipient award agreement cash management requirements.

Effect or potential effect:

Payments to subrecipients may not be in accordance with the cash management requirements outlined in the subaward agreement.

Questioned costs:

None.

Context:

Total amount of federal monies passed through to subrecipients reported in the schedule of expenditures of federal awards for the Research and Development Cluster are \$41,399,744 for the year ended December 31, 2021. Total federal expenditures for the Research and Development Cluster are \$404,219,504 for the year ended December 31, 2021.

Identification as a repeat finding, if applicable:

This is a repeat finding and is related to finding 2020-004 from the prior year.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs (continued)

Recommendation:

The Clinic should review its policies and procedures and internal controls over subrecipient cash management to ensure that subrecipients are paid on a cash reimbursement basis.

Views of responsible officials:

Management agrees with this finding. Following completion of the 2020 audit in March of 2022, management identified and began implementing new controls and enhancements to existing controls to ensure payments to subrecipients are appropriate.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs (continued)

Finding 2021-005

Identification of the federal program:

Federal Agency: United States Department of Education

Federal Cluster/Program: Student Financial Assistance Cluster – Federal Direct Student Loans (Assistance Listing No. 84.268)

Award Periods: July 1, 2020 through June 30, 2021, and July 1, 2021 through June 30, 2022

Criteria or specific requirement (including statutory, regulatory or other citation):

Section 200.303(a) of the Uniform Guidance states the following regarding the auditee and internal control:

“The non-Federal entity must:

- (a) Establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should be in compliance with guidance in “Standards for Internal Control in the Federal Government” issued by the Comptroller General of the United States or the “Internal Control Integrated Framework,” issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).”

34 CFR 685.300(b)(9) requires institutions to “Provide for the implementation of a quality assurance system, as established by the Secretary and developed in consultation with the school, to ensure that the school is complying with program requirements and meeting program objectives.”

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs (continued)

Condition:

The Mayo Clinic College of Medicine and Science (MCCMS) did not document the components of its quality assurance system for the Federal Direct Loan program for the year ended December 31, 2021, in a single location. In addition, MCCMS did not retain documentation of its periodic monitoring and evaluation of its direct loan quality assurance system, including results of the assessments and whether any updates or changes were required.

Cause:

Internal controls were not properly designed to require evidence of periodic monitoring and evaluation to be retained.

Effect or potential effect:

MCCMS is not in compliance with the requirement of its program participation agreement related to the direct loan quality assurance system.

Questioned costs:

None.

Context:

Total Federal Direct Loans for MCCMS were \$14,919,675, representing 99.7% of total Student Financial Assistance Cluster federal expenditures of \$14,969,045.

Identification as a repeat finding, if applicable:

This finding is not a repeat finding from the prior year.

Recommendation:

MCCMS should retain documentation of its periodic monitoring and evaluation of the direct loan quality assurance system.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs (continued)

Views of responsible officials:

The Department of Education (the Department) does not mandate the method by which schools meet the quality assurance requirement. MCCMS has met the requirements, but has not documented this program in a single document in a single location. However, our processes ensure that the procedures we have in place provide assurance that we have designed a quality program.

When processing Federal Direct Loans, the Department allows schools to disburse funds to the student before an approved Common Origination and Disbursement (COD) record has been received. MCCMS Student Financial Aid (SFA) requires an approved COD before any funds are disbursed. This process prevents errors from occurring and ensures disbursement of only accurate Federal Direct Loan funds. In addition, the monthly reconciliation of the Direct Loan (DL) account is documented and maintained.

MCCMS procedures are documented in detailed policies prescribing each step to process Federal Direct Loans. These policies and procedures are reviewed annually and updated as needed by the SFA team. The Mayo Clinic Policy Management Policy requires that “All policies must be reviewed at least every three years, unless federal/state/local laws and or accrediting or regulatory bodies require more frequent policy reviews.” The SFA Team meets weekly. Agendas showing the policies and procedures reviewed are included. Future meetings will include archived copies of policies reviewed, and changes made to improve documentation.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs (continued)

Finding 2021-006

Identification of the federal program:

Federal Agency: United States Department of Education

Federal Cluster: Student Financial Assistance

Award Periods: July 1, 2020 through June 30, 2021, and July 1, 2021 through June 30, 2022

Criteria or specific requirement (including statutory, regulatory or other citation):

Section 200.303(a) of the Uniform Guidance states the following regarding the auditee and internal control:

“The non-Federal entity must:

- (a) Establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should be in compliance with guidance in “Standards for Internal Control in the Federal Government” issued by the Comptroller General of the United States or the “Internal Control Integrated Framework,” issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).”

16 CFR 314.4(b) requires institutions to “Identify reasonably foreseeable internal and external risks to the security, confidentiality, and integrity of customer information that could result in the unauthorized disclosure, misuse, alteration, destruction or other compromise of such information, and assess the sufficiency of any safeguards in place to control these risks. At a minimum, such a risk assessment should include consideration of risks in each relevant area of your operations, including: (1) Employee training and management; (2) Information systems, including network and software design, as well as information processing, storage, transmission and disposal; and (3) Detecting, preventing and responding to attacks, intrusions, or other systems failures.”

16 CFR 314.4(c) requires institutions to “Design and implement information safeguards to control the risks you identify through risk assessment, and regularly test or otherwise monitor the effectiveness of the safeguards’ key controls, systems, and procedures.”

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs (continued)

Condition:

The Mayo Clinic has a security risk program in place that follows the National Institute of Standards and Technology (NIST) framework to assess its information technology risks. The program includes (1) employee training and management; (2) information systems, including network and software design, as well as information processing, storage, transmission, and disposal; and (3) detecting, preventing, and responding to attacks, intrusions, or other systems failures.

However, for the student financial aid system used by Mayo Clinic, the 2021 NIST risk assessment did not cover (2) information systems, including network and software design, as well as information processing, storage, transmission, and disposal; and (3) detecting, preventing, and responding to attacks, intrusions, or other systems failures.

Cause:

The Mayo Clinic security risk program did not include the student financial aid information applications.

Effect or potential effect:

The absence of internal controls and policies and procedures could result in the unauthorized disclosure, misuse, alteration, destruction, or other compromise of student account information.

Questioned costs:

None.

Context:

Under an institution's Program Participation Agreement with the U.S. Department of Education and the GLBA, schools must protect student financial aid information, with particular attention to information provided to institutions by the U.S. Department of Education or otherwise obtained in support of the administration of the federal student financial aid programs. Total expenditures for the Student Financial Assistance Cluster were \$14,969,045 for the year ended December 31, 2021.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs (continued)

Identification as a repeat finding, if applicable:

This finding is not a repeat finding from the prior year.

Recommendation:

We recommend that the Mayo Clinic include the student information systems as part of its annual enterprise-wide risk assessment.

Views of responsible officials:

Management agrees that Banner, the primary information system used to capture Federal Direct Loan information, was not specifically identified in the 2021 Mayo Clinic Information Security annual risk assessment which was primarily designed for compliance with The Health Insurance Portability and Accountability Act (HIPAA) Security rule. However, Banner as a vendor system was evaluated utilizing Mayo Clinic's enterprise process and met the intent of the Gramm-Leach-Bliley Act, required for compliance by the Department of Education. Employees utilizing Banner are subject to the policies governed by the Mayo Clinic Security Committee in alignment with the National Institute of Standards and Technology (NIST).

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs (continued)

Finding 2021-007

Identification of the federal program:

Federal Agency: United States Department of Education

Federal Cluster: Student Financial Assistance

Award Periods: July 1, 2020 through June 30, 2021, and July 1, 2021 through June 30, 2022

Criteria or specific requirement (including statutory, regulatory or other citation):

Section 200.303(a) of the Uniform Guidance states the following regarding the auditee and internal control:

“The non-Federal entity must:

- (a) Establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should be in compliance with guidance in “Standards for Internal Control in the Federal Government” issued by the Comptroller General of the United States or the “Internal Control Integrated Framework,” issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).”

Condition:

As part of the review of the monthly SFRNSLC enrollment report prior to its upload to the National Student Clearinghouse (NSC)/National Student Loan Data System, the Financial Aid Director sampled 10 students from the monthly SFRNSLC enrollment report for accuracy against the student records system and sampled 10 students from the student records system for completeness against the monthly SFRNSLC enrollment report. However, evidence was not retained of the students sampled and the specific data validated as part of the review.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs (continued)

Cause:

Internal controls were not properly designed to require detail evidence of the accounts reviewed and related test attributes to be retained.

Effect or potential effect:

An incorrect enrollment report may be submitted.

Questioned costs:

None.

Context:

Total expenditures for the Student Financial Assistance Cluster were \$14,969,045 for the year ended December 31, 2021.

Identification as a repeat finding, if applicable:

This finding is not a repeat finding from the prior year.

Recommendation:

Specific elements of the review process should be documented by the Financial Aid Director including the students sampled and specific data validated, the results of the review, and the follow-up actions taken, if any, and signed off by the Financial Aid Director to evidence performance of the monthly review.

Views of responsible officials:

Management provided email correspondence documenting the completion of this sampling and testing, without the names of students tested. We will improve documentation to include the students tested in future confirmation of the procedure. We believe the control was evidenced and meets the intent of the specific requirement.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs (continued)

Finding 2021-008

Identification of the federal program:

Federal Agency: United States Department of Education

Federal Cluster: Student Financial Assistance

Award Periods: July 1, 2020 through June 30, 2021, and July 1, 2021 through June 30, 2022

Criteria or specific requirement (including statutory, regulatory or other citation):

Section 200.303(a) of the Uniform Guidance states the following regarding the auditee and internal control:

“The non-Federal entity must:

- (a) Establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should be in compliance with guidance in “Standards for Internal Control in the Federal Government” issued by the Comptroller General of the United States or the “Internal Control Integrated Framework,” issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).”

Condition:

Annual cost of attendance (COA) budgets (by program/by enrollment status) uploaded to Mayo Clinic College of Medicine and Science’s student information system by the Program Manager of Student Financial Aid are not reviewed and approved by another individual for accuracy once the upload was complete.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs (continued)

Cause:

There is currently no internal control in place to perform a secondary review of the data input by the Program Manager of Student Financial Aid.

Effect or potential effect:

COA could be incorrectly uploaded to the student information system, which could cause a student's financial need, and resulting financial aid, to be incorrectly calculated.

Questioned Costs:

None.

Context:

Total expenditures for the Student Financial Assistance Cluster were \$14,969,045 for the year ended December 31, 2021.

Identification as a repeat finding, if applicable:

This finding is not a repeat finding from the prior year.

Recommendation:

The annual COA budgets uploaded into the student information system should be reviewed and approved by a secondary individual for accuracy once the upload by the Program Manager of Student Financial Aid is complete. This review should be documented and signed off by the secondary reviewer.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs (continued)

Views of responsible officials:

Each year our Program Manager sets up each of our financial aid eligible programs in Banner. This includes entering the COA/tuition for each program. The program set-up in Banner requires several steps, many which include a review of our program's COA/tuition. At the time students are appointed to the program, we also validate the tuition charges as we process each student's financial aid. Students receive a program budget sheet showing the COA/tuition at the time of their financial aid offer.

Updated tuition and fee amounts originate with the school/program and are communicated to the SFA Office annually. The SFA Office enters this data, along with cost-of-living allowances (COLA), which comprises the overall cost of attendance (COA). MCCMS SFA may not have a separate individual check the tuition entered in Banner, but there are several steps where tuition is confirmed for accuracy, including confirmation of amounts billed, multiple checks in the set-up process, budget sheet preparation and awarding process.

Moving forward we will have an SFA team member complete the program set-up and a second team member create the budget sheets where the COA/tuition can be verified against the approved tuition rate. This second team member's review will be documented.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs (continued)

Finding 2021-009

Identification of the federal program:

Federal Agency: U.S. Department of Health and Human Services (HHS), Health Resources and Services Administration (HRSA)

Assistance Listing No.: 93.498 COVID-19 Provider Relief Fund and American Rescue Plan (ARP)
Rural Distribution

Criteria or specific requirement (including statutory, regulatory or other citation)

2 CFR Section 200.303 of the Uniform Guidance states the following regarding internal control:

“The non-Federal entity must:

- (a) Establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should be in compliance with guidance in “Standards for Internal Control in the Federal Government” issued by the Comptroller General of the United States or the “Internal Control Integrated Framework”, issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).”

Condition:

Management did not retain supporting documentation over its approval of expenses reported to HRSA in the HHS portal. While management had a robust process to identify and review expenses for allowability under the PRF program, sufficient supporting documentation was not retained to support the process.

Cause:

Management represented they performed a review and approval of PRF expenses for allowability; however, supporting documentation to evidence that the internal controls were sufficiently designed and operating effectively was not maintained.

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs (continued)

Effect or potential effect:

A lack of internal controls over the review and approval of expenses for allowability could result in unallowable expenses being charged to the PRF program.

Questioned costs:

None.

Context:

Total expenses reported in the HHS portal are \$26,966,571.

Total PRF lost revenue and expenditures reported on the SEFA are \$181,999,200 for the year ended December 31, 2021.

Identification as a repeat finding:

This finding is not a repeat finding from the prior year.

Recommendation:

Management should reassess its internal controls over the review and approval of allowability of expenditures.

Views of responsible officials:

All expenditures included by Mayo Clinic in its submissions in the HHS portal were verified against HHS guidance to ensure allowability. Management agrees the documentation supporting the reviews was not maintained. This award has ended, and no further expenditures are expected. Management may reassess its documentation of the review and approval of allowability of expenditures should there be any new or additional funding related to PRF.

EY | Building a better working world

EY exists to build a better working world, helping to create long-term value for clients, people and society and build trust in the capital markets.

Enabled by data and technology, diverse EY teams in over 150 countries provide trust through assurance and help clients grow, transform and operate.

Working across assurance, consulting, law, strategy, tax and transactions, EY teams ask better questions to find new answers for the complex issues facing our world today.

EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. Information about how EY collects and uses personal data and a description of the rights individuals have under data protection legislation are available via ey.com/privacy. EY member firms do not practice law where prohibited by local laws. For more information about our organization, please visit ey.com.

Ernst & Young LLP is a client-serving member firm of Ernst & Young Global Limited operating in the US.

© 2022 Ernst & Young LLP.
All Rights Reserved.

ey.com

Summary Schedule of Prior Audit Findings – For the Years Ended December 31, 2020 and 2019

Finding 2020–001 (and 2019-001)

Federal Program Information

Federal Agencies: U.S. Department of Defense and U.S. Department of Health and Human Services

Pass-Through Entities: Various

Federal Cluster: Research and Development (R&D)

Assistance Listing Nos.: 12.300, 12.420, 12.RD, 93.173, 93.273, 93.286, 93.307, 93.310, 93.350, 93.353, 93.393, 93.394, 93.395, 93.397, 93.398, 93.399, 93.837, 93.838, 93.846, 93.847, 93.853, 93.855, 93.859, 93.865, 93.866, 93.RD

Award Numbers: Various

Award Periods: Various

Summary of Prior Audit Finding

Condition:

The Mayo Clinic's (the Clinic) internal control over Information System (IS) Programmers internal service charges did not require that the initial request for services always be formally documented or approved by the Principal Investigator (PI) or appropriate individual with authority on the grant. In addition, for IS Programmers and the Biomedical Imaging Resource (BIR) Core, the specific grant activity number to be charged was not always documented during the intake process when the initial request for services is made.

Recommendation:

The Clinic should ensure that all R&D awards, subawards, and contracts that use IS Programmer and BIR Core services comply with the updated policies, procedures, and internal controls approved on October 1, 2020.

Status

Information Technology (IT) implemented corrective actions as planned following completion of the 2019 audit. Those corrective actions require that 1) the Principal Investigator, or authorized lab personnel, initiates new requests for service, 2) the intake process captures the requestor and project to be charged, and 3) confirmation is received before work begins. IT continues to supplement these corrective actions with additional communications about expectations, and retrospective confirmations of ongoing work to ensure appropriate documentation exists for both new and ongoing work.

The Biomedical Imaging Resource (BIR) Core developed a process to confirm with the Principal Investigator the award to be charged for the work requested. The confirmation is retained by the BIR Core.

Contact Person

Lance A. Guth, Section Head IT – Administrative, Research & Education Applications

Marco Wageman, Vice Chair – Financial and Accounting Services, Research Finance

Sarah Ward, Vice Chair – Financial and Accounting Services, Research Finance

Finding 2020–002

Federal Program Information

Federal Agency: U.S. Department of Health and Human Services, Health Resources and Services Administration (HRSA)

Assistance Listing No.: 93.461, COVID-19 Claims Reimbursement to Health Care Providers and Facilities for Testing, Treatment, and Vaccine Administration for the Uninsured (COVID-19 Uninsured Program)

Award Numbers: Various

Award Period: February 4, 2020 through December 31, 2020

Summary of Prior Audit Finding

Condition:

The Clinic did not document its compliance with the HRSA COVID-19 Uninsured Program T&Cs.

For certain emergency department and physician office visits that included COVID-19 testing, but COVID-19 was not the primary reason for the related treatment visit and services, the Clinic erroneously billed the HRSA COVID-19 Uninsured Program for the entire encounter, which was not in compliance with the HRSA COVID-19 Uninsured Program regulations.

Internal controls over the determination of a patient's uninsured/self-pay status were not operating effectively. In addition, inadequate support was retained in the patient billing and recordkeeping system related to the determination of the patient's uninsured/self-pay status and in some instances, no support was retained.

Refunds required to be made to the HRSA COVID-19 Uninsured Program were not identified.

Furthermore, a risk exists that the data relevant to the HRSA COVID-19 Uninsured Program stored within the patient accounting system may be inappropriately created or modified. Evidence of the operation of controls identified to address this risk during the fiscal period under audit was not retained.

Recommendation:

The Clinic should implement internal controls to document its review and compliance with the HRSA COVID-19 Uninsured Program T&Cs.

The Clinic should implement sufficiently precise internal controls to review changes to the HRSA COVID-19 Uninsured Program to ensure it is administering the program in compliance with the HRSA COVID-19 Uninsured Program regulations. In addition, internal controls should be implemented to ensure claims submitted to the HRSA COVID-19 Uninsured Program meet the allowability criteria established by the HRSA COVID-19 Uninsured Program regulations before claims are submitted to HRSA for reimbursement.

Standard policies, procedures, and internal controls over the review for patient insurance coverage and review of credit balances should be updated to address the unique aspects of the HRSA COVID-19 Uninsured Program.

Management should retain documentation of the operation of controls responsive to risks related to the data stored in their IT systems as evidence of control activities.

Status

Management has reviewed claims submitted to the HRSA COVID-19 Uninsured Program for potential payments for ineligible services and resubmitted all claims requiring reprocessing due to overpayment.

Contact Person

Sharon M. Kelley, Chair – Revenue Cycle

Michelle Densley, Director – Revenue Compliance

Finding 2020–003**Federal Program Information**

Federal Agencies: U.S. Department of Defense and U.S. Department of Health and Human Services

Pass-Through Entities: Various

Federal Cluster: Research and Development (R&D)

Assistance Listing Nos.: 12.300, 12.RD, 12.420, 43.RD, 47.074, 93.103, 93.172, 93.226, 93.242, 93.273, 93.279, 93.286, 93.307, 93.310, 93.350, 93.353, 93.361, 93.393, 93.394, 93.395, 93.396, 93.397, 93.399, 93.837, 93.838, 93.839, 93.840, 93.846, 93.847, 93.853, 93.855, 93.859, 93.865, 93.866, 93.867, 93.879, 93.884, 93.RD

Award Numbers: Various

Award Periods: Various

Summary of Prior Audit Finding

Condition:

The Clinic maintains a monthly balanced scorecard to monitor that that subrecipient risk assessment are being completed timely. For 6 of 12 months during the fiscal year, there was no evidence of review and approval of the calculated metric.

The Clinic’s principal investigators perform monthly/quarterly reviews of subrecipient financial and performance reports; however, documentation was not consistently completed or retained to evidence the results of the monitoring during the fiscal year.

Recommendation:

The Clinic should ensure that evidence is retained to support the operating effectiveness of established internal controls.

Status

Management has remediated review and approval of the balanced scorecard beginning in 2022.

Expectations regarding documenting the review of subrecipient payments and performance were recommunicated with the appropriate staff in May 2022. Routine reviews of subrecipient performance and progress are being evaluated for enhancement to ensure documentation supporting the results of the monitoring is consistently completed and retained.

Contact Person

Marco Wageman, Vice Chair – Financial and Accounting Services, Research Finance

Sarah Ward, Vice Chair – Financial and Accounting Services, Research Finance

Finding 2020–004

Federal Program Information

Federal Agencies: U.S. Department of Defense and U.S. Department of Health and Human Services

Pass-Through Entities: Various

Federal Cluster: Research and Development (R&D)

Assistance Listing Nos.: 12.300, 12.RD, 12.420, 43.RD, 47.074, 93.103, 93.172, 93.226, 93.242, 93.273, 93.279, 93.286, 93.307, 93.310, 93.350, 93.353, 93.361, 93.393, 93.394, 93.395, 93.396, 93.397, 93.399, 93.837, 93.838, 93.839, 93.840, 93.846, 93.847, 93.853, 93.855, 93.859, 93.865, 93.866, 93.867, 93.879, 93.884, 93.RD

Award Numbers: Various

Award Periods: Various

Summary of Prior Audit Finding

Condition:

The Clinic does not have an internal control in place over the review and approval of subrecipient invoices to ensure that the payment to the subrecipient is limited to the subrecipient's immediate cash needs.

Recommendation:

The Clinic should establish internal controls over the review and approval of subrecipient invoices for cash management at the time of payment to the subrecipients.

Status

Management reviewed existing controls and added transaction detail and compliance confirmation questions to the subaward payment review process. Management also enhanced the review of subrecipient invoices to monitor for unallowable costs and advance payments.

Contact Person

Marco Wageman, Vice Chair – Financial and Accounting Services, Research Finance

Sarah Ward, Vice Chair – Financial and Accounting Services, Research Finance

Corrective Action Plan

Finding 2021-001

Federal Program Information

Federal Agency: U.S. Department of Defense, National Aeronautics and Space Administration, National Science Foundation, and U.S. Department of Health and Human Services

Assistance Listing Nos.: 12.300, 12.RD, 47.070, 93.286, 93.310, 93.353, 93.393, 93.394, 93.395, 93.397, 93.399, 93.837, 93.838, 93.846, 93.847, 93.853, 93.865, 93.866, 93.RD

Award Numbers: Various

Award Period: Various

Corrective Action Planned

Information Technology (IT) implemented corrective actions as planned following completion of the 2019 audit. Those corrective actions require that 1) the Principal Investigator, or authorized lab personnel, initiates new requests for service, 2) the intake process captures the requestor and project to be charged, and 3) confirmation is received before work begins. IT will continue to supplement these corrective actions with additional communications about expectations, and retrospective confirmations of ongoing work to ensure appropriate documentation exists for both new and ongoing work. In addition, management will meet with staff to identify, or create, the documentation to be retained to support implementation of the IS Programmer rate.

Person Responsible for Corrective Action

Lance A. Guth, Division Chair IT – Research Applications

Marco Wageman, Vice Chair – Financial and Accounting Services, Research Finance

Sarah Ward, Vice Chair – Financial and Accounting Services, Research Finance

Completion Date

October 31, 2022

Finding 2021-002

Federal Program Information

Federal Agency: U.S. Department of Health and Human Services, Health Resources and Services Administration (HRSA)

Assistance Listing No.: 93.461, COVID-19 HRSA COVID-19 Claims Reimbursement for the Uninsured Program and the COVID-19 Coverage Assistance Fund (COVID-19 Uninsured Program)

Award Numbers: Various

Award Period: January 1, 2021 through December 31, 2021

Corrective Action Planned

A comprehensive review of the coverage rules in Mayo Clinic's Electronic Health Record (EHR) related to the HRSA COVID-19 Uninsured Program has been completed. EHR billing edits were put in place to review claims prior to submission and ensure compliance with the HRSA COVID-19 Uninsured Program. A review of all HRSA COVID-19 Uninsured Program payments made from 2020 through April 30, 2022 were evaluated to ensure compliance with the HRSA COVID-19 Uninsured Program T&Cs. Refunds were identified in the review process and have been expeditiously refunded according the HRSA COVID-19 Uninsured Program requirements. The detailed plan action steps follow:

- 1) Meet with Mayo Clinic Revenue Cycle Systems and Operations teams to evaluate and update EHR coverage criteria for uninsured patients that may qualify for the HRSA COVID-19 Uninsured Program.
Planned completion date: 01/31/2022
Status: **Complete**
- 2) EHR Billing edits will be put in place to review claims prior to submission and ensure compliance with the allowability criteria for the HRSA COVID-19 Uninsured Program.
Planned completion date: 12/10/2021
Status: **Complete**
- 3) Refine billing process to ensure no additional claims for COVID-19 testing and treatment are submitted to the HRSA COVID-19 Uninsured Program effective 03/22/2022 and for COVID-19 vaccinations effective 04/06/2022.
Planned completion date: 03/22/2022 and 04/06/2022
Status: **Complete**
- 4) A review of all HRSA COVID-19 Uninsured Program payments will be evaluated to ensure compliance with the HRSA COVID-19 Uninsured Program. Any refunds identified in the review process will be expeditiously refunded according the HRSA COVID-19 Uninsured Program requirements.
Planned completion date: 04/30/2022
Status: **Complete**

Person Responsible for Corrective Action

Sharon M Kelley, Chair Revenue Cycle

Michelle Densley, Director Revenue Compliance

Completion Date

See above

Finding 2021-003

Federal Program Information

Federal Agency: U.S. Department of Defense, National Aeronautics and Space Administration, National Science Foundation, and U.S. Department of Health and Human Services
Assistance Listing Nos.: 12.300, 12.420, 12.RD, 43.RD, 47.074, 93.103, 93.172, 93.226, 93.242, 93.273, 93.279, 93.286, 93.307, 93.350, 93.353, 93.361, 93.393, 93.394, 93.395, 93.396, 93.397, 93.837, 93.838, 93.839, 93.840, 93.846, 93.847, 93.853, 93.855, 93.859, 93.865, 93.866, 93.867, 93.884, and 93.RD
Award Numbers: Various
Award Period: Various

Corrective Action Planned

Management implemented corrective actions immediately following completion of the 2020 single audit in March of 2022. Those corrective actions ensure that proper documentation has been and will continue to be retained to support the operating effectiveness of established internal controls.

Person Responsible for Corrective Action

Marco Wageman, Vice Chair – Financial and Accounting Services, Research Finance
Sarah Ward, Vice Chair – Financial and Accounting Services, Research Finance

Completion Date

04/15/2022

Finding 2021-004

Federal Program Information

Federal Agency: U.S. Department of Defense, National Aeronautics and Space Administration, National Science Foundation, and U.S. Department of Health and Human Services
Assistance Listing Nos.: 12.300, 12.420, 12.RD, 43.RD, 47.074, 93.103, 93.172, 93.226, 93.242, 93.273, 93.279, 93.286, 93.307, 93.350, 93.353, 93.361, 93.393, 93.394, 93.395, 93.396, 93.397, 93.837, 93.838, 93.839, 93.840, 93.846, 93.847, 93.853, 93.855, 93.859, 93.865, 93.866, 93.867, 93.884, and 93.RD
Award Numbers: Various
Award Period: Various

Corrective Action Planned

Management developed corrective actions following completion of the 2020 single audit in March of 2022. Those corrective actions include new controls and enhancements to existing controls and are currently being implemented.

Person Responsible for Corrective Action

Marco Wageman, Vice Chair – Financial and Accounting Services, Research Finance
Sarah Ward, Vice Chair – Financial and Accounting Services, Research Finance

Completion Date

09/15/2022

Finding 2021-005

Federal Program Information

Federal Agency: United States Department of Education

Federal Cluster/Program: Student Financial Assistance Cluster – Federal Direct Student Loans
(Assistance Listing No 84.268)

Corrective Action Planned

MCCM has met the requirements but has not documented this program in a single location. To provide evidence of this comprehensive evaluation and assessment, we will take the following steps during our annual review of policy and procedures:

1. Maintain a single Annual Direct Loan Quality Assurance program document outlining:
 - a. Policies and procedures reviewed
 - b. Outcome of review including changes made
 - c. Name of individual conducting the review
 - d. Date the review occurred
2. Archive a copy of the policy and procedures in our financial aid electronic folder each academic year.
3. Maintain any documentation of new federal guidelines or system updates along with confirmation that necessary changes were made according to federal or system requirements.

Person Responsible for Corrective Action

Anne Dahlen, Director of Student Financial Aid/Registrar

Maribeth Foerster, Program Manager Student Financial Aid

Completion Date

9/30/2022

Finding 2021-006

Federal Program Information

Federal Agency: United States Department of Education

Federal Cluster: Student Financial Assistance

Corrective Action Planned

Management agrees that Banner, the primary information system used to capture Federal Direct Loan information, was not specifically identified in the Mayo Clinic Information Security annual risk assessment which was primarily designed for compliance with The Health Insurance Portability and Accountability Act (HIPAA) Security rule.

The following steps will be completed to address the gap identified:

1. Compare the scope of the Mayo Clinic Information Security annual risk assessment and the requirements of the Department of Education, under the Gramm-Leach-Bliley Act and identify any gaps.
2. Determine if edits to the existing annual risk assessment will close the gaps or if a separate risk assessment would be appropriate.
3. Once best approach is determined, complete the risk assessment in the next annual cycle (2023).

Person Responsible for Corrective Action

Sarah Tyson, Senior Manager – Office of Information Security

Anticipated Completion Date

12/31/2023

Finding 2021-007**Federal Program Information**

Federal Agency: United States Department of Education

Federal Cluster: Student Financial Assistance

Corrective Action Planned

As stated, a student sample is reviewed for accuracy prior to submitting the report to the clearinghouse each month. To provide evidence, the Financial Aid Director will retain the names of the student along with the items validated. This will be communicated in an email from the Director to our Assistant Registrar each month prior to submitting the enrollment report to the clearinghouse. Assistant Registrar will retain a copy of the email in our registrar electronic folder within the applicable month archive.

Person Responsible for Corrective Action

Anne Dahlen, Director of Student Financial Aid/Registrar

Delores Henke, Assistant Registrar

Completion Date

9/30/2022

Finding 2021-008**Federal Program Information**

Federal Agency: United States Department of Education

Federal Cluster: Student Financial Assistance

Corrective Action Planned

The COA budget items are reviewed several times during the specific educational program setup in our Banner student record system. Each review is documented in a dashboard retained in our financial aid electronic folder. At this time, each review is completed by one person. In order to maintain a second level of review, we will delegate a second financial aid team member to complete a review. We will maintain evidence of the name of individual completing each COA review and the date the review occurred.

Person Responsible for Corrective Action

Maribeth Foerster, Program Manager Student Financial Aid

Completion Date

12/31/2022

Finding 2021-009**Federal Program Information**

Federal Agency: U.S. Department of Health and Human Services, Health Resources and Services Administration (HRSA)

Assistance Listing No.: 93.461, 93.498 COVID-19 Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution

Award Numbers: Various

Award Period: January 1, 2021 through December 31, 2021

Corrective Action Planned

Management agrees the documentation supporting the reviews was not maintained. This award has ended, and no further expenditures are expected. The review and approval of allowability of expenditures that extends to these funds will no longer be required. Should there be any new or additional funding related to ARP, management will reassess its documentation maintenance practices.

Person Responsible for Corrective Action

Connie Petch, Division Chair Accounting

Completion Date

December 31, 2021